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CHAPTER 1:  Introduction:  Peroxisomes, cell senescence, rates of aging, and 
age related disease 
 
Published:  Giordano CR and Terlecky SR (2012) Peroxisomes, cell senescence, and 
rates of aging  Biochim Biophys Acta 1822:1358-62. 
1.1  Abstract 
 The peroxisome is functionally integrated into an exquisitely complex network of 
communicating endomembranes that is only beginning to be appreciated.  Despite great 
advances in identifying essential components and characterizing molecular 
mechanisms associated with the organelle’s biogenesis and function, there is a large 
gap in our understanding of how peroxisomes are incorporated into metabolic pathways 
and subcellular communication networks, how they contribute to cellular aging, and 
where their influence is manifest on the initiation and progression of degenerative 
disease.  In this introduction, we summarize recent evidence pointing to the organelle 
as an important regulator of cellular redox balance with potentially far-reaching effects 
on cell aging and the genesis of human disease.  
1.2  Cellular senescence and organismal aging 
 The role of cellular senescence in organismal aging burst into our collective 
consciousness with the publication of a paper by Dr. Jan Van Deursen and colleagues 
at the Mayo Clinic College of Medicine in Rochester, Minnesota.  In their landmark 
work, the team showed that eliminating senescent cells in a mouse model delayed 
appearance of age-related disorders (Baker et al., 2011).  Importantly, the strategy was 
effective both when clearance was started from birth, as well as when initiated later in 
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life.  However, in the latter case, already existing pathologies were not reversed, rather 
their progression was thwarted.  In many ways, this research serves as the ultimate 
confirmation of what many had long speculated – that senescent cells amass in tissues 
and organs of aging animals and contribute to their physiological decline.  What a long 
way the field had come from days when cellular senescence was considered an in vitro 
phenomenon, not applicable to the whole animal.  In fact, it is only some eight years 
since Dr. John Sedivy and colleagues at Brown University in Providence, Rhode Island, 
confirmed the existence of senescent cells in the tissue of aging primates (Herbig et al., 
2006). 
 A considerable literature exists concerning exactly what cellular senescence is 
(for example, see (Kuilman et al., 2010) for a detailed overview); therefore, the 
phenomena will only be briefly described here.  Senescent cells have lost their ability to 
replicate, yet remain metabolically active.  The cells are enlarged and express so-called 
senescence markers, including an alkaline β-galactosidase activity, heterochromatin 
and/or DNA damage foci, and the cyclin-dependent kinase inhibitor/tumor suppressor, 
p16Ink4a.  (Eradication of (senescent) cells expressing the latter biomarker was the 
mechanism employed by the Van Deursen group to largely eliminate diseases of aging 
in mice.)  Senescent cells are resistant to apoptosis and exhibit a distinct “secretory 
phenotype” (reviewed in (Coppe et al., 2010)).  They secrete a number of bioactive 
molecules, including cytokines, growth factors, inflammatory mediators, and various 
proteases.  Secretion of these molecules undoubtedly alter the cell and tissue 
microenvironments with potentially important implications on aging and disease 
phenomena.  Indeed, there is an emergent consensus view, articulated by Dr. Manuel 
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Collado and co-authors (Collado et al., 2007) among others, that tissue aging results 
from the combined effects of an accumulation of senescent cells and accompanying 
secretions, and the loss of stem cell renewal capacities.1 
Triggers of replicative senescence include telomere shortening, accumulation of 
reactive oxygen species (ROS) and associated damage to cellular macromolecules, 
DNA alterations and accompanying responses, a loss of cell cycle checkpoint 
regulation, and the effects of environmental or intrinsic stressors including oncogenes.  
Importantly, these activators do not necessarily act alone; rather, they may cooperate to 
elicit the growth stasis and accompanying cellular changes associated with the 
senescent phenotype.   
Is there a reason senescence happens?  A widely supported view is that 
senescence exists to suppress tumor formation; cells that are incapable of dividing 
cannot contribute to cancer – at least not directly.  But as Dr. Judith Campisi (Campisi, 
2005) and others argue, senescence may be antagonistically pleiotropic – beneficial in 
early life to thwart cancer, but permissive of an environment later in life which 
potentiates transformation.  Consider the senescent cell’s tissue milieu; rich in growth-
promoting secreted biomolecules, rich in oxidants, and rich in functionally compromised 
stem cells.  This is an environment ripe for cancerous transformation.  Thus, the thought 
is cancer is held in check early, but may thrive later.  Consistent with this notion is the 
fact that cancer is a disease of aging – the older the individual, the more likely is 
tumorigenesis.   
                                            
1
 The extent to which stem cells actually senesce is not clear; regardless, their diminished function 
certainly compromises tissue integrity.   
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1.3  Peroxisomes 
1.3.1  Overview of biogenesis 
To be able to position peroxisomes as players in cellular aging processes and 
degenerative disease, an overview of their assembly and function is warranted. 
Peroxisome biogenesis is brought about by a series of proteins termed peroxins 
(see (Ma et al., 2011; Rucktaschel et al., 2011) for recent analyses).  The organelle’s 
membrane is derived by growth and division of pre-existing peroxisomes (Lazarow and 
Fujiki, 1985), as well as by recruitment from certain endoplasmic reticulum subdomains 
(Geuze et al., 2003).  Peroxisomal enzymes, synthesized on cytoplasmic ribosomes 
and containing specific targeting signals, are recognized post-translationally and 
directed to the organelle’s membrane.  A surface-associated docking complex then 
engages the to-be-imported enzyme and its cognate receptor, and channels the 
complex to a still rather enigmatic translocation machinery.  Mechanisms exist to 
recycle components of the import apparatus as well as to regulate luminal enzyme 
levels, and organelle number.   
1.3.2  Overview of biological functions 
Peroxisomes are critical contributors to cell metabolism, tissue and organ 
function, and organismal well-being.  They house dozens of enzymes involved in 
biosynthetic reactions (reviewed in (Singh, 1997; Wanders and Waterham, 2006)), 
including those that produce ether phospholipids, as well as bile and docosahexaenoic 
acids.  Among the ether phospholipids produced are plasmalogens, essential 
constituents of myelin, the nerve process insulating material.  Bile acids are well 
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described participants in dietary fat metabolism; docosahexaenoic acids are omega-3 
fatty acids essential for nervous system development and function.  The latter 
molecules also appear to be derivatized into important mediators capable of 
inflammatory-suppression/modulation.  
Peroxisomes also affect inflammation through their ability to degrade 
eicosanoids, signaling molecules with a wide array of biological targets and elicited 
effects.  Peroxisomal enzymes degrade a number of other substrates including 
particular long-chain, very-long-chain, and branched-chain fatty acids.  Defects in such 
processing results in accumulation of these molecules and, in many cases, disease and 
even death ensues.  Metabolism of peroxisomal fatty acids occurs through biochemical 
oxidations; molecular oxygen is the electron acceptor and H2O2 is formed (see 
(Antonenkov et al., 2010) for an overview of peroxisomes as oxidative organelles).  This 
H2O2 and related downstream ROS appear to play important roles in cell signaling and 
communication networks, in hormetic processes, as well as in initiating and progressing 
age-related declines in cell function (reviewed in (Titorenko and Terlecky, 2011)).   
1.3.3  Contribution to cellular ROS levels 
Peroxisomal H2O2 is subject to metabolism by organellar catalase, members of 
the peroxiredoxin family, and glutathione peroxidase (presumably in some combination 
with reduced glutathione and a reductase).  As catalase is the most abundant and 
efficient H2O2 metabolizer, most discussions about peroxisomal antioxidant capacities 
focus on the heme-containing tetrameric enzyme. 
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1.4   Catalase 
1.4.1  Overview of the antioxidant enzyme 
Catalase is a tetrameric enzyme found in almost all living tissue.  The iron-
containing enzyme was the first to be isolated in 1937 by Summer and Dounce from 
bovine liver catalase.  It contains four identical 60 kDa subunits each containing a heme 
(prosthetic) group and NADPH in the active center (Scibior and Czeczot, 2006) – and is 
primarily found in peroxisomes.  This critical antioxidant enzyme protects the cell from 
the harmful metabolic by-product hydrogen peroxide, decomposing it to the less 
reactive molecules, water and oxygen.   Catalase is known to be the most abundant and 
efficient hydrogen peroxide metabolizer (Vainshtein BK, 1981).  It is most often studied 
in the context of free radical/reactive oxygen species metabolism and its role as a 
cellular antioxidant (Lardinois, 1995), among others.     
Catalase is an extremely efficient enzyme and is known to have one of the 
highest turnover rates ever described.  One molecule of catalase is capable of 
converting 6 million molecules of hydrogen peroxide into water and oxygen per minute 
(Rahman, 2007 and Mates et al., 1999). 
The enzyme is sensitive to many molecules including cyanide, azide, hydroxyl 
amine, aminotriazole, and mercaptoethanol (Switala and Loewen, 2002).  Their 
mechanism of inhibition includes interacting with catalase’s active-site heme.  Many 
experimental studies use 3-amino-1,2,4-triazole (3-AT) as a tool to inhibit catalase 
(Koepke JI, 2008 and Milton NG, 2001).  3-AT is an irreversible antagonist that 
covalently binds to the active center of the tetrameric form of catalase containing heme 
groups (Putnam CD, 2000). 
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   In addition to catalases ‘catalatic’ activity in which it decomposes hydrogen 
peroxide to water and oxygen, catalase can act ‘peroxidically’ under conditions of low 
hydrogen peroxide concentrations.  This reaction occurs where in the presence of 
hydrogen peroxide and a suitable hydrogen donor (ethanol, methanol, etc.) catalase 
removes the hydrogen peroxide but oxidizes its substrate (Scibior and Czeczot, 2006).  
Thus, catalases’ peroxidatic activity may actually contribute to cellular damage (Koepke 
et al., 2007). 
Because of catalases’ important role in overall cellular detoxification and as the 
major protective enzyme against oxidative damage, our lab has investigated the use of 
a reengineered form of catalase as a potential targeted protein therapeutic described in 
greater detail below. 
There exist individuals whose catalase levels are reduced due to instability of the 
protein or its mRNA; cells from these subjects display an accelerated aging phenotype 
(Wood et al., 2006).  They amass H2O2, possess elevated levels of oxidized proteins 
and damaged DNA, contain functionally compromised peroxisomes and exhibit a 
growth stasis.  Coupled with their altered, largely swollen and amorphous phenotypes, 
these cells could very well be described as senescent except that they do not express 
the histochemical biomarker, senescent-associated β-galactosidase (Wood et al., 
2006).  Similar progeric effects are seen in cells where catalase is deactivated with the 
irreversible inhibitor, 3-amino-1,2,4-triazole (Koepke et al., 2008).  Coupled with 
powerful epidemiological evidence suggesting that the absence of cellular catalase is 
directly correlated with premature onset of age-related disease (Goth and Eaton, 2000; 
8 
 
 
 
Goth and Vitai, 2003) – a strong case emerges for a critical role of the enzyme in 
preventing oxidative stress in cells.   
1.4.2  Catalase, lifespan, and rate of aging 
Catalase received very high profile attention when studies published by Dr. 
Samuel Schriner and coauthors (Schriner et al., 2005; Schriner and Linford, 2006) 
showed that transgenic mice expressing catalase in mitochondria manifest a 20% 
increase in median lifespan and a 10% extension of maximum lifespan.  (Peroxisomally 
targeted catalase showed a more muted effect, which may stem from how the molecule 
was directed to the organelle – a point considered further below.)  Mitochondrial 
catalase delayed aging phenomena in the heart and eyes, reduced H2O2 levels in cells, 
and decreased mitochondrial DNA damage while maintaining mitochondrial function.  
Fitting these results into a simple model is somewhat problematic (Miller, 2005), 
however, it is probably safe to conclude, as the authors do (Schriner et al., 2005; 
Schriner and Linford, 2006), that reduced cellular oxidative stress positively impacts 
longevity.  Another important conclusion drawn from their studies was that mitochondria 
were now seen as both sources of ROS, and targets of their destructive power.    
More recent studies with these mice confirmed that age-associated declines in 
mitochondrial integrity and function were slowed, but also that (muscle) insulin 
sensitivity and lipid content were maintained at more youthful levels (Lee et al., 2010).  
Based on their important findings, the authors speculated that mitochondrial ROS 
damage the organelle and potentiate insulin resistance in the animals – leading 
ultimately to downstream pathologies including a type II diabetes phenotype.   
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 As important as all of this is, we should not lose sight of the fact that normally, 
catalase is not found in the mitochondria – it is a peroxisomal enzyme.  Perhaps, in 
future work, mechanisms could be developed to direct newly introduced/suitably 
expressed catalase, or an appropriate mimetic, to mitochondria.  However, we are a 
long way off from this at present.  What we are closer to, is understanding that a redox-
sensitive interplay exists between mitochondria and peroxisomes – one that catalase 
may play a very important part.  Moreover, unlike mitochondria, peroxisomes may very 
well be druggable targets in a way mitochondria cannot.  The reader is directed to 
(Terlecky and Koepke, 2007) for further analysis of this latter point.  Additional 
discussion of the peroxisome-mitochondria connection is included below – after a brief 
description of an important study linking catalase, caloric restriction, and longevity. 
- - - - 
As a critical antioxidant and one of the most efficient enzymes ever described, 
catalase has had its share of attention from the aging field.  Studies have documented 
that catalase levels decline with age but are maintained or elevated in more long-lived 
species.  One particularly interesting recent study, headed by Dr. Shugo Watabe, 
looked at the effects of caloric restriction in the freshwater animal, the rotifer 
(Brachionus plicatilis) (Kaneko et al., 2011).  Rotifers live, on average, some 8.8 days.  
Calorically restricted animals live 13.5 – an approximately 50% increase in lifespan.  
Rotifers are parthenogenic zooplankton; they reproduce by an asexual process in which 
daughters are genetically identical to their mothers.  The research team asked what 
happened to offspring of ad libitum-fed animals, versus those subjected to a restricted 
diet.  Not unexpectedly, animals from fed mothers displayed a typical (~9.5 day) 
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lifespan, which could be extended to 14.4 days by a calorie limited diet.  Interestingly, 
offspring from calorically restricted mothers lived 12.7 days when not nutritionally 
limited, and 16.8 days when the diet was modified.  A lifespan enhancing trait was 
transmitted, presumably by an epigenetic process, to otherwise genetically identical 
offspring.   
 Dr. Watabe and colleagues identified that activity – it was catalase (Kaneko et 
al., 2011).  The antioxidant enzyme was expressed at higher levels in offspring of 
calorically restricted mothers.  Manganese superoxide dismutase, a powerful 
mitochondrial antioxidant enzyme, showed no such behavior.  Does the increased 
catalase activity protect the organism from oxidative stress and contribute to its 
longevity?  The overwhelming conclusion of this study was that it absolutely does.  Two 
final points regarding this work; first, the research is of interest not only from a rate of 
aging perspective, but it also provides evidence of “transgenerational plasticity” with its 
accompanying “adaptive” potential (Kaneko et al., 2011).  Second, regarding catalase 
and caloric restriction; this work confirms and extends what has already been shown in 
a number of model organisms.  Specifically, levels of the enzyme are increased in cells 
of animals whose caloric intake is limited.   
1.4.3  Catalase supplementation and a peroxisome-mitochondria redox interplay 
 Catalase is progressively mislocalized (to the cytosol) as cells age and approach 
replicative senescence (Legakis et al., 2002; Koepke et al., 2007).  Concomitantly, 
these cells produce ROS, manifest an ever more compromised peroxisomal import 
apparatus, and proliferate the organelle in an apparent attempt to compensate for 
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functional shortfalls.2  As pointed out above, these same phenomena are seen when 
catalase is missing due to protein or message instabilities, or when the enzyme is 
chemically inactivated (Wood et al., 2006; Koepke et al., 2008).  Importantly, restoration 
of peroxisomal catalase through use of a genetically engineered variant of the enzyme, 
called catalase-SKL, delays appearance of senescence markers in aging cells (Koepke 
et al., 2007).  Cellular ROS are reduced and, interestingly, mitochondrial integrity is 
restored.  Specifically, catalase-SKL expression reestablishes mitochondrial membrane 
potential (normally dissipated as cells age (Hagen et al., 1997)) and reduces 
mitochondrial ROS production (normally elevated in senescing cells (Hagen et al., 1997; 
Koepke et al., 2007)). 
 The latter results suggest a redox-sensitive peroxisome-mitochondria interplay is 
at work in cells.  Importantly, this extends evidence of organelle cross-talk and 
functional cooperation previously summarized by Dr. Michael Schrader and colleagues 
(Schrader and Yoon, 2007; Camoes et al., 2009).  With the suggestion of such a 
relationship in mind, it is probably not surprising then, that inactivating catalase with 3-
amino-1,2,4-triazole drives mitochondria to a depolarized (Koepke et al., 2008), ROS-
producing, state (Koepke et al., 2008; Ivashchenko et al., 2011).  Peroxisomal catalase 
is cytoprotective; its absence, mislocalization, or inactivation is progeric on cells.  Which 
begs the question; can the antioxidant enzyme be introduced to cells – and if so, would 
we not expect a significant effect on age-, or oxidative stress-induced cellular 
pathologies? 
                                            
2
 Peroxisome proliferation may also reflect impaired turnover of the organelle.  Chaperone-mediated 
autophagy is compromised with age (Cuervo et al., 2000) ; whether or not autophagic processes directly 
responsible for peroxisome turnover are similarly affected is not clear.  However, see relevant references 
included in Kuilman et al., 2010 and Hubbard et al., 2012 regarding links between cell senescence/aging 
and impaired autophagic pathways.   
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1.4.4  Cell penetrating catalase-SKL 
 Catalase-SKL contains a reengineered peroxisome targeting signal at its carboxy 
terminus.  This enzyme interacts more avidly with the peroxisome import receptor, 
Pex5p (Koepke et al., 2007), and is more efficiently imported into peroxisomes (Koepke 
et al., 2007).  It is important to note that the peroxisome contains a unique mechanistic 
import apparatus as it accommodates fully folded proteins – permitting the organelle to 
be druggable.  The molecule was developed into a protein therapeutic by adding a cell 
penetrating peptide near the amino terminus, along with a polyhistidine tag – used for 
purifying the recombinant enzyme (see Fig. 1.1 schematic).  The following is a brief 
summary of the demonstrated efficacy of the cell penetrating antioxidant enzyme 
(hereafter referred to as CAT-SKL) in a number of cell biological, physiological, and 
pathophysiological contexts.  
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Figure 1.1.  CAT-SKL construct.  See text for additional description.  Image appears in 
Biochim Biophys Acta. 2012 by Giordano, C.R. and Terlecky, S.R.  
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In a human cell model for psoriasis, CAT-SKL reduces tumor necrosis factor-α-
(TNF-α) induced ROS and downstream inflammatory cytokine production (Young et al., 
2008).  In primary explants of human skin, a topically applied hydrogel preparation of 
CAT-SKL reduced ultraviolet light-induced lipid peroxidation by more than 60% as 
compared to a formulation base alone (Terlecky, unpublished).  The molecule, when 
formulated with appropriate excipients including skin penetrating agents, enters (mouse) 
skin and reduces H2O2 levels (Terlecky, unpublished).  Importantly, repeat insult patch 
test results indicate the CAT-SKL hydrogel elicited no “contact sensitization” reactions 
of any kind when applied over ten weeks to human subjects (Terlecky, unpublished). 
 The results in skin may be relevant to radiation dermatitis – a side effect of 
certain cancer treatments.  Collaborative studies conducted at our own institution (Price 
et al., 2009) showed that CAT-SKL inhibited photodynamic therapy-induced apoptosis 
in murine leukemia cells.  In contrast, the catalase inhibitor, 3-amino-1,2,4-triazole, 
potentiated the response.  These studies are important in that they demonstrate a role 
for H2O2 in photodynamic therapy’s pro-apoptotic effects, and suggest that CAT-SKL 
might be beneficial, that is, protective, if applied to tissue adjacent to that undergoing a 
photodynamic therapy-based treatment regimen.  Also, the idea that inhibition of 
antioxidant activity enhances photo- or radiation-killing may have important implications 
for tumor elimination strategies. 
 ROS and resultant oxidative stress are thought to be the main drivers of 
ischemia-reperfusion and hypoxia-reoxygenation injury in the heart.  Our work with a 
neonatal ventricular myocyte model showed CAT-SKL protected cells against these 
injurious events (Undyala et al., 2011).  Coupled with our unpublished evidence that the 
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targeted antioxidant reduces the area of necrosis, as a function of the area at risk, in 
rats exposed to a 30 minute ischemic event – the suggestion is that CAT-SKL may 
represent a potentially powerful new therapeutic modality for the protection of heart 
tissue from oxidative damage. 
 In two other disease models included in chapters below, CAT-SKL reduced the 
toxic effects of soluble β-amyloid peptides on cultured embryonic rat 
hippocampal/cortical neurons, and sensitized otherwise resistant breast cancer cells to 
the tyrosine kinase inhibitor, gefitinib (Giordano et al., 2012).  With respect to the 
former, these studies corroborate work from Dr. Nibaldo Inestrosa and colleagues 
(Inestrosa et al., 2013) showing a protective role for peroxisomes and peroxisomal 
catalase in β-amyloid induced neurodegeneration. 
 Non-SKL derivatized cell penetrating catalase molecules have also been 
employed in a number of systems including those designed to have the enzyme enter 
skin (Jin et al., 2001), to modulate ischemia-reperfusion injury in the heart (Huang et al., 
2011), and to identify H2O2-dependent signaling pathways (Watanabe et al., 2003).  
Regarding this last point; our unpublished work looking at gene arrays and the effects of 
CAT-SKL suggest elimination of CAT-SKL-sensitive ROS may reintroduce cell cycle 
checkpoint control in senescing cells.  The fact that catalase-SKL delays appearance of 
senescence markers (Koepke et al., 2007), whereas mislocalized catalase is associated 
with the senescent state (Legakis et al., 2002), is certainly consistent with these 
preliminary results.  
 One large omission from these completed or ongoing studies is a longitudinal 
analysis, in animals, of the effects of supplementing peroxisomal catalase.  This could 
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be accomplished, for example, in a transgenic background with catalase-SKL as the 
introduced exogenous gene.  Catalase-SKL would be the preferred transgene to assure 
more robust peroxisome trafficking with age (Legakis et al., 2002; Koepke et al., 2007).  
An alternative approach could involve regular (intraperitoneal or subcutaneous) 
administration of the recombinant protein, CAT-SKL.  There are advantages and 
disadvantages of both approaches including the considerable time and expense of the 
requisite protocols.  However, generation of these animals would permit not only a 
longevity study, but also an evaluation of their disease resistance after appropriate 
crosses or physiological perturbations.  One could reasonably expect such animals to 
delay onset of age-related degenerative disease and perhaps even live longer than 
control animals.  Of course, this is simply conjecture at this point.    
- - - - 
 Some final thoughts on catalase.  One recurring question is why does catalase 
possess a weak perosixome targeting signal – a property of the enzyme seen across 
evolutionary diverse organisms.  Is it that a kinetically delayed import process permits 
proper folding and assembly of constituent protein and heme subunits?  Is it, as 
speculated previously (Terlecky et al., 2006), that import of the enzyme is sufficiently 
robust in young cells/organisms and that the compromised compartmentalization seen 
in aging occurs after reproductive age and cannot be selected against evolutionarily?  Is 
it that advantages exist for catalase to be partially localized to the cytosol?  With respect 
to the latter, consider that during red blood cell development, precursor cells eliminate 
intracellular organelles (Gronowicz et al., 1984).  Perhaps a partial cytosolic localization 
preserves antioxidant capacities in the mature red blood cell.  
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 Lastly, overexpression of catalase in and of itself is not a panacea.  Several 
studies over the years have shown that enhanced levels of antioxidant enzymes or 
mimetics may actually sensitize cells to toxic insult – not insulate them.  As pointed out 
recently by Dr. Epstein and colleagues (Li et al., 2006), catalase overexpression in β-
cells of the mouse pancreas actually sensitizes the animal to diabetes.  Their 
explanation, and one supported by an emerging consensus, is that non discriminate 
metabolism of ROS in cells may very well be detrimental.  ROS in small amounts 
(~bursts) and in particular locations, represent critical components of signaling 
cascades and related communication networks.  They cannot be indiscriminately 
metabolized by broad-acting, non-targeted antioxidant strategies.   
 1.5  Conclusions and perspectives 
 Fig. 1.2 depicts a schematized version of two cells; a young cell at early 
passage, and an old cell at, or near, replicative senescence.  The albeit simplified 
rendering reveals several important points.  First, ROS can emanate from peroxisomes 
and mitochondria – even in young cells.  The idea has emerged that these organelles 
might release a small but continuous stream of the reactive molecules to maintain 
readiness of the antioxidant response as well as to appropriately regulate cell signaling, 
cell communication, and network integrating activities.  The sum total of these 
“hormetic” or “preconditioning” pathways may very well be the anti-aging programs 
reviewed in (Titorenko and Terlecky, 2011).  However, the perspective of this article has 
been on what happens when these ROS are produced beyond a specific threshold – 
when they begin to amass and damage cell constituents and to initiate more pro-aging 
programs.  As we depict in the figure, peroxisomes and  
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mitochondria release ROS – with each organelle affected by the process.  Peroxisomes 
proliferate with age (Legakis et al., 2002; Ivashchenko et al., 2011), as do mitochondria 
(Lee et al., 2002).  Peroxisomes are impaired in their ability to import their constituent 
enzymes, (Legakis et al., 2002; Ivashchenko et al., 2011), and begin to manifest 
functional deficits.  Mitochondrial functionality is also reduced – for example, their ability 
to maintain a membrane potential is impaired (Hagen et al., 1997; Koepke et al., 2007).  
It should be noted that mitochondrial DNA is exquisitely sensitive to oxidative stress and 
an accumulation of mutations is seen as a major driver of mammalian aging (Kujoth et 
al., 2005).  
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Figure 1.2.  Schematic representation of cellular senescence and its impact on 
organelles, ROS production, and cell architecture.  A.  As described in the text, early 
passage/young cells contain peroxisomes and mitochondria that are fully capable of 
processing ROS produced in situ.  B.  Late passage/old cells are less able to carry out 
these processes and amass the reactive metabolites.  As a consequence they manifest 
changes to organelles and the cell itself as illustrated. Image appears in Biochim 
Biophys Acta. 2012 by Giordano, C.R. and Terlecky, S.R.  
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It is nearly impossible to tease out where ROS begin and end in the cell.  Is H2O2 
produced first in the peroxisome and then “efficiently” diffused to mitochondria where it 
attacks perhaps more delicate components of the electron transport chain?  Or does 
trafficking of the reactive metabolite and its downstream derivatives originate in 
mitochondria – the cell’s “fiery furnace”?  Continuing with unanswered questions, only 
little has been included here about the precise targets of organellar, or otherwise 
produced, ROS.  What signaling pathways, communication networks, and pro- or anti-
aging programs are actually modulated by these reactive molecules?  It has been 
questioned whether aging represents a sort of end point with respect to oxidative 
damage to cellular constituents – or is it the culmination of an as yet undefined, 
development program?  What is clear is that cellular ROS – and H2O2  in particular, is as 
suggested by Drs. Teng Lu and Toren Finkel, a “primary mediator” of in vitro 
senescence and in vivo aging (Lu and Finkel, 2008).  Echoing the importance of H2O2, 
Drs. Michael Lisanti, Federica Sotgia and coauthors suggest the molecule, via its ability 
to “drive accelerated aging”, constitutes a major player in the etiology of inflammation 
and cancer (Lisanti et al., 2011).   
 What has long been ignored when considering the nexus of oxidative stress, 
aging, and the development of degenerative disease is a role for peroxisomes.  
Although the extent of this role is yet to be completely defined – it is quite clear that 
peroxisomes will continue to emerge as critical contributors to these processes.   
1.6  Overview of chapters 
 In the research described below, we investigate for the first time, a broader 
approach to disease treatment – focusing on the peroxisome and the restoration of 
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organellar catalase.  We employ a novel antioxidant enzyme, CAT-SKL, which we show 
effectively targets appropriate oxidative stress and accompanying inflammatory 
mediators – the precise driving forces established for many degenerative diseases.  The 
idea that metabolizing ROS may play a role in reducing toxic insult associated with 
disease models is not new; however, implicating peroxisomes as critical contributors to 
such defenses is. 
 As an overarching hypothesis then, we suggest that restoring cellular 
oxidative equilibrium with a peroxisomally targeted antioxidant will have 
protective effects against the cellular pathologies associated with cancer, 
diabetic retinopathy and amyloid-beta exposure.  The work presented in the 
following chapter shows that in an in vitro breast cancer model, CAT-SKL sensitizes 
otherwise resistant human breast cancer cells to the tyrosine kinase inhibitor, gefitinib 
(Giordano et al., 2012).  In chapter 3, the enzyme’s ability to thwart early retinal 
dysfunction associated with the diabetic state in vivo is chronicled.  These results are 
particularly important because they suggest an ability of CAT-SKL to cross the blood-
retinal barrier – a boundary considered an extension of the blood brain barrier.  With our 
evidence of the protein biologic efficacy in a neural setting, we asked whether or not it 
would thwart amyloid-beta-induced toxicity (chapter 4) in neuronal cell cultures.  Our 
results show that it does, and we have embarked on experiments in an in 
vivo/preclinical setting to confirm and extend these observations.    The data support an 
overall conclusion that the peroxisome is a major site of cellular ROS metabolism and 
critical metabolic pathway control.   
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CHAPTER 2:  A targeted enzyme approach to sensitization of tyrosine kinase 
inhibitor-resistant breast cancer cells 
 
Published:  Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, 
Terlecky SR, and Boerner JL (2012) A targeted enzyme approach to sensitization of 
tyrosine kinase inhibitor-resistant breast cancer cells Experimental Cell Research 
318:2014-2021. 
2.1  Abstract 
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
(TKI) of potential use in patients with breast cancer. Unfortunately, in clinical studies, 
gefitinib is often ineffective indicating that resistance to EGFR inhibitors may be a 
common occurrence in cancer of the breast. EGFR has been shown to be 
overexpressed in breast cancer, and in particular remains hyperphosphorylated in cell 
lines such as MDA-MB-468 that are resistant to EGFR inhibitors. Here, we investigate 
the cause of this sustained phosphorylation and the molecular basis for the 
ineffectiveness of gefitinib. We show that ROS, known to damage cellular 
macromolecules and to modulate signaling cascades in a variety of human diseases 
including cancers, appear to play a critical role in mediating EGFR TKI-resistance. 
Furthermore, elimination of these ROS through use of a cell-penetrating catalase 
derivative sensitizes the cells to gefitinib. These results suggest a new approach for the 
treatment of TKI-resistant breast cancer patients specifically, the targeting of ROS and 
attendant downstream oxidative stress and their effects on signaling cascades. 
 
30 
 
 
 
2.2  Introduction 
Epidermal growth factor receptors (EGFR) are part of the ErbB family (or 
epidermal growth factor family) composed of receptor tyrosine kinases (Jorissen et al., 
2003; DeYulia and Carcamo, 2005). EGFR is activated by binding of its ligand, 
epidermal growth factor (EGF), leading to dimerization of the receptor and stimulation of 
intracellular kinase activity. Upon dimerization, autophosphorylation occurs, eliciting 
downstream signaling cascades involved in cell survival and increased cellular 
proliferation (Jorissen et al., 2003; DeYulia and Carcamo, 2005). In some breast 
cancers, EGFR is overexpressed, although tyrosine kinase inhibitors targeting EGFR 
(EGFR TKIs) have yet to demonstrate uniform efficacy in the clinic (Tan et al., 2004; 
Baselga et al., 2005). Interestingly, in breast cancer cell lines resistant to EGFR TKIs, 
EGFR-phosphorylation is often maintained at high levels in the presence of the TKI 
(Mueller et al., 2008), indicating that EGFR may continue to signal to promote cell 
growth and survival. This is supported by evidence that targeted knockdown of EGFR 
expression can decrease growth and survival of EGFR TKI-resistant breast cancer cells 
(Irwin et al., 2011). 
Mechanisms of EGFR inhibitor resistance in all cancers are the focus of many 
researchers and specific insights have been realized (Wheeler et al., 2010). The most 
common mutation known to occur in EGFR is a truncation resulting in a deletion of 
exons 2-7; the resultant molecule is known as EGFRvIII. Importantly, this mutation 
occurs in 86% of gliomas and is thought to mediate resistance to EGFR inhibitors (Lo, 
2010). Resistance mechanisms involve upregulation of parallel signaling tyrosine kinase 
receptors including insulin like growth factor receptor (IGF-1R), vascular endothelial 
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growth factor (VEGFR), and Met as well as the constitutive activation of downstream 
molecules including Akt and MAPK (reviewed in (Wheeler et al., 2010)). These EGFR 
TKI resistance pathways circumvent EGFR TKIs by the activation of additional signaling 
pathways. 
An additional mechanism to explain the somewhat disappointing overall 
response of breast tumors to EGFR TKIs is the possibility that the EGFR still has the 
ability to signal in the absence of innate EGFR kinase activity. Indeed, it has been 
clearly demonstrated that additional tyrosine kinases can phosphorylate the EGFR 
independent of ligand. For example, c- Src phosphorylates a kinase-impaired EGFR on 
its autophosphorylation sites as well as several additional tyrosines (Stover et al., 1995; 
Amos et al., 2005). In addition, another EGFR family member, HER2, also has the 
ability to phosphorylate the EGFR on its autophosphorylation sites (Spivak-Kroizman et 
al., 1992). Furthermore, it has been shown that a point mutation in the HER2 kinase 
domain results in constitutive phosphorylation of EGFR in the presence of EGFR TKIs 
(Wang et al., 2006). These data indicate that, even without the EGFR kinase activity, 
phosphorylation of the EGFR may occur to promote cell growth and survival pathways. 
The EGFR TKI-resistance seen in certain cancer cells may result from an ROS-
induced inactivation of an EGFR-associated tyrosine phosphatase (Chen et al., 2006). 
In this context, a role for ROS and accompanying oxidative stress in the initiation and 
progression of breast cancer has been suggested and variously supported in a number 
of studies (Benhar et al., 2002; Bollig-Fischer et al., 2010; Liou and Storz, 2010). 
Oncogenes with tyrosine kinase activity, including HER2 in breast cancer cells, can 
induce the upregulation of cellular/oncogenic ROS and influence the metabolic 
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transformation of cancer cells (Lee et al., 1998). Furthermore, the cancer cell redox 
state can affect the function of oncogenic kinases (Benhar et al., 2002). 
In order to examine the potential link between cellular ROS and EGFR TKI-
resistance, we employed a targeted antioxidant enzyme, CAT-SKL, to reduce oxidant 
levels in breast cancer cell line models expressing high levels of ROS and EGFR. Our 
results indicate that CAT-SKL sensitizes previously resistant MDA-MB-468 cells to the 
anti-cancer effects of the EGFR-targeted TKI, gefitinib. EGFR inhibitors are of great 
potential value as therapies in breast cancer models; resistance presents a major 
challenge to this treatment modality. CAT-SKL, a H2O2 metabolizing protein therapeutic 
shown to be effective in a number of in vitro and pre-clinical indications (Koepke et al., 
2007; Young et al., 2008; Undyala et al., 2011), thus represents a potentially powerful 
new means of combating this devastating disease. 
2.3  Results 
2.3.1   EGFR remains tyrosine phosphorylated in breast cancer cells resistant to TKIs 
Despite EGFR overexpression in more than 30% of breast cancers, clinical trials 
using EGFR targeted therapies have failed to show a significant benefit in disease-free 
and overall survival (Tan et al., 2004; Baselga et al., 2005). Breast cancers 
overexpressing EGFR have a poor clinical outcome, therefore emphasizing a need to 
more effectively target EGFR in these cancers. To examine the effects of gefitinib on 
EGFR phosphorylation, we cultured two human breast cancer cell lines in the presence 
of the TKI. In SUM149 cells, phosphorylation of EGFR at tyrosine 1068 was reduced in 
response to gefitinib, whereas EGFR phosphorylation at tyrosine 1068 in MDA-MB-468 
33 
 
 
 
cells was unaffected (Fig. 2.1A). Inhibitory growth curves further document the 
sensitivity of SUM149 cells to gefitinib (IC50 values of 6.8 μM for SUM149 cells and 
14.1 μM for the MDA-MB-468 cells (Fig. 2.1B; dotted lines = 95% confidence intervals)). 
We previously documented this trend of EGFR tyrosine phosphorylation in the presence 
of gefitinib correlating with resistance to effects on viability by EGFR TKIs and 
established the inhibition of EGFR kinase activity with gefitinib ((Mueller et al., 2008); 
Supplementary figure a2.1). Here we further demonstrate that in MDA-MB-468 cells, 
autophosphorylation specifically at tyrosine 1068 is regulated independently of EGFR 
kinase activity. 
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Figure 2.1.  EGFR phosphorylation and TKI sensitivity of breast cancer cell lines. 
(A) SUM149 and MDA-MB-468 cells were treated with 0.5 μM gefitinib for 30 minutes. 
Lysates were then prepared, separated by SDS-PAGE, and immunoblotted using anti-
EGFR or anti-pY1068-EGFR antibodies. Control = vehicle control treated; gef = gefitinib 
treated; IB = immunoblot. (B) SUM149 or MDA-MB-468 cells were cultured with 
increasing concentrations of gefitinib for 72 hours. MTT colorimetric assays were 
performed to assess cell viability. Fraction of surviving cells was determined and IC50 
values were calculated from sigmoidal dose response curves. 95% confidence intervals 
for each curve appear as dashed lines. Log [geftinib] = log of each dose of gefitinib used 
in M. Image appears in Experimental Cell Research. 2012 by Giordano, CR et al.  
Figure contributed by Boerner JL.    
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2.3.2  Elevated ROS levels in TKI-resistant breast cancer cells 
Deregulation of EGFR tyrosine phosphorylation could be elevated by ROS 
through any number of distinct mechanisms. Therefore, we sought to determine the 
baseline level of ROS in MDA-MB-468 cells compared to a gefitinib-sensitive breast 
cancer cell line, in this case, SUM149. Using a DCF-fluorescence assay that measures 
total intracellular ROS, we found that oxidant levels in MDA-MB-468 cells were nearly 
10 fold higher when directly compared to the SUM149 cells (Fig. 2.2; black bars). To 
determine if ROS production was altered by gefitinib treatment, we incubated both cell 
lines with 0.5 μM gefitinib for 30 minutes. Interestingly, ROS production was not altered 
by gefitinib in either cell line (Fig. 2.2; white bars). These results led us to consider that 
ROS production in MDA-MB-468 cells may regulate EGFR tyrosine phosphorylation and 
subsequent biological resistance to gefitinib. 
2.3.3  EGFR tyrosine phosphorylation is regulated by reactive oxygen 
To examine the role of ROS in modulating EGFR tyrosine phosphorylation, we 
examined the process in cells treated with the antioxidant, N-acetyl cysteine (NAC), or 
the oxidizer, H2O2, as seen in Fig. 2.3A and 2.3B (immunoblots quantified in 
Supplementary figures a2.2A and a2.2B). Quenching ROS decreased EGFR tyrosine 
phosphorylation in gefitinib-treated MDA-MB-468 cells. In contrast, enhancing oxidative 
stress in SUM149 cells with H2O2 rendered them unable to decrease EGFR tyrosine 
phosphorylation.  
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Figure 2.2.  ROS levels are elevated in TKI-resistant breast cancer cells.  SUM149 
and MDA-MB-468 cells were treated with 0.5 μM gefitinib for 30 minutes.  ROS 
production was measured using the fluorescent dye, 2’,7’-dichlorofluorescin diacetate 
(DCF-DA), which measures reactive oxygen on a per cell basis. The percentage of cells 
positive for ROS was determined from an average of three independent experiments. 
Control = vehicle control treated; gef = gefitinib treated.  Image appears in Experimental 
Cell Research. 2012 by Giordano, CR et al.  Figure contributed by Boerner, JL.    
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Figure 2.3.  EGFR tyrosine phosphorylation is regulated by reactive oxygen. (A) 
MDA-MB-468 cells were treated with 0.5 μM gefitinib for 30 minutes and/or 50 mM N-
acetyl cysteine for the last 10 minutes as indicated.  Cell lysates were 
immunoprecipitated using anti-EGFR antibodies and immunoblotted with anti-EGFR or 
anti-phosphotyrosine antibodies.  (B) SUM149 cells were treated with 0.5 μM gefitinib 
and/or 5 mM H2O2.  Cell lysates were immunoprecipitated using anti-EGFR antibodies 
and immunoblotted with anti-EGFR or anti-phosphotyrosine antibodies.  Control = 
vehicle control treated; gef = gefitinib treated; NAC = N-acetyl cysteine treated; IB = 
immunoblot; IP = immunoprecipitation.  Image appears in Experimental Cell Research. 
2012 by Giordano, CR et al.  Figures contributed by Boerner,JL.    
Figure 2.3A 
Figure 2.3B 
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These results support the model that in breast cancer cells, ROS modulates 
EGFR phosphorylation in the presence of an EGFR TKI. 
2.3.4  CAT-SKL transduction of MDA-MB-468 cells 
NAC was abandoned as a potential therapeutic due to its toxicity in our long-term 
growth assays (data not shown). Instead, we employed a novel cell-penetrating 
catalase derivative, called CAT-SKL (Wood et al., 2006; Terlecky and Koepke, 2007; 
Price et al., 2009; Undyala et al., 2011). This molecule is designed to enter cells and, by 
virtue of a modified targeting signal, efficiently traffic to peroxisomes. Once there, it 
metabolizes H2O2 produced both within the organelle, as well as elsewhere in the cell, 
and restores, to varying extents, oxidative balance in cells (Wood et al., 2006; Terlecky 
and Koepke, 2007; Price et al., 2009; Undyala et al., 2011). This targeted enzyme 
approach has shown efficacy in a number of cellular and preclinical indications and 
works, at least in part, by controlling inflammatory processes (Young et al., 2008; 
Undyala et al., 2011). In order to demonstrate transduction of MDA-MB-468 breast 
cancer cells, we biotinylated CAT-SKL and tracked its entry into the cells (Fig. 2.4A). 
MDA-MB- 468 cells were incubated with 100 nM CAT-SKL for 1 to 4 hours. Protein 
lysates were isolated and blotted with streptavidin-alkaline phosphatase labeled 
antibodies. Importantly, biotinylated- CAT-SKL was detected inside the MDA-MB-468 
cells after 1 hour of incubation (Fig. 2.4B). 
2.3.5  CAT-SKL reduces ROS in MDA-MB-468 cells 
Although we have shown that CAT-SKL was able to enter MDA-MB-468 cells, we 
needed to confirm that the enzyme was able to quench ROS in this breast cancer 
model. To accomplish this, MDA-MB-468 cells were incubated with 1 μM CAT-SKL for 4 
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hours and ROS production was determined by measuring DCF-fluorescence (Figs. 2.5A 
and 2.5B). Importantly, CAT-SKL was able to decrease ROS production by about 48% 
in MDA-MB-468 cells (Fig. 2.5B).  In addition, when H2O2 specifically was measured 
using an Amplex® Red based assay, a 21% decline was seen (Fig. 2.5C). Taken 
together, these experiments demonstrate that CAT-SKL is able to enter MDA-MB-468 
cells and significantly reduce ROS production. 
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Figure 2.4.  CAT-SKL transduction of MDA-MB-468 cells.  (A)  CAT-SKL was 
biotinylated as described (16-18).  CAT-SKL (“C”) and CAT-SKL after biotinylation (“CB”) 
were dot-blotted onto nitrocellulose and probed with anti-catalase antibodies (and 
alkaline phosphatase secondary antibodies) or streptavidin alkaline phosphatase as 
indicated.  (B)  MDA-MB-468 cells were incubated with biotinylated CAT-SKL (100 nM) 
for 0, 1, 2, and 4 hours as indicated.  Cells were then washed, harvested, and blotted 
with streptavidin-alkaline phosphatase.  Arrow indicates migration of biotinylated-CAT-
SKL. Image appears in Experiment Cell Research. 2012 by Giordano, CR et al.  Figures 
contributed by Giordano, CR.    
 
 
 
Figure 2.4A 
Figure 2.4B 
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To determine if H2O2 decreased viability of the MDA-MB-468 cells, 1 mM H2O2 
was added to the cells for 2 hours and the effects on cell viability were assessed by the 
MTT assay, a measure of mitochondrial reductase activity. As expected, H2O2 
decreased viability in the MDA-MB-468 cells by almost 50% (Fig. 2.5D; black bars). In 
contrast, in cells pretreated with CAT-SKL, exogenously added H2O2 was largely 
without effect (Fig. 2.5D). CAT-SKL treatment alone had no effect on cell viability, 
demonstrating that the enzyme is not toxic to human breast cancer cells. Essentially 
similar results were obtained when trypan blue (dye) exclusion assays were employed 
to directly determine cell viability (Fig. 2.5E). 
2.3.6  CAT-SKL sensitizes MDA-MB-468 cells to gefitinib 
To determine if CAT-SKL reduction of ROS production is sufficient to reduce 
EGFR tyrosine phosphorylation in the presence of 1 μM gefitinib, we measured EGFR 
phosphorylation at tyrosine 1068 in MDA-MB-468 cells after a 4 hour treatment with 1 
μM CAT-SKL. Once again, EGFR tyrosine phosphorylation was not reduced with 
gefitinib treatment; however, co-treatment with gefitinib and CAT-SKL resulted in an 
almost complete loss of EGFR tyrosine phosphorylation at 1068 (Fig. 2.6A; left panel). 
This is in contrast to the treatment of SUM149 cells with gefitinib and CAT-SKL. 
Specifically, EGFR tyrosine phosphorylation is abrogated with gefitinib treatment and 
actually modestly inhibited by CAT-SKL itself (Fig. 2.6A; right panel).  These data 
suggest that the general phenomenon of inhibiting ROS production in cancer cells may 
decrease tyrosine phosphorylation of key pro-growth and survival proteins. 
To determine if CAT-SKL could sensitize MDA-MB-468 cells to the anti-
proliferation effects of gefitinib, we treated cells with vehicle or 1 μM gefitinib in the 
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presence or absence of 1 μM CAT-SKL in a 7 day proliferation assay. MDA-MB-468 
cells continued to proliferate with 1 μM gefitinib or 1 μM CAT-SKL treatment alone (Fig. 
2.6B; triangles). However, co-treatment of MDA-MB-468 cells with gefitinib and CAT-
SKL decreased cell proliferation by nearly 50% (Fig. 2.6B; left panel; diamonds). This 
decrease in proliferation was statistically significant and provides evidence, for the first 
time, of a targeted antioxidant enzyme sensitizing cancer cells to a TKI. Taken together, 
these data suggest that CAT-SKL may represent a new therapeutic approach for the 
treatment of EGFR TKI-resistant breast cancers. 
Previously we have shown that SUM149 cells are sensitive to EGFR inhibitors 
including gefitinib (Figure 2.1B; 2.3). Here we demonstrate that gefitinib treatment 
decreases cell proliferation by 50% in the SUM149 cells (Fig. 2.6B; right panel). As with 
the MDA-MB-468 cells, CAT-SKL alone failed to inhibit cell proliferation in the SUM149 
cells. However, combining gefitinib and CAT-SKL produced an additional 25% decrease 
in cell proliferation compared to gefitinib treatment alone (Fig. 2.6B; right panel). Taken 
together, these data suggest that for breast cancers that express high levels of EGFR 
and ROS, a combination antioxidant and TKI treatment strategy may elicit a greater 
effect than, or overcome resistance to, EGFR-targeted TKI therapy 
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Figure 2.5A 
Figure 2.5B and C 
Figure 2.5D and E 
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Figure 2.5.  Effect of CAT-SKL on ROS levels in MDA-MB-468 cells.  (A) Cells were 
pretreated or not (“UT”) with CAT-SKL (1 μM) for 4 hours and then examined for the 
presence of ROS using DCF-DA (25 μM).  The accompanying histogram represents 
MetaMorph®-based quantification of the cellular fluorescence intensities seen in the 
ROS images.  (B)  Cellular fluorescence intensities from three experiments (including 
the one shown in (A)) were pooled and normalized to the untreated control value 
(arbitrarily set at 100) to permit comparison.  Results presented are the mean  1 SD.  
(C)  H2O2 was specifically measured employing the Amplex
® Red Reagent (10-acetyl-
3,7-dihydroxy-phenoxazine).  The decline is statistically significant; *p-value < 0.01.  
(D,E) MDA-MB-468 cells were pretreated with CAT-SKL (1 μM) for 4 hours and then 
challenged with H2O2 for 2 hours (1 mM).  Cell viability was determined either using the 
water soluble tetrazolium cell proliferation assay (WST-1) (D), or by quantitative trypan 
blue exclusion assays (E). Image appears in Experimental Cell Research. 2012 by 
Giordano, CR et al.  Figures contributed by Giordano, CR.    
 
 
 
 
Figure 2.6A 
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Figure 2.6.  CAT-SKL decreases EGFR tyrosine phosphorylation in the presence 
of gefitinib and sensitizes MDA-MB-468 cells to the TKI.  (A) MDA-MB-468 and 
SUM149 cells were incubated with 1 μM CAT-SKL for 4 hours followed by 30 minutes 
with 1 μM or 0.5 μM gefitinib, respectively.  Cell lysates were prepared, separated by 
SDS-PAGE, and immunoblotted using anti-EGFR, anti-pY1068-EGFR, anti-pMAPK, or 
anti-β-actin antibodies.  (B) MDA-MB-468 and SUM149 cells were treated with 1 μM or 
0.5 μM gefitinib, respectively, 1 μM CAT-SKL, or the combination for 7 days.  Cells were 
counted on days 1, 4 and 7 as described in materials and methods.  Growth curves 
were plotted over time. * p-value = 0.05. Image appears in Experimental Cell Research. 
2012 by Giordano, CR et al.  Figures contributed by Boerner, JL.    
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2.4  Discussion 
In this report we have provided evidence of a role for ROS production in 
mediating resistance to EGFR inhibitors through maintenance of EGFR tyrosine 
phosphorylation.  Specifically, we found that inhibiting ROS production using a novel 
inhibitor of H2O2 production, CAT-SKL, sensitized resistant MDA-MB-468 breast cancer 
cells to EGFR kinase inhibition by gefitinib. In doing so, EGFR tyrosine phosphorylation, 
and cell proliferation were reduced. As EGFR inhibitors have yet to show consistent 
value in the clinical treatment of breast cancer, these data provide striking evidence for 
the efficacy of a combination of CAT-SKL and gefitinib in the treatment of EGFR 
expressing tumors. 
How CAT-SKL elicits its effect remains to be further investigated, but in light of 
our observations that CAT-SKL treatment has a role in attenuating EGFR 
phosphorylation, a plausible mechanistic explanation may involve CAT-SKL-dependent 
reactivation of a phosphatase (PTP) that targets the EGFR. It is known that PTPs 
contain an active cysteine that is required for phosphorylation and that ROS modify this 
site (reviewed in (Tonks, 2006)). Inhibition of ROS production by antioxidants has been 
shown to “reactivate” tyrosine PTPs; including PTP1B, TCPTP, SHP2, SHP1, CD45, 
PTPκ, and PTP-PEST (Tonks, 2006). Importantly, PTP1B, SHP1, and PTPκ have been 
shown to dephosphorylate EGFR. In addition, SHP1 and PTPκ have been implicated as 
tumor suppressors, implying that loss of the function of these PTPs promotes cancer 
progression. Future work will address the hypothesis that downregulation of ROS by 
CAT-SKL treatment can reverse PTP inactivation and thus allow for dephosphorylation 
of EGFR, and re-establishment of sensitivity to gefitinib. 
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The work of others has established that dysregulated ROS 
production/metabolism plays a crucial role in many human diseases, including cancer 
(Benhar et al., 2002; Liou and Storz, 2010). Furthermore, ROS have been linked to 
aberrant EGFR phosphorylation resulting in modifications of downstream signaling 
cascades. Our work here has shown that treatments with antioxidants such as NAC 
were able to reduce ROS and potentiate the effects of gefitinib on EGFR 
phosphorylation. However, when growth curves were performed with NAC, cell viability 
was compromised, suggesting it is a poor clinical option for breast cancer patients. Our 
results indicate that transduced CAT-SKL was able to significantly reduce cellular ROS 
and gefitinib-sensitize otherwise resistant breast cancer cells that express high levels of 
ROS without compromising cell viability. Breast cancer treatment is limited for certain 
patients due to insensitivity to EGFR TKIs. Furthermore, constitutively active EGFR 
phosphorylation is a common characteristic of many breast cancers.  Reducing ROS 
production with a safe, targeted enzyme approach employing CAT-SKL may represent 
a new treatment modality for a deadly disease. 
2.5  Materials and Methods 
Cell culture.  SUM149 cells were maintained in Ham’s F-12 supplemented with 5% 
FBS, 1 μg/mL hydrocortisone, and 5 μg/mL insulin. MDA-MB-468 cells were grown in 
DMEM supplemented with 10% FBS. Both cell lines were cultured with 2.5 μg/mL 
amphotericin B and 25 μg/mL gentamicin. For vehicle control treated cells, dimethyl 
sulfoxide was added at 0.1% final concentration. 
SDS-PAGE/Immunoblotting.  Lysates were prepared from the indicated cells in 
CHAPS lysis buffer (10 mM CHAPS, 50 mM Tris-pH 8.0, 150 mM NaCl, and 2 mM 
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EDTA with 10 μM NaOVa and 1X protease inhibitor cocktail (EMD Biosciences, 
Philadelphia, PA)). For immunoblotting, 10 μg of protein lysates were separated by 
SDS-PAGE and transferred to Immobilon P. Membranes were blocked in either 5% 
nonfat dry milk or 5% BSA for 1 hour at 25°C or 5% BSA. Primary antibodies utilized in 
this study include: anti-EGFR and anti-pY1068 EGFR from Cell Signaling (Danvers, 
MA); anti-pMAPK and anti-actin from Sigma (St. Louis, MO); and anti-pTyrosine from 
Invitrogen (Carlsbad, CA). Anti-mouse and anti-rabbit IgG-HRP was used from Cell 
Signaling and enhanced chemiluminescence (ECL) reagents were from GE Healthcare 
Life Sciences (Piscataway, NJ). Experiments were repeated at least three times.  
Dot blot analyses were performed with streptavidin alkaline-phosphatase 
(1:1000) or anti-catalase antibodies (1:4000) and goat anti-rabbit-alkaline-phosphatase 
(1:5000) and developed with the NBT/BCIP color development substrate (Thermo 
Scientific). Protein transduction was performed as follows; 100 nM of biotinylated CAT-
SKL was added for 0, 1, 2, and 4 hours, cells were washed with PBS, and harvested 
directly into standard 2X sample buffer. Proteins were separated by 10% SDS-PAGE, 
and then transferred to a nitrocellulose membrane and blocked for 1 hour in 5% nonfat 
dry milk in Tween-containing, tris buffered saline. Membranes were probed with anti-
streptavidin alkaline phosphatase (1:1000) and developed with NBT/BCIP. 
Biotinylation of CAT-SKL.  CAT-SKL containing an 11 arginine peptide transduction 
domain and a modified peroxisomal targeting signal was expressed, purified, and 
biotinylated as described in (Terlecky et al., 2001; Terlecky, 2002; Koepke et al., 2007; 
Young et al., 2008). 
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Cell viability and cell growth assays.  For testing cell viability, two approaches were 
employed; enzymatic assays that measure metabolic activity and a dye-exclusion assay 
that distinguishes live from dead cells. For the generation of IC50 curves, 1,000 MDA-
MB-468 or SUM149 cells per well were incubated for 72 hours with various 
concentrations of gefitinib (dissolved in dimethyl sulfoxide). At this point, cell viability 
was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), as per manufacturer’s protocol. For the sensitivity to H2O2 experiments, cells 
were plated at 400,000 cells per well, pretreated with CAT-SKL (1 μM) for 4 hours, and 
challenged with H2O2 (1 mM) for 2 hours. MDA-MB-468 cell viability was determined 
using the water soluble tetrazolium cell proliferation assay (WST-1) from Millipore 
following the manufacturer’s protocol. For the latter, 200,000 cells, pretreated with CAT-
SKL and challenged with H2O2 as described above, were incubated with 0.2% trypan 
blue (final concentration) for 3-5 minutes and the percentage of non-viable (blue) cells 
were determined microscopically with a hemocytometer.  
Growth assays were performed by plating MDA-MB-468 or SUM149 cells in 
triplicate in 6-well plates at 35,000 cells per well (day 0). The next day, and every other 
day thereafter for seven days, the cells were treated with 0.1% dimethyl sulfoxide 
(vehicle control), or gefitinib, and/or CAT-SKL at the indicated dosages. The number of 
cells was determined using a Coulter counter on days 1, 4, and 7. Each experiment was 
repeated at least three times. 
Measurement of ROS.  H2O2 measurements were performed using the Amplex® Red 
Hydrogen Peroxide/Peroxidase Assay Kit from Molecular Probes® following the 
manufacturer’s protocol. After treatment with 1 μM CAT-SKL for 4 hours at 37°C, cells 
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were washed twice with Hank’s balanced salt solution, harvested in the Amplex® Red 
reagent/horse radish peroxidase working solution, incubated at room temperature for 30 
minutes, and fluorescence was measured on a microplate reader (excitation 530 nm 
and emission 590 nm). 2’,7’-dichlorofluorescin diacetate (DCF-DA) was used as 
previously described (Legakis et al., 2002); live cells were imaged for ROS production. 
Briefly, cells were treated with or without 1 μM CAT-SKL for 4 hours, washed twice with 
Hank’s balanced salt solution and incubated for 10 minutes with 25 μM DCF-DA. After 
washing again, microscopic analysis was performed using the Zeiss LSM 510 META 
NLO confocal microscope at the Wayne State University School of Medicine 
Microscopy, Imaging, & Cytometry Resources Core. Cellular ROS was quantified either 
by counting the cells that stain positive for ROS or by using MetaMorph® (Molecular 
Devices) image analysis software to quantitate cellular fluorescence intensities. 
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Appendix Chapter 2 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure a2.1.  EGFR remains tyrosine phosphorylated in MDA-MB-
468 in the presence of gefitinib. MDA-MB-468 cells were treated with 0.1, 0.5, and 1 
μM gefitinib for 30 minutes, 24 hours, 48 hours, or 72 hours as indicated.  Lysates were 
prepared and immunoblotted using antibodies to EGFR, pEGFR Y1068, and pMAPK. 
Image appears in Experimental Cell Research. 2012 by Giordano, CR et al.  Figures 
contributed by Boerner, JL.    
 
 
 
Supplementary figure a2.1 
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Supplementary figure a2.2.  Quantification of immunoblots. (A and B) EGFR 
tyrosine phosphorylation immunoblots were digitized and quantified using 
AlphaEaseFC.  Immunoblots from three experiments represented by Fig. 2.3A (A) or 
Fig. 2.6A (B) were included in the quantification. Image appears in Experimental Cell 
Research. 2012 by Giordano, CR et al.  Figures contributed by Boerner, JL.    
 
 
 
 
 
 
Supplementary figure a2.2A and a2.2B 
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CHAPTER 3:  Towards peroxisome-targeted therapy for diabetic retinopathy 
3.1  Abstract 
 Preclinical studies have highlighted retinal oxidative stress in the pathogenesis of 
diabetic retinopathy. Here we evaluated whether or not a treatment designed to 
enhance peroxisomal catalase reduces oxidative stress in retinal cells cultured in high 
glucose and corrects early retinal pathophysiology as determined by a surrogate 
biomarker in diabetic mice.  Human retinal Müller, pigment epithelial, and photoreceptor 
cells were chronically exposed to normal or high glucose levels and treated with a cell-
penetrating derivative of the peroxisomal enzyme catalase (called CAT-SKL). H2O2 
levels were measured using a quantitative fluorescence-based assay. For in vivo 
studies, streptozotocin (STZ)-induced diabetic C57Bl/6 mice were treated 
subcutaneously once a week for 4 months with CAT-SKL; untreated age-matched non-
diabetic controls and untreated diabetic mice were also studied. Manganese-enhanced 
magnetic resonance imaging (MEMRI) was used to analytically assess the efficacy of 
CAT-SKL treatment on diabetes-evoked oxidative stress-related pathophysiology in 
vivo.  Both Müller and retinal pigment epithelial cells (RPE) demonstrated an increase in 
high glucose-induced H2O2 production. After catalase transduction, peroxide production 
was significantly lowered in both lines. In contrast, the photoreceptors, a transformed 
line, showed no such induction of H2O2 in response to high glucose culture conditions, 
but did respond to the targeted antioxidant. In studies in vivo, CAT-SKL-treated diabetic 
mice had similar body weights and glycated hemoglobin levels as untreated diabetic 
mice; these metrics were different from those in controls. Subnormal intraretinal uptake 
59 
 
 
 
of manganese in the diabetic mice was improved by catalase supplementation.  This 
proof-of-concept study sets the stage for future more thorough investigations involving 
augmentation of peroxisomal catalase as a potential therapy for diabetic retinopathy. 
3.2  Introduction 
  Accumulating evidence supports diabetes-evoked retinal oxidative stress as a 
pathogenic factor in experimental diabetic retinopathy (Du et al., 2003; Kowluru et al., 
2006a; Kowluru et al., 2006b; Kanwar et al., 2007). However, targeting such stress 
using conventional antioxidant treatment is complicated by the fact that ROS play a 
central role in a number of normal cellular activities including endomembrane signaling 
cascades, communication networks, and metabolic regulatory complexes (Lee et al., 
2012). Here, we examine a new targeted approach to addressing these concerns that is 
focused on peroxisomes. 
  The peroxisome is a critical but understudied subcellular constituent that is 
involved in a number of important redox-based metabolic processes in the cell 
(Ivashchenko et al., 2011; Terlecky et al., 2012). These peroxisomal reactions are 
significant contributors to the oxidative load in aged cells and in several degenerative 
diseases - including diabetes (Giordano et al., 2012; Terlecky et al., 2012).  
Peroxisomal ROS accumulates for a number of reasons including, perhaps most 
importantly, mislocalization or impaired activity of catalase, its major resident antioxidant 
enzyme (Terlecky et al., 2006; Terlecky et al., 2012). Diabetes reduces whole retinal 
catalase levels, although a specific contribution from peroxisomes has not been 
extensively investigated (Zhang et al., 1996; Kowluru et al., 1997; Kocak et al., 2000; 
Obrosova et al., 2006; Sadi et al., 2008). The goal of this study was to begin to 
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determine if targeting peroxisomes with catalase supplementation could reduce 
oxidative stress in retinal cells exposed to high glucose conditions, and, if an in vivo 
biomarker sensitive to antioxidant treatment in diabetic models was also positively 
responsive to targeted catalase treatment. These initial studies were designed to set the 
stage for more extensive long term drug testing. 
  In this feasibility study, H2O2 levels were first evaluated in retinal (Müller, RPE, 
and photoreceptor) cell lines chronically exposed to high glucose levels and treated with 
CAT-SKL - a cell penetrating catalase derivative designed to traffic to peroxisomes ((as 
described above) and references therein). Next, we examined whether or not CAT-SKL 
might be useful in vivo using MEMRI, a non-invasive measurement of intraretinal uptake 
of manganese ion (Mn2+, a strong MRI contrast agent) as an analytical biomarker for the 
extent of calcium ion inflow that occurs in the retina in awake and freely moving animals 
(Berkowitz et al., 2006; Berkowitz et al., 2008; Berkowitz et al., 2009b). In diabetic rats 
and mice, intraretinal uptake of manganese is subnormal well before the appearance of 
diabetes-evoked retinal histopathology (Berkowitz et al., 2007b; Berkowitz et al., 2009a; 
Berkowitz et al., 2012).  Importantly, antioxidant therapies that correct these early 
MEMRI impairments also correct later diabetic retinopathy (Berkowitz et al., 2007b; 
Berkowitz et al., 2009a). For these reasons, we employed MEMRI to begin an analysis 
of CAT-SKL’s in vivo efficacy.  
3.3  Results 
3.3.1  Cell culture 
  First we confirmed that CAT-SKL can enter retinal cells.  Müller and RPE cell 
lines in normal and high glucose media conditions were treated with biotinylated CAT-
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SKL for 0, 1, 2, and 4 hours. Transduction was observed within 1 hour of incubation 
(Figure 3.1A).  To confirm transduced CAT-SKL increases peroxisomal catalase, the 
protein was measured in both Müller and RPE cells by SDS-PAGE and then 
immunoblotted for anti-catalase antibodies in the presence or absence of 1 μM CAT-
SKL for 24 hours (Figure 3.1B and D).  In addition, the activity of catalase was 
measured enzymatically showing a significant increase (p<0.05) in catalase activity 
when treated with 1 μM CAT-SKL for 24 hours (Figure 3.1C and E.)  Both Müller and 
RPE cell lines cultured with chronically higher glucose concentrations (HG) 
demonstrated an increase in H2O2 levels compared to those cultured in normal glucose 
(NG) conditions (Figure 3.2A and 2B). Importantly, supplementing peroxisomal catalase 
with CAT-SKL was found to prevent supernormal peroxide buildup in both cell lines 
(Figure 3.2). Furthermore, enzymatically inactive CAT-SKL elicited no significant effect 
on cellular H2O2 levels (Figure 3.2A).    Since RPE cells are normally polarized in the 
retina, culturing cells on a filtered transwell plate was employed to obtain a physical and 
metabolic state that is theoretically more closely aligned with the cells’ normal 
physiological circumstance. Again, an increase in H2O2 was observed between NG and 
HG concentrations and CAT-SKL treatment in HG conditions reduced H2O2 levels back 
to approximately those seen in the NG condition (Figure 3.3A).   
 In contrast to RPE and Müller cells, when transformed photoreceptors were 
examined (Figure 3.3B), no induction in H2O2 between NG and HG cultured conditions 
was noted. Nonetheless, treatment with CAT-SKL significantly reduced H2O2 levels in a 
manner requiring the active recombinant enzyme (Figure 3.3B).  
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 These results demonstrate that supplementing peroxisomal catalase can be an 
effective treatment for reducing levels of hyperglycemia-evoked H2O2 in retinal cells. 
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Figure 3.1A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 B       Figure 3.1C 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 D       Figure 3.1E 
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Figure 3.1.  CAT-SKL transduction of retinal cells.  (A) Müller and RPE cells were 
cultured in normal (5 mM) glucose (NG) or high (17.5 mM) glucose (HG) media as indicated.  
The cells were treated for 0, 1, 2, and 4 hours with biotinylated CAT-SKL (100 nM), washed, 
and harvested.  Transduction was documented by blotting with streptavidin-alkaline 
phosphatase.  Bands shown migrate at position expected for CAT-SKL.  Müller (B,C.) and RPE 
(D,E.) cells were transduced with 1 μM CAT-SKL (indicated as “CAT-SKL”) or without (indicated 
as “UT”) for 24 hours, washed and harvested in PBS.  Equal amounts of protein were separated 
by SDS-PAGE and probed with anti-catalase and anti-β-actin antibodies or catalase activity was 
measured enzymatically (* indicates p<0.05).    
 
 
Figure 3.2A       Figure 3.2B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  Enzymatically-active CAT-SKL reduces H2O2 levels in Müller and RPE 
cells.   Müller (A) and RPE (B) cells were cultured over several passages in normal (5 mM) 
glucose (NG) or high (17.5 mM) glucose (HG) media.  Replicate cultures of HG cells were then 
treated with 1 μM CAT-SKL for 24 hours as indicated.  H2O2 levels was measured using the 
Amplex® Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) assay kit.  Results presented, 
means +/- one standard deviation of four or more samples, are normalized to the HG value 
(arbitrarily set at 100).  In (A), cells were also transduced with 1 μM enzymatically-inactive (heat 
denatured) CAT-SKL (indicated as CAT-SKL).  Bars represent mean ± SEM for triplicate 
samples.  Means followed by the same letter are not significantly different according to Tukey’s 
Multiple Comparison Test (p>0.05). 
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Figure 3.3A       Figure 3.3B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  CAT-SKL’s effects on polarized RPE and photoreceptor cells. Polarized 
RPE (A) and photoreceptor (B) cells were treated as in Figure 3.2 except that for the polarized 
RPE cells, H2O2 levels were measured in the basolateral receiving well.  Bars represent mean ± 
SEM for quadruplicate samples.  Means followed by the same letter are not significantly 
different according to Tukey’s Multiple Comparison Test (p>0.05). 
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3.3.2  Model characteristics 
 Having established the usefulness of CAT-SKL as an effective antioxidant in 
retinal cells, we next began an investigation into its effectiveness in vivo.  First we 
examined staining of the 70 kDa peroxisomal membrane protein (PMP70) in both 
control and diabetic mice.  We have previously noted increased peroxisome numbers in 
aged, diseased or xenobiotic treated cells (Legakis et al., 2002; Wood et al., 2006; 
Koepke et al., 2008; Ivashchenko et al., 2011).  Perhaps not unexpectedly, we found 
that in the diabetic animal’s retina, PMP70 staining (red intensity) is substantially 
increased compared to their counterpart controls (Figure 3.4A and B).  The reason for 
this induction is not clear – one explanation is that the disease state causes an 
alteration in regulating peroxisome growth and division, leading to increased growth of 
the organelle in the absence of normal cellular cues.  Alternatively the organelle 
proliferates to compensate for mitochondrial deficits – recall the mitochondrial-
peroxisomal interplay discussed above.  Compromised degradation (pexophagy) in the 
diabetic retina may also be considered.      
 Glycated hemoglobin (A1c) was examined in all groups and as expected for the 
diabetic mouse model, the A1c range was lower (p<0.05) in age-matched non-diabetic 
controls (5.3 – 7.0%) as compared to either the non-treated diabetic animals (12.0 – 
14.4%) or the treated diabetic mice (10.9 – 15.7%); no differences in A1c between 
diabetic groups were found (p>0.05). The range of body weights were also different 
between age-matched non-diabetic controls (30 – 36 g) and untreated (17 – 23 g) and 
treated (18 – 23 g) diabetic groups; again the two diabetic groups did not differ (p>0.05) 
in their final body weight.  
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Figure 3.4A and B  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Peroxisomal staining in diabetic and control mouse retinas.  Control (A) 
and diabetic (B) mouse retinas were stained with the peroxisomal membrane protein marker 
PMP70 (red) and SYTOX® Green Nucleic Acid Stain (green).  Asterisks indicate area of inserts; 
higher magnifications of the inner plexiform layer of the retina showing increased peroxisomal 
staining in diabetic mice compared to control counterparts.  
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3.3.3  MEMRI 
 We next began to determine the effectiveness of CAT-SKL treatment in vivo 
using the previously established antioxidant-sensitive early diabetes-evoked metric: 
decreased intraretinal manganese uptake as measured by MEMRI (Berkowitz et al., 
2007b; Berkowitz et al., 2009a). As summarized in Figure 3.5, CAT-SKL treatment 
significantly (p<0.05) improved uptake in both the inner and outer retina. 
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  Manganese uptake in the retina of diabetic mice is partially corrected 
with the targeted antioxidant CAT-SKL. Data are shown as a function of distance from the 
retina/non-retina borders, where 0% is the vitreous/retina border and 100% is the retina/choroid 
border. Shaded regions near borders likely include some signal from outside of the retina and 
were not included in the analysis.  White boxes outline central retinal regions analyzed. For 
those areas tested, * indicates common depths in untreated and treated diabetic groups that are 
significantly different Mn2+ in uptake from controls (p<0.05, two-tailed t-tests).  Red line = 
control, blue line = diabetic + CAT-SKL, green line = diabetic. Experiments contributed by 
Giordano, CR along with Berkowitz BA.      
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3.4  Discussion  
 In this study, we found, for the first time, that treatment with a peroxisome-
specific catalase molecule (CAT-SKL) significantly corrected hyperglycemia-induced 
oxidative stress in retinal cells as well as improved early ion channel dysregulation in 
diabetic retinopathy in vivo. The present studies take advantage of the recent availability 
of CAT-SKL to begin to test for a contribution of peroxisomal oxidative stress to diabetic 
retinopathy. It is now clear that retinal oxidative stress is a pathogenic factor in diabetic 
retinopathy, based, in part, on previous studies using a variety of non-specific/non-
targeted antioxidants, all of which prevented the development of diabetic retinopathy 
(Kowluru et al., 1996; Kowluru et al., 1997; Kowluru et al., 2001; Kowluru et al., 2006b; 
Kanwar et al., 2007). Questions remain as to how antioxidants are best introduced into 
the retina with minimal perturbation of normal cellular functions involving brief and often 
continuous oxidative bursts on endomembrane signaling, inter- and intracellular 
communication networks, and coordinated metabolic regulation (Lee et al., 2012). The 
results in this study raise the possibility that targeting peroxisomal oxidative stress is a 
novel and effective treatment strategy for diabetic retinopathy. 
 This proof-of-concept study had some limitations. For example, we were unable 
to determine how effectively CAT-SKL reduced retinal oxidative stress in the diabetic 
mice. Furthermore, based on the incomplete correction of the diabetes-induced 
subnormal MEMRI retinal profiles - possibly because the dose employed was 
suboptimal, it is clear that additional, more thorough dose-response studies are 
warranted. We anticipate that once CAT-SKL’s pharmacodynamics and 
pharmacokinetics are better defined, we will be able to further examine the impact of the 
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protein therapeutic on retinal ROS levels and catalase levels, as well as the actual 
development of diabetic retinopathy. Also, we did not examine the impact of CAT-SKL 
in non-diabetic controls in vivo. Collecting data from this control group would have 
informed about the drug’s toxicity which is relevant in future studies but not necessary in 
this proof-of-concept phase. 
 These present results are in-line with our previous studies showing that MEMRI 
is a powerful and sensitive assay to document beneficial effects of antioxidant strategies 
designed to treat early diabetes-evoked retinal pathophysiology (Marmorstein et al., 
2006; Berkowitz et al., 2007b; Lu et al., 2007; Berkowitz et al., 2009a). For example, we 
found that α-lipoic acid effectively reversed the subnormal intraretinal manganese 
uptake (measured by MEMRI) in diabetic mice (Berkowitz et al., 2007b).  Furthermore, 
we showed that overexpression of the copper/zinc binding antioxidant, superoxide 
dismutase, dramatically impacted diabetes-induced early MEMRI lesions and later 
diabetic retinopathy (Berkowitz et al., 2009a).  MEMRI is a non-invasive technique that 
measures retinal open / closed status of L-type voltage gated calcium ion channels, 
crucial components of intracellular communication (Drapeau and Nachshen, 1984; 
Carlson et al., 1994; Marmorstein et al., 2006; Berkowitz et al., 2007a; Cross et al., 
2007; Lu et al., 2007; Berkowitz et al., 2011). While it is not yet clear how retinal 
oxidative stress (due to diabetes) leads to impaired intraretinal uptake on MEMRI, the 
current data, and those from our other studies, continue to underscore the usefulness of 
MEMRI as providing a sensitive surrogate for antioxidant efficacy.  
 The pathogenesis of diabetic retinopathy is not completely understood, although 
there is strong consensus that increased oxidative stress is a major contributor (Kowluru 
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et al., 1996; Kowluru et al., 1997; Kowluru et al., 2001; Kowluru et al., 2006b; Kanwar et 
al., 2007). There are several potential ways in which oxidative stress in diabetic mice 
could be generated including impaired activity of the major antioxidant defense 
enzymes, including catalase and/or superoxide dismutase (Kowluru et al., 1997; 
Obrosova et al., 2006). Also, because in this study we found improvements in both inner 
and outer retina, it is intriguing that the photoreceptor inner segments contain at least 
60-65% of retinal mitochondria and are the primary retinal region that immunostains for 
catalase (and presumably peroxisomes) (Atalla et al., 1987). Perhaps improvements in 
outer retinal oxidative stress lead to downstream improvements in inner retina oxidative 
stress. To the best of our knowledge, treatment targeted to increasing peroxisomal 
catalase levels alone has not been investigated in diabetic retinopathy. The present 
findings raise the possibility that such highly specific supplementation of the powerful 
antioxidant enzyme will be useful in diabetic retinopathy. 
3.5  Materials and Methods 
 All animals were treated in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals, the Association for Research in 
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision 
Research, and Institutional Animal and Care Use Committee authorization. Animals 
were housed and maintained in normal 12 h:12 h light-dark cycle laboratory lighting, 
unless otherwise noted. 
Cell culture. Human retinal pigment epithelium (ARPE-19) cells were obtained from 
American Type Culture Collection (ATCC, Manassas, VA).  Spontaneously immortalized 
human Müller cells (MIO-M1) were a gift from Dr. G. Astrid Limb and were maintained 
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as previously described (Shamsuddin and Kumar, 2011). Transformed 661W 
photoreceptor cells were grown and maintained as described previously (al-Ubaidi et 
al., 1992; Tan et al., 2004).  The retinal cell lines were grown in Dulbecco's Modified 
Eagle Medium (DMEM) or Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM:F12) with  normal glucose (NG) (5 mM) or DMEM with high glucose (HG) (17.5 
mM). Chronic normal or high glucose cells were acquired after 10 passages in media 
supplemented with either normal or high glucose concentrations.  
CAT-SKL transduction.  CAT-SKL was purified and characterized as previously 
described (Koepke et al., 2007; Young et al., 2008; Giordano et al., 2012).  To track 
entry into cells, the molecule was biotinylated on primary amines (Koepke et al., 2007; 
Giordano et al., 2012).  Cells were treated with biotinylated-CAT-SKL (100 nM) for 0, 1, 
2, and 4 hours at which time they were harvested into sample buffer.  Proteins were 
separated by SDS-PAGE and then transferred to a nitrocellulose membrane.  The 
membrane was blocked using 5% non-fat milk and probed with streptavidin-alkaline 
phosphatase (diluted 1:1000).  Reactive proteins were visualized with the NBT/BCIP 1-
Step Solution (Thermo Scientific).   
Catalase activity.  Catalase enzymatic activity was determined by its ability to 
decompose H2O2 as described in (Storrie and Madden, 1990).  Here, equal numbers of 
cells where added to 1 mg/ml BSA, 0.02 M imidazole (pH 7.0), 0.2% Triton-X 100, 
0.06% H2O2 (prepared fresh) in PBS, and the reaction incubated at room temperature 
for 15 min.  Titanium oxysulfate stop solution was then added and resultant absorbance 
at 405 nm was measured on a microplate reader. Catalase transduction of Müller and 
RPE cells was accomplished by treating cells (or not) with 1 μm CAT-SKL for 24 hours. 
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Confirmation of transduction was made by western blot analysis. Cells were harvested 
in PBS, equal amounts of protein were separated by SDS and transferred to a 
nitrocellulose membrane.  Antibodies utilized included anti-catalase and anti-β-actin, 
diluted 1:4000 and 1:10000, respectively. 
Measurement of H2O2.  Müller, RPE, and photoreceptor cells were plated at 20,000 
cells per well in 96-well plates and treated with or without 1 μM CAT-SKL for 24 hours at 
37°C.  Where indicated, heat inactivated CAT-SKL was prepared by boiling at 100°C for 
3 min, cooling to room temperature, and resuspending as appropriate in cell culture 
media. For polarized RPE experiments, HTS Transwell-96 System, 0.4 μm 
polycarbonate membranes were utilized (Corning Incorporated, New York).  Cells were 
plated at 6,000 cells per well and treated as described above except that oxidant 
measurements were performed on the conditioned media in the receiving well.  H2O2 
levels were determined using the Amplex® Red Hydrogen Peroxide/Peroxidase Assay 
Kit (Molecular Probes®) following the manufacturer’s protocol.  Briefly, cells were 
washed with Hank’s balanced salt solution, treated with the Amplex® Red reagent (10-
acetyl-3,7-dihydroxyphenoxazine)/horseradish peroxidase working solution and 
incubated for 2 hours at room temperature protected from light.  Fluorescence units 
were obtained using a microplate reader (excitation 544 nm and emission 590 nm). 
Background fluorescence in wells containing media alone was subtracted from all data 
points. 
Mice.  At 2 months of age, 20 g male C57Bl/6 mice (Jackson Laboratories, Bar Harbor, 
ME) were randomly divided into the following groups: non-diabetic age-matched 
controls, diabetics, diabetics with treatments (diabetic + CAT-SKL). 
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Diabetes.  Diabetes was induced in mice with starting weights of 16 to 20 g by 
streptozotocin (STZ), (60 mg/kg; 10 mM citrate buffer (pH 4.5) intraperitoneal injection, 
within 10 minutes of preparation, once a day for 5 consecutive days. Body weight and 
blood glucose levels were monitored twice weekly. Insulin (neutral protamine 
Hagedorn), administered to mice as needed based on bodyweight and blood glucose 
levels but not more than twice weekly, allowed slow weight gain while maintaining 
hyperglycemia (blood glucose levels higher than 400 mg/dl). Mice that lost weight 
and/or had blood glucose levels greater than 600 mg/dl were given 0.1 - 0.2 units of Lilly 
Humulin N insulin. Normal rodent chow (Purina TestDiet 5001; Richmond, IN, which 
contains 11.2% fat, 26% protein, and 62.7% carbohydrate) and water were provided ad 
libitum. Dehydrated animals were administered saline as needed.   A1c was measured 
(Glyco-Tek affinity columns, kit 5351; Helena Laboratories, Beaumont, TX) from blood 
collected after each MEMRI experiment. Blood was drawn from the left ventricle, after 
puncture, into a capillary tube and stored in an Eppendorf tube with a small amount of 
heparin to prevent coagulation. The blood was kept at 4°C until analysis within one 
week following the MEMRI experiment. 
CAT-SKL. A random subset of diabetic mice treated subcutaneously with CAT-SKL (1 
mg/kg) weekly for 3 months, starting 1 week after initiation and confirmation of the 
diabetic state. Two treated diabetic mice had relatively low A1c values (8.6 and 8.9%) 
and were excluded from the final analysis. Note that the control and diabetic mice data 
had been reported in a previous study (Berkowitz et al., 2012).  At the end of the 4-
month study period, untreated controls (n = 7), diabetic animals (n = 7), and  diabetic 
animals treated with CAT-SKL(n = 5) underwent MEMRI examination.  
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Immunohistochemical staining.  Mouse retinas were fixed in 4% paraformaldehyde, 
0.05 M L-lysine, and 0.01 M sodium periodate in 0.01 M phosphate buffer pH 7.4 for 5 
minutes at room temperature.  Permeabilization was performed using 0.05% Triton X-
100 in phosphate buffered saline solution for 10 minutes in a moist chamber 
environment and then washed three times with 0.01 M phosphate buffer.  Tissue was 
blocked with 1% BSA (Sigma-Aldrich) and 10% goat serum (Invitrogen) in 0.01 M 
phosphate buffer for 30 minutes to block unspecific binding of antibodies.  Tissue was 
then incubated with rabbit anti-PMP70 (abcam) 1:500 for 1 hour at room temperature.  
Slides were washed three times with 0.01 M phosphate buffer and incubated with the 
secondary antibody Alexa Fluor 546 goat anti-rabbit (Molecular Probes) 1:1500 for 1 
hour at room temperature covered from light.  Slides were washed and incubated with 
SYTOX® GREEN nuclear label 1:150,000 for two minutes and rinsed with deionized 
water.  Coverslips were mounted with VECTASHIELD (Vector Laboratories, Inc.).  
Microscopic analysis was performed using the Leica TCS SP2 confocal microscope 
located in the Department of Anatomy and Cell Biology’s microscope facility at Wayne 
State University School of Medicine. 
MEMRI.  The methodologies for measuring MEMRI in mice has been described in detail 
previously (Berkowitz et al., 2012). Briefly, all animals were maintained in darkness for 
16 to 20 hours before manganese injection. All procedures (i.e., weighing, injecting 
MnCl2, anesthetic administration, and MRI examination) were performed under dim red 
light or darkness. MnCl2 was administered as an intraperitoneal injection (66 mg 
MnCl2•4H2O / kg) on the right side of the awake animal. After this injection, animals 
were maintained in dark conditions for another 3.5 to 4 hours. Immediately before the 
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MRI experiment, animals were anesthetized with urethane (36% solution 
intraperitoneally; 0.083 ml/20 g animal weight, prepared fresh daily; Aldrich, Milwaukee, 
WI). MRI data were acquired on a 7T system (Clinscan). Retinal partial saturation T1 
data were acquired using a dual coil mode on a 7 T BrukerClinscan system: Several 
single spin-echo (time to echo [TE] 13 ms, 7 x 7 mm2, matrix size 160×320, slice 
thickness 600 μm) images were acquired at different repetition times [TRs] in the 
following order (number per time between repetitions in parentheses): TR 0.15 s (6), 
3.50 s (1), 1.00 s (2), 1.90 s (1), 0.35 s (4), 2.70 s (1), 0.25 s (5), and 0.50 s (3). To 
compensate for reduced signal-noise ratios at shorter TRs, progressively more images 
were collected as the TR decreased. 
MRI analysis.  MEMRI data of central retinal data (± 1 mm from the center of the optic 
nerve) were analyzed using the region-of-interest such as those highlighted in the top 
insert of Figure 3.5 for mice.  The white region-of-interest indicates the part of central 
retina (including optic nerve (ON)) that was linearized for the control, untreated diabetic 
and treated diabetic (diabetic + CAT-SKL) groups. Quantitative analysis was as follows: 
single images acquired with the same TR were first registered (rigid body) and then 
averaged. These averaged images were then registered across TRs. The same 
regions-of-interest as above were analyzed by calculating 1/T1 maps by first fitting to a 
three-parameter T1 equation (y=a + b*(exp(-c*TR)), where a, b, and c are fitted 
parameters) on a pixel-by-pixel basis using R (v.2.9.0, R Development Core Team 
[2009]). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing. ISBN 3–900051–07–0) scripts developed in-house, and the 
minpack.lm package (v.1.1.1, Timur V. Elzhov and Katharine M. Mullen minpack.lm: R 
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interface to the Levenberg-Marquardt nonlinear least-squares algorithm found in 
MINPACK. R package version 1.1–1). The reciprocal (1/T1) values directly reflect 
manganese levels. Central intraretinal 1/T1 profiles were obtained as detailed elsewhere 
(Bissig and Berkowitz, 2011). Values from the superior and inferior retina were 
averaged. Note that only those animals that took up manganese above baseline (i.e., 
~0.6 s−1) were included in the final analysis. 
Statistical analysis.  Drug-treated versus untreated cell culture H2O2 values were 
compared using student t-tests. Comparison of MEMRI data between groups were 
performed using individual t-tests at different locations of the intraretinal profiles. In all 
cases, p<0.05 was considered statistically significant. 
79 
 
 
 
3.6  References 
al-Ubaidi MR, Font RL, Quiambao AB, Keener MJ, Liou GI, Overbeek PA and Baehr W 
(1992) Bilateral retinal and brain tumors in transgenic mice expressing simian 
virus 40 large T antigen under control of the human interphotoreceptor retinoid-
binding protein promoter. The Journal of cell biology 119:1681-1687. 
Atalla L, Fernandez MA and Rao NA (1987) Immunohistochemical localization of 
catalase in ocular tissue. Current eye research 6:1181-1187. 
Berkowitz BA, Bissig D, Bergman D, Bercea E, Kasturi VK and Roberts R (2011) 
Intraretinal calcium channels and retinal morbidity in experimental retinopathy of 
prematurity. Molecular vision 17:2516-2526. 
Berkowitz BA, Bissig D, Patel P, Bhatia A and Roberts R (2012) Acute systemic 11-cis-
retinal intervention improves abnormal outer retinal ion channel closure in 
diabetic mice. Molecular vision 18:372-376. 
Berkowitz BA, Gradianu M, Bissig D, Kern TS and Roberts R (2009a) Retinal ion 
regulation in a mouse model of diabetic retinopathy: natural history and the effect 
of Cu/Zn superoxide dismutase overexpression. Investigative ophthalmology & 
visual science 50:2351-2358. 
Berkowitz BA, Gradianu M, Schafer S, Jin Y, Porchia A, Iezzi R and Roberts R (2008) 
Ionic dysregulatory phenotyping of pathologic retinal thinning with manganese-
enhanced MRI. Investigative ophthalmology & visual science 49:3178-3184. 
Berkowitz BA, Roberts R, Goebel DJ and Luan H (2006) Noninvasive and simultaneous 
imaging of layer-specific retinal functional adaptation by manganese-enhanced 
MRI. Investigative ophthalmology & visual science 47:2668-2674. 
 
A. 
80 
 
 
 
Berkowitz BA, Roberts R, Oleske DA, Chang M, Schafer S, Bissig D and Gradianu M 
(2009b) Quantitative mapping of ion channel regulation by visual cycle activity in 
rodent photoreceptors in vivo. Investigative ophthalmology & visual science 
50:1880-1885. 
Berkowitz BA, Roberts R, Penn JS and Gradianu M (2007a) High-resolution 
manganese-enhanced MRI of experimental retinopathy of prematurity. 
Investigative ophthalmology & visual science 48:4733-4740. 
Berkowitz BA, Roberts R, Stemmler A, Luan H and Gradianu M (2007b) Impaired 
apparent ion demand in experimental diabetic retinopathy: correction by lipoic 
Acid. Investigative ophthalmology & visual science 48:4753-4758. 
Bissig D and Berkowitz BA (2011) Same-session functional assessment of rat retina 
and brain with manganese-enhanced MRI. NeuroImage 58:749-760. 
Carlson RO, Masco D, Brooker G and Spiegel S (1994) Endogenous ganglioside GM1 
modulates L-type calcium channel activity in N18 neuroblastoma cells. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 
14:2272-2281. 
Cross DJ, Flexman JA, Anzai Y, Sasaki T, Treuting PM, Maravilla KR and Minoshima S 
(2007) In vivo manganese MR imaging of calcium influx in spontaneous rat 
pituitary adenoma. AJNR American journal of neuroradiology 28:1865-1871. 
Drapeau P and Nachshen DA (1984) Manganese fluxes and manganese-dependent 
neurotransmitter release in presynaptic nerve endings isolated from rat brain. 
The Journal of physiology 348:493-510. 
81 
 
 
 
Du Y, Miller CM and Kern TS (2003) Hyperglycemia increases mitochondrial superoxide 
in retina and retinal cells. Free radical biology & medicine 35:1491-1499. 
Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, Terlecky SR and 
Boerner JL (2012) A targeted enzyme approach to sensitization of tyrosine 
kinase inhibitor-resistant breast cancer cells. Experimental Cell Research 
318:2014-2021. 
Ivashchenko O, Van Veldhoven PP, Brees C, Ho YS, Terlecky SR and Fransen M 
(2011) Intraperoxisomal redox balance in mammalian cells: oxidative stress and 
interorganellar cross-talk. Molecular biology of the cell 22:1440-1451. 
Kanwar M, Chan PS, Kern TS and Kowluru RA (2007) Oxidative damage in the retinal 
mitochondria of diabetic mice: possible protection by superoxide dismutase. 
Investigative ophthalmology & visual science 48:3805-3811. 
Kocak G, Aktan F, Canbolat O, Ozogul C, Elbeg S, Yildizoglu-Ari N and Karasu C 
(2000) Alpha-lipoic acid treatment ameliorates metabolic parameters, blood 
pressure, vascular reactivity and morphology of vessels already damaged by 
streptozotocin-diabetes. Diabetes, nutrition & metabolism 13:308-318. 
Koepke JI, Nakrieko KA, Wood CS, Boucher KK, Terlecky LJ, Walton PA and Terlecky 
SR (2007) Restoration of peroxisomal catalase import in a model of human 
cellular aging. Traffic (Copenhagen, Denmark) 8:1590-1600. 
Koepke JI, Wood CS, Terlecky LJ, Walton PA and Terlecky SR (2008) Progeric effects 
of catalase inactivation in human cells. Toxicology and applied pharmacology 
232:99-108. 
82 
 
 
 
Kowluru RA, Atasi L and Ho YS (2006a) Role of mitochondrial superoxide dismutase in 
the development of diabetic retinopathy. Investigative ophthalmology & visual 
science 47:1594-1599. 
Kowluru RA, Kern TS and Engerman RL (1997) Abnormalities of retinal metabolism in 
diabetes or experimental galactosemia. IV. Antioxidant defense system. Free 
radical biology & medicine 22:587-592. 
Kowluru RA, Kern TS, Engerman RL and Armstrong D (1996) Abnormalities of retinal 
metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. 
Diabetes 45:1233-1237. 
Kowluru RA, Kowluru V, Xiong Y and Ho YS (2006b) Overexpression of mitochondrial 
superoxide dismutase in mice protects the retina from diabetes-induced oxidative 
stress. Free radical biology & medicine 41:1191-1196. 
Kowluru RA, Tang J and Kern TS (2001) Abnormalities of retinal metabolism in diabetes 
and experimental galactosemia. VII. Effect of long-term administration of 
antioxidants on the development of retinopathy. Diabetes 50:1938-1942. 
Lee J, Giordano S and Zhang J (2012) Autophagy, mitochondria and oxidative stress: 
cross-talk and redox signalling. The Biochemical journal 441:523-540. 
Legakis JE, Koepke JI, Jedeszko C, Barlaskar F, Terlecky LJ, Edwards HJ, Walton PA 
and Terlecky SR (2002) Peroxisome senescence in human fibroblasts. Molecular 
biology of the cell 13:4243-4255. 
Lu H, Xi ZX, Gitajn L, Rea W, Yang Y and Stein EA (2007) Cocaine-induced brain 
activation detected by dynamic manganese-enhanced magnetic resonance 
83 
 
 
 
imaging (MEMRI). Proceedings of the National Academy of Sciences of the 
United States of America 104:2489-2494. 
Marmorstein LY, Wu J, McLaughlin P, Yocom J, Karl MO, Neussert R, Wimmers S, 
Stanton JB, Gregg RG, Strauss O, Peachey NS and Marmorstein AD (2006) The 
light peak of the electroretinogram is dependent on voltage-gated calcium 
channels and antagonized by bestrophin (best-1). The Journal of general 
physiology 127:577-589. 
Obrosova IG, Drel VR, Kumagai AK, Szabo C, Pacher P and Stevens MJ (2006) Early 
diabetes-induced biochemical changes in the retina: comparison of rat and 
mouse models. Diabetologia 49:2525-2533. 
Sadi G, Yilmaz O and Guray T (2008) Effect of vitamin C and lipoic acid on 
streptozotocin-induced diabetes gene expression: mRNA and protein 
expressions of Cu-Zn SOD and catalase. Molecular and cellular biochemistry 
309:109-116. 
Shamsuddin N and Kumar A (2011) TLR2 mediates the innate response of retinal 
Muller glia to Staphylococcus aureus. Journal of immunology 186:7089-7097. 
Storrie B and Madden EA (1990) Isolation of subcellular organelles. Methods in 
enzymology 182:203-225. 
Tan E, Ding XQ, Saadi A, Agarwal N, Naash MI and Al-Ubaidi MR (2004) Expression of 
cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in 
transgenic mice. Investigative ophthalmology & visual science 45:764-768. 
Terlecky SR, Koepke JI and Walton PA (2006) Peroxisomes and aging. Biochimica et 
biophysica acta 1763:1749-1754. 
84 
 
 
 
Terlecky SR, Terlecky LJ and Giordano CR (2012) Peroxisomes, oxidative stress, and 
inflammation. World journal of biological chemistry 3:93-97. 
Wood CS, Koepke JI, Teng H, Boucher KK, Katz S, Chang P, Terlecky LJ, 
Papanayotou I, Walton PA and Terlecky SR (2006) Hypocatalasemic fibroblasts 
accumulate hydrogen peroxide and display age-associated pathologies. Traffic 
(Copenhagen, Denmark) 7:97-107. 
Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd Savoy L and Terlecky SR (2008) 
Reactive oxygen species in tumor necrosis factor-alpha-activated primary human 
keratinocytes: implications for psoriasis and inflammatory skin disease. The 
Journal of investigative dermatology 128:2606-2614. 
Zhang H, Agardh CD and Agardh E (1996) Retinal nitro blue tetrazolium staining and 
catalase activity in rat models of diabetes. Graefe's archive for clinical and 
experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und 
experimentelle Ophthalmologie 234:324-330. 
 
 
  
 
 
 
 
 
 
85 
 
 
 
CHAPTER 4:  Amyloid-beta neuroprotection mediated by a targeted antioxidant 
 
Publilshed:  Giordano CR, Terlecky LJ, Bollig-Fischer A, Walton PA, and Terlecky SR 
(2014) Scientific Reports 4:4983. 
4.1  Abstract 
Amyloid-beta (Aβ)-induced neurotoxicity is a major contributor to the pathologies 
associated with Alzheimer’s disease (AD).  The formation of ROS, an early response 
induced by the peptide and oligomeric derivatives of Aβ, plays a significant role in 
effecting cellular pathogenesis.  Here we employ particularly toxic forms of Aβ with 
cultured primary cortical/hippocampal neurons to elicit ROS and drive cellular 
dysfunction.  To prevent and even reverse such effects, we utilized a cell-penetrating, 
peroxisome-targeted, protein biologic – called CAT-SKL.  We show the recombinant 
enzyme enters neurons, reverses Aβ-induced oxidative stress, and increases cell 
viability.  Dramatic restorative effects on damaged neuronal processes were also 
observed.  In addition, we used DNA microarrays to determine Aβ’s effects on gene 
expression in neurons, as well as the ability of CAT-SKL to modify such Aβ-induced 
expression profiles.  Our results suggest that CAT-SKL, a targeted antioxidant, may 
represent a new therapeutic approach for treatment of disorders, like Alzheimer’s 
disease, that are driven through oxidative stress.  Preclinical testing is ongoing.   
4.2  Introduction 
AD is a progressive neurodegenerative disorder caused by multiple conspiring 
pathologies including misprocessing of the amyloid precursor protein (to Aβ peptide and 
related higher order structures); tau phosphorylation, relocalization, and deposition; 
activity of presenilins and the effects of specific ε4 alleles of apolipoprotein E; α 
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synuclein/Lewey body accumulation; and is potentiated by the effects of aging (Selkoe, 
2011; Holtzman et al., 2012; Huang and Mucke, 2012).  Thus, a barrage of anti-
proteostatic effects are brought to bear on neurons, with devastating consequences. 
In this report, we concentrate on the neurocompromising effects of Aβ peptides, 
molecules thought to trigger a cascade of early neuropathogenic activities.  In particular, 
we focus on soluble forms of the toxic Aβ-peptide, called amyloid β-derived diffusible 
ligands - or ADDLs(Klein, 2002).  These Aβ-derivatives are thought to interact with 
specific cell surface receptors to trigger ROS formation and associated downstream 
cytotoxic effects(Klein, 2002).  Indeed, ADDLs may initiate a self-perpetuating spiral of 
toxic Aβ-formation/deposition, and cell pathology (Saraiva et al., 2012). 
To confer neuroprotection in our culture model, we targeted the response arm of 
Aβ-toxicity; specifically the formation of ROS.  This was accomplished in a manner 
distinct from previously employed (and failed (Petersen et al., 2005; Brewer, 2010; 
Polidori and Nelles, 2013; Persson et al., 2014)) approaches of flooding cells with non-
targeted antioxidants.  It is becoming well understood that cells employ ROS as 
effectors of signaling, communication and metabolic regulatory networks, and that these 
molecules cannot be indiscriminately quenched (Droge, 2002; Hsieh and Yang, 2013).  
Our approach is to target a powerful antioxidant, in this case catalase(Chance, 1948; 
Vainshtein et al., 1981), to the peroxisome where an accumulating literature suggests 
the enzyme maintains and/or reestablishes oxidative balance without side-effects.  To 
accomplish this, we employed CAT-SKL, a genetically engineered recombinant 
derivative of catalase containing a cell penetrating peptide at its amino terminus and an 
altered, more efficient peroxisomal targeting signal at its carboxy terminus.  The results 
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with CAT-SKL have been dramatic in a number of cellular and preclinical settings 
(Young et al., 2008; Price et al., 2009; Undyala et al., 2011; Giordano et al., 2012; 
Giordano and Terlecky, 2012).  Here the targeted catalase molecule was able to protect 
rat primary cortical/hippocampal cultures from ADDL-induced cytotoxicity as manifest by 
effects on ROS production, gene expression, neurite formation, and overall cell viability.    
4.3  Results 
4.3.1  ADDL characterization and toxicity.   
Freshly prepared ADDLs were characterized to document the nature of the 
oligomeric species created.  The Aβ peptide used to generate ADDLs is 42 amino acids 
(~4.5 kDa).  A gel filtration column was prepared with G-50 Sephadex beads, a sizing 
column that excludes proteins greater than 30 kDa.  Sample fractions of ADDLs were 
collected and compared to the behavior of 67 kDa and 1.4 kDa control polypeptides.  
The prepared ADDLs were confirmed to be mainly larger oligomeric species, displaying 
an excluded migration pattern similar to the 67 kDa protein (Fig. 4.1A).  Therefore, in 
our hands, ADDLs contain largely oligomeric assemblies of Aβ – consistent with the 
results reported by others (Lue et al., 1999; McLean et al., 1999; Wang et al., 1999; 
Klein, 2002).  Soluble forms of Aβ accumulate in the human brain and are thought to 
cause the functional deficits that precede neuronal death. Indeed, these ADDLs are 
considered to be a major driver of the early stages and progression of AD.  To 
determine if freshly prepared ADDLs were toxic to primary neuronal cultures, several 
concentrations of the oligomeric peptide were added to cells.  The cells employed were 
embryonic day 18 Sprague Dawley rat cortical/hippocampal neurons.  Cells were 
harvested from fresh brain tissue, plated, and differentiated as described in the 
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methods.   After 7 days of differentiation, the neurons displayed axons and dendrites, 
and are known to form synapses and conduct action potentials(Brewer et al., 1993; 
Brewer and Price, 1996).  Our neuronal cultures stained positive for the dendritic 
marker, MAP-2, (see Fig. 4.4 below) and the axonal marker, neurofilament-68 (data not 
shown).   
Cellular mitochondrial dehydrogenase activity was measured by absorbance 
spectroscopy to determine cellular viability after treatment with ADDLs at 0.1, 1, and 10 
μM for 24 hours (Fig. 4.1B).  Compared to untreated neurons, 1 and 10 μM ADDLs 
significantly reduced metabolic activity as indicated by the decrease in formazan dye 
formed (p<0.05), thus confirming toxicity of the ADDL preparations to neurons as 
previously reported (Klein, 2002).   Metastable intermediates of insoluble Aβ fibrils, 
called protofibrils were also prepared for this study but showed no toxicity compared to 
a vehicle control (Fig. 4.1B); further strengthening the notion that soluble oligomers of 
Aβ are the more harmful state of the peptide.   
As introduced above, Aβ induces ROS production in cells of the brain.  Here, we 
specifically measured H2O2 in primary neuronal cultures and found that addition of 1 μM 
ADDLs for 24 hours significantly increased levels of ROS (p<0.05) (Fig. 4.1C). An 
unrelated peptide had no such effects (Fig. 4.1C). 
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Figure 4.1.  ADDL-induced toxicity in primary cortical/hippocampal neurons. (A) 
ADDLs were subjected to gel filtration (using Sephadex G-50 beads) to characterize 
their sizing behavior.  Any molecule greater than 30 kDa is excluded from the column 
(~fraction 20).  Red line = ADDLs, blue line = 67 kDa protein, and green line = 1.4 kDa 
peptide.  Y-axis is normalized protein intensity as quantified by Image J software.  (B) 
Primary rat cortical/hippocampal cultures were treated with ADDLs (0.1, 1, and 10 μM), 
and protofibrils (10 μM) as indicated, for 24 hours.  Cell viability was determined using 
the water soluble tetrazolium cell proliferation assay (WST-1). Bars represent mean ± 
SEM for triplicate samples.  Means followed by the same letter are not significantly 
different according to Tukey’s Multiple Comparison Test (p>0.05).  (C) Hydrogen 
peroxide production was measured using the Amplex® Red reagent (10-acetyl-3,7-
dihydroxyphenoxazine).  ADDLs (1 μM for 24 hours) induced hydrogen peroxide 
production in primary rat cortical/hippocampal neurons.  Statistical analysis was 
performed using one-way analysis of variance (ANOVA).  When ANOVA indicated 
significant treatment effects, means were separated using Tukey’s Multiple Comparison 
Test.  Bars represent mean ± SEM for quadruplicate samples.  Means followed by the 
same letter are not significantly different (p>0.05). Similar results were seen in three 
additional experiments.    
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4.3.2  CAT-SKL transducibility.   
We utilized CAT-SKL, which has been shown to robustly metabolize H2O2 within 
the peroxisome and other cellular compartments, and restore oxidative equilibrium 
within cells (Koepke et al., 2007; Young et al., 2008; Price et al., 2009; Undyala et al., 
2011; Giordano et al., 2012), to determine the role of H2O2 and related ROS in ADDL-
induced neurotoxicity.  Transduction of the targeted antioxidant has been documented 
in a number of cell types, with entry confirmed within 1 hour of addition (Giordano et al., 
2012).   To demonstrate transduction of CAT-SKL in neurons, we tracked cell entry of a 
biotinylated form of the recombinant enzyme (Fig. 4.2A).  Immunofluorescence analysis 
confirmed catalase staining was significantly increased in CAT-SKL treated neurons 
compared to vehicle or a non-transducible form of the recombinant enzyme (Fig. 4.2B).  
Similar transduction results were obtained in live cells with a CAT-SKL molecule 
covalently conjugated to red fluorescent spheres (Supplementary figure a4.1A), ruling 
out potential artefactual fixation anomalies.  Importantly, CAT-SKL - FluoSpheres® was 
enzymatically active – confirming no loss of quaternary structure for the obligate 
tetramer (Supplementary figure a4.1B).  As expected, catalase activity and 
immunoreactivity were increased in CAT-SKL-treated neuronal cultures after a 24 hour 
incubation (Fig. 2C,D). 
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Figure 4.2.  CAT-SKL transduction of primary cortical/hippocampal neurons.  (A) 
Primary rat cortical/hippocampal neurons were treated with 100 nM biotinylated CAT-
SKL for 0, 1, 2, and 24 hours, washed, and harvested in sample buffer.  Transduction 
was demonstrated by probing cell extracts with streptavidin alkaline phosphatase 
(SAP).  β-actin was used as a loading control.  Results shown are from same probed 
blot.  Full-length blots are presented in Supplementary Figure 2a.  (B) Cells were treated 
with vehicle, 1 μM CAT-SKL, or 1 μM catalase for 24 hours.  Cells were then washed, 
fixed, and immunostained for catalase (red fluorescence) and 4’,6-diamidino-2-
phenylindole (DAPI) (blue fluorescence).  Statistical analysis was performed using one-
way ANOVA.  When ANOVA indicated significant treatment effects, means were 
separated using Tukey’s Multiple Comparison Test.  Bars represent mean ± SEM for 
replicate samples (n=8).  Means followed by the same letter are not significantly 
different (p>0.05).  Scale bar = 20 μm.  Catalase enzymatic activity (C) and 
immunoreactivity (D) was measured after 24 hour treatment with 1 μM CAT-SKL or 
without (indicated as vehicle).  Cells were washed, harvested in PBS, and equal 
amounts of protein were separated by SDS-PAGE.  Antibodies utilized include anti-
catalase and anti-β-actin (n=3).   
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4.3.3  Neuroprotective effects of CAT-SKL.   
We next examined the protective effects of CAT-SKL against ADDL-induced 
neuronal toxicity.  To accomplish this, cellular mitochondrial dehydrogenase activity was 
measured by absorbance spectroscopy to determine cell viability in neurons pretreated 
with 1 μM CAT-SKL and subsequently challenged with 1 μM ADDLs.  Pretreatment with 
CAT-SKL exhibited a protective effect against ADDLs as evidenced by an increase in 
cell viability (Fig. 4.3A).  Likewise the peroxisomal proliferator Wy-14,643, which 
previously has been shown to increase endogenous catalase levels (Santos et al., 
2005; Inestrosa et al., 2013), also is protective when added prior to ADDL challenge 
(Fig. 4.3B).  Furthermore, pretreatment with 1 μM CAT-SKL and/or 100 μM Wy-14,643 
also reduced ADDL-induced H2O2 levels (Fig. 4.3C).     
 Fluorescence microscopy was employed to extend our quantitative biochemical 
results.  Here, primary neuronal cultures were stained for microtubule associated 
protein-2 (MAP-2), a dendritic marker.  Compared to a vehicle control (Fig. 4.4A), 1 μM 
ADDLs triggered a retraction in dendritic arborization (branching of dendrites), which 
resulted in decreased cell body clustering (Fig. 4.4B).  Importantly, CAT-SKL added 
before or after ADDL treatment protected against these effects (Fig. 4.4C,D).  Similar 
effects on dendrites were observed with the peroxisome proliferator Wy-14,643 (data 
not shown). 
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Figure 4.3.  Neuroprotective effects of CAT-SKL against ADDL-induced 
neurotoxicity.  (A) Primary rat cortical/hippocampal neurons were pretreated with CAT-
SKL (1 μM) for 24 hours and subsequently challenged with ADDLs (1 μM) for 24 hours.  
(B) Cells were pretreated with the peroxisomal proliferator Wy-14,643 (100 μM) for 48 
hours and then challenged with ADDLs (10 μM) for an additional 24 hours.  Cell viability 
was determined using the water soluble tetrazolium cell proliferation assay (WST-1).  
Statistical analysis was performed using one-way ANOVA.  When ANOVA indicated 
significant treatment effects, means were separated using Tukey’s Multiple Comparison 
Test.  Bars represent mean ± SEM for triplicate samples.  Means followed by the same 
letter are not significantly different (p>0.05).  (C) Neurons were pretreated with CAT-
SKL (1 μM) for 24 hours and/or Wy-14,643 (100 μM) for 48 hours.  Amount of H2O2 
produced in cells was determined by the Amplex® Red reagent (10-acetyl-3,7-
dihydroxy-phenoxazine) (n=4).  Similar results were seen in three additional 
experiments. 
 
Figure 4.3A Figure 4.3B 
Figure 4.3C 
0
50
100
150
200
250
300
350
ADDL CAT-SKL

ADDL
C
e
ll
 V
ia
b
il
it
y
(a
b
s
o
rb
a
n
c
e
 u
n
it
s
)
0
500
1000
1500
2000
2500
3000
3500
4000
ADDL (10 M)
Wy-14,643 (100 M)
_
+ +
_ _
+
a
a
b
C
e
ll
 V
ia
b
il
it
y
(a
b
s
o
rb
a
n
c
e
 u
n
it
s
)
0
25
50
75
100
125
150
ADDL CAT-SKL

ADDL
Wy-14,643

ADDL
CAT-SKL
+
Wy-14,643

ADDL
H
yd
ro
g
e
n
 P
e
ro
x
id
e
(f
lu
o
re
s
c
e
n
c
e
 u
n
it
s
)
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Effects of CAT-SKL on ADDL-induced neurite degeneration in primary 
rat cortical/hippocampal neurons.  Primary rat cortical/hippocampal neurons were 
treated as follows:  (A) Vehicle control for 24 hours.  (B) ADDLs (1 μM) for 24 hours.  
(C) CAT-SKL (1 μM) for 24 hours, followed by ADDLs (1 μM) for 24 hours.  (D) ADDLs 
(1 μM) for 24 hours, followed by CAT-SKL (1 μM) for 24 hours.  Neurons were 
immunostained with anti-MAP-2 antibodies (a dendritic marker), and visualized with 
AlexaFluor 488-goat anti-mouse antibodies (green fluorescence).  Scale bar = 20 μm. 
 
 
 
Figure 4.4A-D 
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Primary neuronal cultures were also stained for PMP70, a peroxisomal 
membrane protein.  Since CAT-SKL resides in the peroxisome and alters its oxidative 
environment, we hypothesized that there would be an effect on peroxisome number or 
morphology between treatments.  We have previously reported peroxisomal 
proliferation in aged, diseased, or xenobiotic-treated cells(Legakis et al., 2002; Wood et 
al., 2006; Koepke et al., 2008; Ivashchenko et al., 2011). The molecular basis for this 
induction is unclear; we have speculated that it happens to compensate for 
compromised peroxisome functioning or to assist mitochondria in metabolizing 
pathological levels of ROS (Giordano and Terlecky, 2012).  Alternatively, rates of 
pexophagy may be compromised (Huybrechts et al., 2009).  Here, in neurons, we find 
that ADDLs also triggered significant increases in peroxisomal numbers, evident both 
within cell processes and cell bodies (Fig. 5a,b) (p<0.05).  Importantly, pre-and post-
treatments with CAT-SKL significantly reversed these changes, resulting in peroxisomal 
staining more akin to that seen in untreated cells (Fig. 5c,d) (p<0.05).   
4.3.4  CAT-SKL and ADDL-induced mitochondrial impairment.   
Mitochondria and peroxisomes may share a redox-based dynamic relationship 
whereby changes in oxidant handling or overall function of one organelle, impacts the 
structural and functional integrity of the other(Koepke et al., 2007; Koepke et al., 2008; 
Ivashchenko et al., 2011; Walton and Pizzitelli, 2012; Wang et al., 2013).  For example, 
if the ability of peroxisomes to metabolize H2O2 is abrogated, mitochondria depolarize 
and begin producing ROS themselves (Koepke et al., 2007; Koepke et al., 2008; 
Ivashchenko et al., 2011; Walton and Pizzitelli, 2012).  In contrast, if peroxisomal 
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antioxidant capacity is enhanced, mitochondria repolarize and reduce oxidant 
production (Koepke et al., 2007).   
 In our culture studies, ADDLs cause neuronal mitochondria ROS production and 
depolarization (Fig. 6).  The former is seen as an increase in red fluorescence emitted 
by a mitochondrial ROS-sensitive dye; the latter by an increase in the monomeric 
(green fluorescence) form of the JC-1 dye.  Importantly, CAT-SKL significantly reversed 
these effects if supplied after ADDL treatment; or prevented them if provided 
prophylactically (p<0.05) (Fig. 6).   
4.3.5  ADDLs, CAT-SKL, and glutathione S-transferase.   
DNA microarray experiments were performed to determine the gene expression 
profiles of cells treated with ADDLs, CAT-SKL or CAT-SKL → ADDLs, as compared to 
untreated (control) cells.  Importantly, 79 genes showing significant expression level 
changes were in common between treatments (see Venn diagram – Fig. 7a).  Mining of 
functional association pathways with Ingenuity Systems’ Pathway Analysis software 
highlighted glutathione S-transferase (GST), a critical cellular detoxifying enzyme, 
among genes specifically altered by the treatments.  Furthermore, upstream regulatory 
analysis predicted that the specific isoform, GSTπ, was inactivated by ADDLs (Fig. 7b).  
This analysis, which was implemented using Ingenuity Systems software, can predict 
transcription factors involved in the gene expression changes observed in the data sets, 
and whether or not they are activated or inhibited.  GST was investigated further 
because of the dramatically reduced levels in post-mortem brains of AD patients (Lovell 
et al., 1998).   
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 Western blotting of ADDL-treated neurons revealed GSTπ levels to be reduced 
(Fig. 7c).  However, the effects of ADDL treatment on GSTπ were reversed when CAT-
SKL was present, either before or after ADDL treatment (Fig. 7d).  A heat inactivated 
form of CAT-SKL had no such effects on restoring GSTπ levels (Fig. 7d). 
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Figure 4.5.  CAT-SKL thwarts ADDL-induced proliferation of peroxisomes.  
Primary rat cortical/hippocampal neurons were treated as follows:  (A) Vehicle control 
for 24 hours. (B) ADDLs (1 μM) for 24 hours. (C) CAT-SKL (1 μM) for 24 hours followed 
by ADDLs (1 μM) for 24 hours. (D) ADDLs (1 μM) for 24 hours followed by CAT-SKL (1 
μM) for 24 hours.  Neurons were immunostained with anti-PMP70 (70 kDa peroxisomal 
membrane protein) antibodies followed by AlexaFluor 546 goat anti-rabbit antibodies 
(red fluorescence).  Quantification (inset) was accomplished using Image J shareware.  
Statistical analysis was performed using one-way ANOVA.  When ANOVA indicated 
significant treatment effects, means were separated using Tukey’s Multiple Comparison 
Test.  Bars represent mean ± SEM for replicate samples (n=5).  Means followed by the 
same letter are not significantly different (p>0.05).  Scale bar = 20 μm. 
 
 
 
 
 
 
 
Figure 4.5A-D 
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Figure 4.6.  CAT-SKL’s effects on mitochondria in ADDL-treated neurons.  Left 
panel:  Mitochondrial ROS was determined using the MitoTracker® Red CM-H2XRos 
selective probe (red fluorescence).  Right panel:  Mitochondrial depolarization was 
visualized using the JC-1 mitochondrial potential sensor (green fluorescence).  
Quantification (insets) was accomplished using Image J shareware.  Statistical analysis 
was performed using one-way ANOVA.  When ANOVA indicated significant treatment 
effects, means were separated using Tukey’s Multiple Comparison Test.  For left and 
right inset graphs, bars represent mean ± SEM for replicate samples (n=6 and n=8, 
respectively).  Means followed by the same letter are not significantly different (p>0.05).     
Scale bar = 20 μm.
Figure 4.6 left and right panels 
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Figure 4.7A Figure 4.7B 
Figure 4.7C 
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Figure 4.7.  CAT-SKL protects neurons from GSTπ depletion in ADDL treated 
neurons.  (A) Venn diagram illustrating 79 overlapping genes between treatments.  A 
total of 432 genes were altered in ADDLs, 427 in CAT-SKL, and 338 in CAT-SKL 
followed by ADDL treatments.  Complete lists of genes are available in Supplementary 
Table a4.1.  (B) Upstream regulator analysis was used to identify potential molecules 
upstream responsible for the observed gene expression changes in the dataset.  Blue 
indicates upstream regulator GSTπ is predicted to be inactivated. Nuclear factor 
(erythroid-derived 2)-like 2 (NFE2L2) is a transcription factor involved in increasing the 
expression of various antioxidant enzymes including: heme oxygenase-1 (HMOX1), 
UDP-glucuronosyltransferase (UGT1A6), and NAD(P)H quinone oxidoreductase 1 
(Nqo1), among others.  (C) Vehicle and ADDL (1 μM) treated neurons for 24 hours.  
Bands are taken from same western blot.  Quantification of western blots normalized to 
β-actin.  (D) Lane assignments left to right:  Vehicle control: cells pretreated with 
enzymatically inactive CAT-SKL (1 μM) - indicated with line through for 24 hours, 
followed by ADDL (1 μM) for 24 hours; cells pretreated with CAT-SKL (1 μM) for 24 
hours, followed by ADDL (1 μM) for 24 hours; cells treated with ADDL (1 μM) for 24 
hours, followed by enzymatically inactive CAT-SKL (1 μM) for 24 hours; cells treated 
with ADDL (1 μM) for 24 hours, followed by CAT-SKL (1 μM) for 24 hours.  
Quantification of western blots normalized to β-actin (n=3).  
Figure 4.7D 
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4.4  Discussion 
The importance of soluble oligomeric forms of Aβ as a major driving force in the 
initial stages of AD has been receiving ever wider acceptance (Lue et al., 1999; McLean 
et al., 1999; Wang et al., 1999; Klein, 2002; Selkoe, 2011).  Here, we confirm the 
toxicity of ADDLs in rat primary neuronal cultures.  In addition, we show these effects 
are prevented or reversed by the peroxisomally targeted antioxidant enzyme, CAT-SKL.  
How catalase supplementation of peroxisomes exerts such dramatic protective effects 
on neurons is not completely clear.  Indeed, there is only limited understanding of 
peroxisome involvement in AD, despite the clear importance of the organelle in overall 
cell physiology.  What is known is that peroxisome activity is upregulated in early states 
of the disease, an apparent initial response to Aβ’s effects (Cimini et al., 2009; Fanelli et 
al., 2013).  At later stages of the disease, changes in peroxisome number, activity, and 
oxidative balance are observed (Santos et al., 2005; Inestrosa et al., 2013).  
Plasmalogens, critical ether-linked phospholipids synthesized initially in peroxisomes, 
are present at diminished levels in the AD brain.  Accompanying this lipid perturbation 
are elevated levels of very long chain fatty acids, potentially toxic molecules normally 
metabolized in the organelle.  Finally, in the AD brain peroxisome density increases in 
neuronal cell bodies (Kou et al., 2011). 
Despite the uncertainty regarding peroxisomes and their role in neuronal health 
and Aβ-induced cytotoxicity, the results presented in this work suggest that an 
oxidatively-balanced peroxisome is a desirable goal.  Neuronal cells with peroxisomes 
made resistant to enhanced oxidative stress by addition of catalase, are robustly 
protected against the toxic effects of Aβ.  ROS are present at reduced levels, the 
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exquisitely complex neuronal architecture is maintained or regenerated, and viability is 
enhanced.   
Effects of CAT-SKL are not restricted to peroxisomes.  The targeted antioxidant 
once again reverses mitochondrial dysfunction, at least at the level of oxidant 
production and organelle polarity (Fig. 6).  Changes in mitochondrial form and function 
are known to accompany AD pathogenesis (Hirai et al., 2001; Garcia-Escudero, 2013; 
Xie et al., 2013).  The nature of the redox-based interplay between peroxisomes and 
mitochondria is a fascinating topic for future investigation, both within and without the 
context of AD.   
An important validation of the culture system employed in these studies was the 
demonstration, by DNA microarray analysis, that expression of the detoxifying enzyme 
GSTπ was compromised by ADDLs (and reversed by CAT-SKL).  GSTπ is a critically 
important cellular enzyme and there is no clear understanding of why the enzyme is 
present in greatly diminished concentrations in the AD brain.  It is not known to what 
extent decreased transcription and translation contributes – versus a destabilization or 
degradation of the fully synthesized molecule.  In our culture model, whatever 
mechanism is responsible for reduced levels of the enzyme, they are sensitive to CAT-
SKL’s redox-balance-creating effects.  The fact that GST is inactivated by the lipid 
peroxidation product 4-hydroxynonenal, supports the damage by oxidation theory 
(Lovell et al., 1998).   
Targeted antioxidant prophylaxis is a relatively new concept, and is gaining 
momentum in this time of considerable question about the safety and efficacy of more 
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traditional antioxidants (Petersen et al., 2005; Brewer, 2010; Polidori and Nelles, 2013; 
Watson, 2013; Persson et al., 2014).  Is it the non-selective quenching of oxidants that 
is detrimental?  Or perhaps the high concentrations required of molecules needed in 
stoichiometric amounts.  Regardless, our work suggests CAT-SKL possess powerful 
neuroprotective effects against Aβ-induced neurotoxicity; preclinical testing is the next 
step and has commenced.   
4.5  Materials and Methods 
Primary neuronal cultures.  E18 Sprague Dawley rat cortex/hippocampus tissue was 
obtained from BrainBits®.  Preparation and cell plating was performed following the 
manufacturer’s protocol.  Briefly, cell culture plates were coated overnight using 
standard cell culture conditions with poly-D-lysine (50 μg/mL) (Sigma-Aldrich).  Rat 
cortex/hippocampus tissue was incubated in 2 mg/mL papain for 10 minutes at 37°C.  
Cell dispersal was performed using a sterile glass Pasteur pipette.  Sample containing 
the dispersed cells was transferred to a new tube and centrifuged at 200 x g for 1 
minute.  The supernatant was discarded and the pellet was resuspended in NbActiv1TM 
media (BrainBits®).  Cells were plated and incubated under normal cell culture 
conditions for 7 days to allow differentiation.  Media was changed every 3 days. 
ADDL preparation.  Aβ 1-42 peptide was purchased from California Peptide Research, 
Inc.  ADDL preparation was carried out as previously documented (Klein, 2002).  Briefly, 
monomerization of amyloid-beta 1-42 was performed by incubating with 1,1,1,3,3,3-
hexafluoror-2-propanol (HFIP) (Sigma-Aldrich) to a final concentration of 1 mM and 
incubated at room temperature for 1 hour.  The amyloid-beta-HFIP solution was then 
placed on ice for an additional 10 minutes and aliquoted under a fume hood in 
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Eppendorf tubes which allowed for HFIP evaporation overnight.  ADDL preps were 
performed by resuspending the dried peptide in dimethyl sulfoxide to generate a 5 mM 
stock.  The 5 mM solution was additionally diluted into NbtActiv1TM medium for 24 hours 
at 5°C and then centrifuged for 10 minutes at 14,000 x g.  The resultant supernatant 
was transferred to a new tube to make a 100 μM ADDL preparation to work from.  
Protofibrils were formed by modifying the above protocol and leaving the peptide in 
dimethyl sulfoxide for 24 hours at 37°C and then diluting into NbtActiv1TM.   
Gel filtration.  Sephadex G-50 beads were suspended and gently swirled in dH2O and 
allowed to swell at room temperature.  A Poly-Prep column (BIO-RAD) was filled with 
the swollen bead suspension and allowed to settle to a ~10 mL bed volume.  The 
column was then re-equilibrated with PBS.  Equal volumes/concentrations of 
polypeptide samples were added to the top of the bed volume and additional PBS was 
added through the column. A Bio-Dot microfiltration system (BIO-RAD) was readied 
containing a nitrocellulose membrane.  100 μL fractions were collected directly into the 
Bio-Dot microfiltration system.  After applying vacuum to affix polypeptides on the 
membrane surface, the membrane was stained with Ponceau S.  Quantification of 
polypeptide levels in fractions was determined using National Institutes of Health’s 
Image J public domain shareware.  Additional characterization showed polypeptide 
staining was linearly responsive to amount loaded (data not shown).     
CAT-SKL.  The recombinant protein biologic was expressed and purified as previously 
described (Young et al., 2008).  It was biotinylated as described in (Terlecky, 2002) to 
track entry into primary rat cortical/hippocampal neurons.  Equal numbers of plated 
neurons were treated or not with 100 nM biotinylated CAT-SKL for 0, 1, 2, and 24 hours, 
107 
 
 
 
and harvested in PBS.  Proteins were separated by SDS-PAGE, and transferred to a 
nitrocellulose membrane.  The membrane was blocked with 5% nonfat dry milk and 
biotinylated CAT-SKL was visualized with streptavidin alkaline-phosphatase (1:1000). 
Anti-β-actin antibodies (1:10000) were used to identify β-actin which served as a 
loading control.  These antibodies were developed by the nitro-blue tetrazolium chloride 
and 5-bromo-4-chloro-3’-indolyphosphate p-toluidine salt (NBT/BCIP) 1-Step Solution 
(Thermo Scientific).   
Catalase staining in neurons.  Neurons were plated onto poly-D-lysine coated 
coverslips as described above and fixed for 10 minutes in 3.7% paraformaldehyde and 
permeablized with 0.1% Triton X-100.  Sites that non-specifically bind to antibodies 
were blocked with 5% normal goat serum for 15 minutes.  Cells were then incubated 
with rabbit anti-catalase antibodies (1:100) for 1 hour, washed with 0.01% Tween-20 in 
phosphate buffered saline, and incubated with goat anti-rabbit Alexafluor 546 antibodies 
(1:15000) for 1 hour.  Neurons were then mounted with ProLong®Gold antifade reagent 
with 4',6-diamidino-2-phenylindole (Invitrogen).  Microscopic analysis was performed 
using the Zeiss ApoTome Imaging system from the Microscopy, Imaging and Cytometry 
Resources Core Facility (MICR), at the Wayne State University School of Medicine.   
Catalase enzymatic activity and immunoreactivity.  Equal numbers of plated 
neurons were treated or not with 1 μM CAT-SKL for 24 hours.  Cells were then washed 
3 times and harvested in PBS.  Protein concentrations were measured using the 
Bradford Reagent (ThermoScientific).  Catalase enzymatic activity was determined by 
its ability to decompose H2O2 as previously described (Koepke et al., 2008; Price et al., 
2009).  Here, equal protein concentrations of neuronal cultured lysates were added to a 
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final concentration of 1 mg/mL bovine serum albumin, 0.02 M imidazole, 0.2% Triton-X, 
and 0.06% H2O2 in phosphate buffered saline.  Samples were incubated for 15 minutes 
at room temperature and a titanium oxysulfate stop solution was applied.  Absorbance 
units at 405 nm were measured on a microplate reader.  For western blots, equal 
amounts of protein were separated by SDS-PAGE, transferred to nitrocellulose, blocked 
and probed with anti-catalase antibodies (1:4000) and anti-β-actin antibodies (1:10000).  
Cell viability measurements.  Rat cortical/hippocampal neurons were plated on a 96-
well plate in equal numbers (~100,000 cells) per well.  Cells were then pretreated with 
CAT-SKL (1 μM) for 24 hours or the peroxisome proliferator Wy-14,643 (100 μM) 
(Sigma-Aldrich) for 48 hours and then challenged with ADDLs (0.1, 1, and 10 μM) for 24 
hours.  Cellular viability was determined by measuring metabolic activity using the water 
soluble tetrazolium dye (WST-1); ELISA based assay kit (Millipore).  Absorbance of 
samples was measured in a microplate reader at 420 nm, with a reference wavelength 
of 600 nm.   
H2O2 measurements.  H2O2 was measured using the Amplex
® Red (10-acetyl-3,7-
dihydroxyphenoxazine) Hydrogen Peroxide/Peroxidase Assay Kit (Molecular Probes®, 
Inc.).  Rat cortical/hippocampal neurons were plated on to 96-well plates in equal 
numbers and pretreated with an unrelated control peptide (1 μM), CAT-SKL (1 μM), 
and/or Wy-14,643 (100 μM) for 24 hours following ADDL treatment (1 μM) for an 
additional 24 hours.  Neurons were washed two times with Hank’s balanced salt 
solution and treated with the Amplex reagent following the manufacturer’s protocol.  
Fluorescence units were analyzed by a microplate reader using excitation and emission 
wavelengths of 530 and 590 nm, respectively.     
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Fluorescence microscopy.  Primary rat cortical/hippocampal neurons were plated on 
coated 2 cm2 glass coverslips following the manufacturer’s protocol (BrainBits®).  All 
drug applications were performed blindly.  After 7 days of differentiation, neurons were 
treated with the following concentrations:  ADDL (1 μM), CAT-SKL (1 μM), Wy-14,643 
(100 μM).  Slides were washed three times with Hank’s balanced salt solution between 
treatments, and then fixed and stained with the appropriate antibodies.  Primary and 
secondary antibodies employed include: anti-MAP-2 (1:800) (Millipore) coupled with 
AlexaFluor 488 goat anti-mouse (1:500) (Life Technologies); and anti-PMP70 (1:500) 
(abcam®) coupled with AlexaFluor 546 goat anti-rabbit (1:15000) (Invitrogen).  
Microscopic analysis was performed using the Leica TCS SP2 confocal microscope 
located in the Department of Anatomy and Cell Biology’s microscope facility at the 
Wayne State University School of Medicine, and Zeiss ApoTome Imaging System from 
MICR, also at the Wayne State University. 
Mitochondrial assays.  For mitochondrial ROS and membrane potential assays, 
neurons were grown and maintained as described above except that coverslips were 
pre-coated with 100 μg/mL poly-D-lysine. Neurons were 1)  pre-treated with 1 μM CAT-
SKL for 24 hours, and post-treated with 1 μM ADDL for an additional 24 hours, or 2)  
pre-treated with 1 μM ADDL for 24 hours and then post-treated with 1 μM CAT-SKL for 
an additional 24 hours.  Mitochondrial ROS production was determined by using 
MitoTracker® Red CM-H2XRos (Invitrogen).   Medium containing 200 nM of the 
Mitotracker probe was incubated with neurons for 20 minutes at 37°C, 5% CO2, and 
washed with Hank’s balanced salt solution.  Mitochondrial membrane potential was 
determined using the JC-1 mitochondrial potential sensor (Invitrogen).  Depolarized 
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mitochondria appear as diffuse green structures.  Medium containing 2 μg/mL of the JC-
1 dye was incubated with the neurons for 20 minutes, and washed with Hank’s 
balanced salt solution.  Cells from both treatment protocols were imaged using the 
Zeiss ApoTome Imaging system from the MICR. 
DNA microarray analysis.  Cells were maintained and treated as described above, 
washed twice and harvested in PBS (2 plates per condition).  Total RNA was isolated 
from cell pellets using an RNeasy Midi Kit from Qiagen.  Quantity and quality of all 
mRNA samples was determined by analysis with the NanoDrop 1000, Agilent 
Bioanalyzer and the Agilent RNA 6000 Nano Kit (Agilent Technologies).  Whole-
genome expression was measured by a 2-color microarray approach using Agilent 
SurePrint G3 Rat GE 8X60K arrays (Agilent Technologies) at the Applied Genomics 
Technology Center Core, Wayne State University.  Feature analysis and data extraction 
was performed using Agilent Feature Extraction software version 11.5.1.1, where for 
matched biological replicates the log10 expression ratios are CAT-SKL-treated (cy5-
labeled) relative to control vehicle-treated sample (cy3-labeled). P values and ratios of 
detection for Agilent probes (background subtracted and lowess normalized) were 
averaged for sample replicates. A threshold of significance for ADDL, ADDL→CATSKL 
and CAT-SKL was set at p<=.01 and a threshold of significance for CATSKL→ADDL 
was set at p<=.001. The two filters were used to yield relatively similarly sized sets of 
significant annotated transcripts for each treatment that would be applicable to 
downstream pathway analysis. Duplicate significant probes were gene-averaged. 
Systems and pathway-level analysis for enrichment and biological meaning from 
resulting data was accomplished using Ingenuity Systems software (Redwood City, 
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CA).  MIAME compliant data sets were uploaded to the Gene Expression Omnibus 
(GEO) website, and are available through accession number GSE55369.   
GST quantification.  GSTπ expression was quantified by western blot analysis using 
Image J software.  Cells were washed with Hank’s balanced salt solution and harvested 
into cell lysis buffer (Cell Signaling).  Protein quantification was made using the Bradford 
reagent (ThermoScientific).  For western blots, equal amounts of protein were loaded to 
SDS-PAGE, transferred to a nitrocellulose membrane, and blocked with 5% non-fat 
milk.  Antibodies utilized included anti-GSTπ (MBL International Corporation) (1:1000) 
coupled with goat anti-rabbit-HRP antibodies (1:5000); and anti-β-actin antibodies 
(1:10000) coupled with goat anti-mouse-AP antibodies (1:5000). 
Statistical analysis.  Where appropriate, statistical analysis was performed in 
GraphPad Prism version 5.0 using one-way analysis of variance (ANOVA).  When 
ANOVA indicated significant treatment effects, means were separated using Tukey’s 
Multiple Comparison Test. 
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Appendix Chapter 4 
Supplementary figure a 4.1A 
 
 
 
 
 
 
 
 
 
Supplementary figure a 4.1B 
 
 
 
 
 
 
 
Supplementary figure a4.1.  CAT-SKL-FluoSpheres®.  (A) CAT-SKL-FluoSpheres® 
(0.1 μM) was added or not to cortical/hippocampal neurons for 24 hours.  DIC = 
differential interference contrast microscopic image.  (B)  CAT-SKL-FluoSpheres® are 
enzymatically active similar to the unmodified CAT-SKL molecule.  FluoSpheres® 
themselves were not able to metabolize H2O2.  Scale bar = 20 μm.   
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Supplementary table a4.1.  List of genes identified by microarray analysis with significant changes in gene expression.  A 
threshold of significance for ADDL, ADDL→CATSKL and CAT-SKL was set at p<=.01 and a threshold of significance for 
CATSKL→ADDL was set at p<=.001.  
 
CATSKL, 
CATSKL + 
ADDL, ADDL 
(79) 
 
CATSKL 
(425) 
 
CATSKL_p-
value 
 
CATSKL_
LogRatio(
Base10) 
 
CATSKL+ADDL 
(336) 
 
CATSKL+
ADDL_p-
value 
 
CATSKL+ADDL_Lo
gRatio(Base10) 
 
ADDL+CATSKL
(135) 
 
ADDL+CA
TSKL_p-
value 
 
ADDL+CATSKL_Lo
gRatio(Base10) 
 
ADDL 
(430) 
 
ADDL_
p-value 
 
ADDL_Lo
gRatio 
(Base 10) 
ACADL 4930571K
23Rik 
7.40E-03 -0.004 A2M 1.23E-08 0.437 ABRA 3.30E-03 0.395 1700020N15Rik/
Gm6812 
8.88E-
03 
0.062 
ADAMTS9 AADAT 1.01E-03 0.389 AADAT 1.55E-04 0.676 ACSM3 3.58E-03 0.041 A2M 2.78E-
05 
0.301 
APOC1 ACACA 3.80E-03 -0.209 ABHD3 3.20E-04 0.256 ADAMTS15 5.34E-03 0.398 ABHD14B 9.28E-
03 
0.018 
APOE ACADL 4.80E-03 0.242 ACACA 5.83E-05 -0.288 ADRA1D 2.88E-03 0.224 ACADL 9.61E-
04 
0.234 
ARX ADAM23 5.80E-03 -0.192 ACADL 1.96E-05 0.285 AEBP1 1.13E-03 0.348 Acot1 7.81E-
03 
0.212 
ASIC4 ADAMTS9 4.84E-03 0.326 ACSS1 8.16E-05 0.264 AIF1 8.30E-04 0.242 ACSS1 1.04E-
04 
0.257 
BTBD17 ADCYAP1
R1 
6.50E-03 0.382 ADAMTS9 1.99E-07 0.582 AMY2A 1.06E-04 0.26 ADAMTS1 1.33E-
03 
-0.21 
C10orf54 AGPS 9.46E-03 -0.222 ADM 2.62E-05 0.284 ANXA3 2.67E-03 0.26 ADAMTS9 6.06E-
04 
0.418 
C1QL1 AIF1 2.45E-08 0.415 AGT 6.22E-09 0.428 APOC2 4.98E-03 -0.304 ADCYAP1 6.14E-
03 
-0.174 
CDCA7L ALS2CR8 5.48E-03 -0.288 AJUBA 9.92E-04 0.296 Apol3/LOC68135
1 
4.86E-03 0.261 ADM 5.90E-
04 
0.284 
CDK14 ANGPTL4 2.68E-03 0.347 ALDH1L1 9.64E-05 0.266 AREG/AREGB 6.22E-03 0.002 AFP 2.05E-
03 
-0.217 
CDK2 ANKLE2 6.75E-03 -0.32 AMPD3 1.54E-04 0.257 ARG1 4.04E-04 0.32 AGPAT9 4.31E-
06 
-0.37 
CENPT ANKRD26 3.75E-03 -0.395 ANGPTL4 1.69E-04 0.3 ASB15 9.74E-03 0.262 AGRP 2.19E-
03 
-0.233 
114 
 
 
 
 
CATSKL, 
CATSKL + 
ADDL, ADDL 
(79) 
 
CATSKL 
(425) 
 
CATSKL_p-
value 
 
CATSKL_
LogRatio(
Base10) 
 
CATSKL+ADDL 
(336) 
 
CATSKL+
ADDL_p-
value 
 
CATSKL+ADDL_Lo
gRatio(Base10) 
 
ADDL+CATSKL
(135) 
 
ADDL+CA
TSKL_p-
value 
 
ADDL+CATSKL_Lo
gRatio(Base10) 
 
ADDL 
(430) 
 
ADDL_
p-value 
 
ADDL_Lo
gRatio 
(Base 10) 
CHD2 ANKRD66 6.44E-04 -0.259 ANKLE2 4.94E-04 -0.254 ASB2 9.16E-03 -0.166 AGT 2.12E-
04 
0.416 
CHST7 APAF1 5.70E-03 -0.18 ANXA1 8.11E-04 0.272 BHLHE40 4.63E-03 -0.214 AGTR1 2.18E-
04 
-0.456 
CSF1 APOC1 4.69E-05 0.384 AOX1 5.72E-06 0.554 C3 3.40E-03 0.332 ALDH1L1 3.48E-
04 
0.258 
CSPG4 APOD 2.65E-03 0.312 APLN 1.37E-04 0.285 C7 6.89E-06 0.345 ANGPT1 1.91E-
03 
0.252 
CTSH APOE 2.45E-04 0.403 APOC1 8.01E-08 0.42 CA8 8.80E-03 0.169 ANKRD33B 4.54E-
04 
-0.275 
CYP2J2 APPL2 8.65E-03 0.184 APOD 7.62E-07 0.418 CALCR 8.43E-03 -0.156 APLN 3.67E-
03 
0.25 
CYP4F8 ARG1 2.32E-04 0.408 APOE 9.91E-10 0.455 CAV1 1.02E-04 0.446 APOA2 4.84E-
03 
0.263 
EFS ARHGAP1
1A 
2.10E-03 0.26 APPL2 6.27E-04 0.281 CCL25 3.53E-03 -0.2 APOC1 6.40E-
05 
0.365 
ENTPD2 ARHGAP1
8 
6.95E-03 0.252 AQP4 2.40E-08 0.399 CCL3L1/CCL3L3 5.48E-13 0.667 APOE 5.75E-
06 
0.41 
FABP7 ARX 1.94E-03 0.319 ARG1 4.30E-04 0.263 CDC14A 8.38E-03 0.236 AQP4 1.90E-
04 
0.358 
FAM89A ASF1B 5.66E-03 0.566 ARHGAP18 4.94E-04 0.236 Cdca7 5.74E-03 0.258 ARC 4.32E-
03 
-0.191 
FRAS1 ASIC4 1.52E-03 0.215 ARHGEF19 5.70E-04 0.318 CHDH 4.52E-03 -0.196 ARHGAP24 5.42E-
06 
-0.344 
GJA1 ATM 6.61E-03 -0.654 ARX 6.79E-09 0.439 CHRDL1 2.16E-03 0.32 ARHGEF19 6.95E-
05 
0.475 
GPR37L1 AXIN2 9.59E-03 -0.264 ASF1B 3.61E-04 0.402 CKMT2 8.69E-03 -0.54 ARHGEF9 9.98E-
03 
-0.221 
GSTA2 AXL 7.94E-04 0.026 ASIC4 1.41E-04 0.26 CNKSR1 9.19E-03 -0.196 ARL4D 1.04E-
03 
-0.227 
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Gstt3 BTBD17 1.29E-04 0.266 ASPM 3.60E-05 0.278 CNR1 8.44E-03 0.17 ARPP21 1.45E- 
04 
-0.252 
IGF1 C10orf54 1.32E-03 0.288 ATP1A2 5.70E-08 0.386 COL1A1 3.34E-08 0.835 ARRDC2 5.10E-
03 
-0.024 
ITGB5 C1QL1 1.32E-04 0.346 BCAN 1.38E-06 0.335 CORT 1.14E-03 0.226 ARX 5.86E-
06 
0.308 
JAM2 C3 1.26E-10 0.595 BCAS1 4.36E-10 0.47 CRH 5.98E-05 0.276 ASIC4 5.18E-
03 
0.188 
KANK1 C5 7.73E-03 -0.238 BDH2 2.95E-04 0.351 Cxcl12 7.19E-04 0.275 ASPG 9.88E-
03 
0.417 
MCM3 C7 3.05E-05 0.336 BMP4 1.65E-05 0.554 CXCL2 5.32E-03 0.678 ASPM 2.35E-
03 
0.224 
MDFIC CA8 7.72E-03 0.192 BMP7 3.16E-05 0.298 CYBA 5.60E-03 0.19 ATP1A2 3.54E-
06 
0.387 
MEIS1 CACNG5 6.06E-04 -0.23 BTBD17 1.03E-05 0.305 Cyp2d22 7.60E-04 0.262 BCAN 5.01E-
04 
0.269 
MGST1 CALCA 3.96E-03 0.323 C10orf54 1.15E-06 0.338 DAB2 3.64E-03 -0.013 BCAS1 1.58E-
03 
0.218 
MLC1 CAPN13 2.60E-03 -0.242 C1QL1 6.17E-04 0.284 DICER1 6.90E-03 0.355 BIRC5 1.21E-
03 
0.222 
MSX1 CAV1 4.06E-08 0.494 C3 2.76E-05 0.358 DUXA 2.08E-03 -0.217 BMP3 3.88E-
03 
-0.242 
MYO6 CCDC125 5.36E-03 -0.362 C4orf50 6.10E-06 -0.526 EGR2 5.64E-03 0.18 BTBD17 6.01E-
05 
0.285 
NCAPH CCDC175 3.85E-03 -0.327 C7 1.24E-04 0.258 ELK4 3.70E-03 -0.013 C10orf54 3.39E-
03 
0.201 
NDRG2 CCDC8 8.87E-03 0.174 CARTPT 4.28E-04 0.229 EMR1 4.56E-10 0.596 C11orf95 3.66E-
03 
-0.306 
NFE2L2 CCL3L1/C
CL3L3 
7.34E-10 0.53 CASP6 4.99E-04 0.418 Entpd4 9.62E-03 -0.404 C1QL1 5.78E-
03 
0.249 
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NTRK2 CCNB2 8.04E-03 0.203 CAV1 2.76E-05 0.325 F5 5.72E-03 -0.418 C3 2.10E-
03 
0.283 
NXPH1 Cd163l1 7.50E-03 -0.368 CAV2 1.93E-04 0.469 Fam60a 4.46E-03 -0.207 C4orf50 6.58E-
03 
-0.262 
PDPN CD1D 7.39E-03 0.55 CBS 4.86E-05 0.273 FASLG 2.31E-04 0.341 C5 9.42E-
03 
-0.231 
PLD1 CD2AP 3.75E-03 -0.222 CCL3L1/CCL3L3 8.66E-08 0.501 FBXO36 3.16E-03 0.304 C7 1.75E-
05 
0.31 
PLEKHD1 CD55 2.08E-04 0.516 CCNA2 5.77E-07 0.353 FOXO4 8.51E-03 -0.248 CAND2 3.75E-
03 
0.192 
PPIC CD99L2 6.15E-03 -0.18 CCNB1 5.52E-04 0.254 GFAP 7.31E-03 -0.092 CAPN5 8.36E-
03 
-0.264 
PRODH CDC14A 2.85E-03 -0.686 CCNB1IP1 3.70E-05 -0.454 GPC3 1.27E-03 -0.286 CASP12 3.24E-
03 
-0.232 
RGCC Cdca7 1.20E-03 0.317 CDCA3 2.16E-06 0.33 Gpr165 6.66E-03 -0.104 CBFA2T2 5.55E-
03 
-0.315 
RREB1 CDCA7L 5.88E-03 0.182 Cdca7 5.21E-05 0.317 GPR18 2.49E-03 -0.1 CBS 5.14E-
04 
0.238 
RRM2 CDK14 1.87E-03 -0.284 CDCA7L 5.24E-06 0.316 GPR50 3.40E-03 0.617 CBX6 1.40E-
03 
-0.21 
S100A16 CDK2 1.54E-03 0.279 CDHR1 1.49E-12 0.578 GRAMD3 4.81E-03 0.186 CCDC8 5.90E-
03 
0.206 
S100B CENPT 7.95E-03 0.236 CDK1 6.82E-06 0.306 Gsta3 1.30E-03 0.336 CCL3L1/CCL3L3 2.15E-
03 
-0.283 
S1PR1 CEP72 9.51E-03 0.292 CDK14 1.25E-04 -0.268 GTF3C3 6.64E-03 -0.089 CCNA2 4.23E-
03 
0.266 
SALL1 CERS6 8.81E-03 -0.218 CDK2 5.21E-05 0.314 HLA-B 9.06E-03 0.226 CD302 7.32E-
03 
0.184 
SALL3 Ces1f/Cesl
1 
9.90E-04 -0.517 CDKN1C 3.68E-09 0.434 HMOX1 5.99E-05 0.268 CDC20 9.14E-
03 
0.172 
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SCRG1 CHD2 3.39E-03 -0.253 CDKN2C 4.65E-04 0.268 HMX3 1.31E-03 -0.36 CDCA2 5.90E-
03 
0.397 
SDC4 CHIA 5.58E-03 0.227 CENPQ 8.25E-04 0.25 HOXB13 3.68E-03 -0.342 CDCA3 3.98E-
04 
0.274 
SEPP1 CHST7 7.70E-03 0.186 CENPT 9.47E-06 0.33 HTR2B 6.10E-03 0.021 Cdca7 1.27E-
03 
0.27 
8-Sep CKS2 8.92E-03 0.186 CERS6 7.46E-04 -0.222 HTRA1 2.46E-03 0.322 CDCA7L 3.42E-
03 
0.254 
SERINC5 CMYA5 3.32E-03 0.215 Ces1f/Cesl1 9.65E-05 -0.365 Ifitm6 7.02E-03 -0.233 CDHR1 9.65E-
15 
0.686 
SLC1A3 CNNM1 7.31E-03 -0.204 CHD2 3.46E-05 -0.276 IL1A 4.64E-03 0.359 CDK1 5.85E-
03 
0.209 
SLC32A1 CNOT6L 9.19E-03 -0.211 CHST7 1.02E-04 0.274 IL1B 6.15E-05 1.007 CDK14 3.64E-
03 
-0.198 
SMPDL3A COL14A1 9.74E-03 0.2 CKAP2 6.33E-05 0.265 KIF11 2.13E-04 0.293 CDK2 2.28E-
03 
0.239 
SOX10 COL1A1 2.15E-03 -0.009 CKS2 2.36E-04 0.256 KIF18B 1.29E-03 0.292 CDKN1C 1.42E-
03 
0.206 
SPARCL1 CORT 2.37E-05 0.329 CMTM5 7.53E-05 0.27 KLF2 2.45E-04 0.25 CDT1 6.26E-
03 
-0.108 
SPP1 CPEB4 9.43E-03 -0.207 CNP 4.59E-04 0.251 KRIT1 4.89E-03 0.183 CENPT 5.36E-
04 
0.296 
TCF7L2 CPT1A 9.40E-03 0.314 COL16A1 9.78E-04 0.22 LDHC 3.57E-03 0.24 CH25H 2.95E-
04 
-0.268 
TIMELESS CRH 2.45E-07 0.382 CORT 3.93E-08 0.394 LFNG 1.88E-03 0.266 CHD2 6.33E-
03 
-0.176 
TMEM100 CRTAP 8.74E-03 -0.168 CPEB4 9.19E-04 -0.229 LILRA6 9.31E-03 -0.264 CHST7 2.38E-
03 
0.203 
TOP2A CRYAB 6.50E-03 -0.028 CPT1A 5.94E-05 0.291 LOC304903 3.19E-03 0.306 CIDEA 1.90E-
05 
-0.299 
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TXNIP CSF1 3.98E-04 0.342 CPT2 2.56E-04 0.31 LOC682360 6.01E-03 -0.246 CLDN5 6.86E-
03 
-0.381 
UBE2T CSPG4 4.83E-03 0.302 CRH 7.26E-05 0.28 LOC685608 
(includes others) 
5.82E-03 -0.44 CLIC1 4.36E-
03 
-0.21 
VAMP8 CTDSPL2 3.35E-03 -0.264 CROT 7.30E-04 0.233 LOC688793 
(includes others) 
2.27E-03 -0.272 CMTM5 2.63E-
03 
0.254 
VCAM1 CTGF 3.95E-03 0.198 CSF1 1.39E-06 0.43 LOC691670 8.12E-03 -0.574 CMYA5 1.15E-
03 
0.284 
WDR16 CTSH 1.04E-06 0.518 CSPG4 2.21E-06 0.388 LPL 2.45E-03 0.032 COL16A1 9.95E-
03 
0.185 
ZCCHC24 Cxcl12 9.14E-03 0.194 CTNND1 7.55E-04 -0.242 LRG1 1.47E-03 -0.564 COL6A1 5.48E-
03 
-0.192 
 CXCL16 9.20E-03 0.283 CTSH 3.88E-09 0.495 MAGEB3 7.65E-04 -0.324 CORIN 1.99E-
03 
-0.587 
 CYBA 6.65E-05 0.365 Cxcl12 3.75E-04 0.357 MARC1 4.03E-04 -0.307 CPT2 6.02E-
03 
0.228 
 CYP2J2 1.70E-03 0.424 CXCL14 2.40E-06 0.322 MAS1 5.67E-03 0.182 CREM 4.63E-
03 
-0.196 
 Cyp2t4 9.12E-03 0.388 CYBA 3.74E-07 0.363 Mbp 1.17E-06 -0.361 CRH 4.53E-
04 
0.231 
 Cyp4a14 2.56E-04 -0.27 CYP2J2 1.36E-05 0.394 MGAT4C 1.62E-03 -0.349 CRHR1 1.55E-
03 
-0.26 
 Cyp4f16/G
m9705 
3.46E-03 0.231 CYP4F12 7.55E-05 0.477 MMP13 6.34E-04 0.489 CROT 1.41E-
04 
0.261 
 CYP4F2 2.90E-03 -0.231 CYP4F8 1.71E-04 0.607 MORC2 4.80E-03 0.25 CRYAB 3.05E-
04 
-0.256 
 CYP4F8 6.05E-03 0.658 CYP7B1 5.49E-09 0.432 MRPL50 4.99E-04 0.338 CSF1 7.36E-
04 
0.277 
 CYTIP 5.84E-03 0.272 DDIT4L 2.79E-06 0.364 MS4A8B 8.06E-03 -0.236 CSF3 6.22E-
03 
0.193 
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 DCAF17 8.46E-03 -0.186 DECR1 3.80E-06 0.322 MTF1 8.81E-03 0.174 CSPG4 6.15E-
03 
0.273 
 DCC 3.88E-03 -0.187 DHRS4 7.00E-04 0.33 MYH1 1.34E-04 0.398 CSRNP1 2.12E-
03 
-0.24 
 DCLK3 9.69E-03 0.183 DLGAP5 3.08E-04 0.24 MYH8 2.60E-03 0.248 CTSH 1.27E-
03 
0.362 
 DDC 3.22E-05 0.421 DMRT3 2.28E-04 0.294 MYLK 6.44E-03 -0.302 Cxcl12 8.72E-
04 
0.272 
 DEGS2 6.32E-03 -0.083 DPYSL3 9.83E-04 -0.212 MYO10 6.77E-03 -0.034 CXCL14 7.55E-
03 
0.252 
 DEPDC1B 4.93E-03 0.359 ECI1 2.71E-04 0.276 NCEH1 5.16E-03 0.188 CXCR4 2.92E-
03 
0.263 
 DLK1 3.50E-04 -0.238 EDEM3 3.42E-04 -0.294 NOS1AP 1.71E-03 -0.398 CXorf57 3.57E-
04 
-0.257 
 DLX5 9.88E-03 0.188 EDNRB 5.10E-06 0.297 NPL 2.29E-04 0.278 CYB5R1 7.38E-
03 
0.2 
 DPP4 5.89E-03 0.358 EFS 1.96E-05 0.332 NRARP 6.96E-05 0.272 CYBA 3.32E-
05 
0.308 
 DUXA 4.86E-03 -0.261 EMR1 8.63E-05 0.312 NRL 7.02E-04 -0.622 Cyp11b1/Cyp11b
3 
1.71E-
03 
-0.23 
 EARS2 3.32E-03 -0.282 ENPP2 4.93E-05 0.328 Oacyl 4.69E-03 0.252 CYP2J2 7.00E-
04 
0.452 
 ECE1 7.88E-03 -0.25 ENTPD2 1.05E-10 0.502 OAS2 3.94E-03 -0.199 Cyp3a62 5.40E-
03 
-0.22 
 EFS 8.30E-04 0.284 EPB41L2 3.76E-05 0.386 OLFML2A 4.38E-03 0.444 CYP4F12 5.00E-
03 
0.401 
 EIF2AK2 4.99E-03 -0.365 EPHA3 2.55E-04 -0.241 Olfr124 2.96E-03 0.032 CYP4F8 9.71E-
03 
0.506 
 EIF2C4 9.71E-03 -0.19 ERBB2 1.71E-05 0.36 Olfr212/Olfr213 8.08E-03 0.33 CYP7B1 1.93E-
04 
0.32 
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 EMP1 9.58E-03 -0.046 F3 1.93E-04 0.246 OR6C68 3.45E-03 0.3 Dclk1 6.58E-
03 
-0.177 
 EMR1 3.50E-09 0.53 FABP7 1.03E-09 0.452 PAX3 4.64E-03 -0.192 DDIT4L 3.59E-
03 
0.324 
 ENPP1 4.94E-03 -0.202 FAM181B 1.49E-06 0.35 PCOLCE2 7.46E-03 0.635 DDR2 1.26E-
03 
0.214 
 ENPP2 3.23E-04 0.3 FAM64A 3.40E-05 0.281 PDE4B 1.76E-03 -0.218 DECR1 1.66E-
03 
0.211 
 ENTPD2 2.11E-04 0.387 FAM89A 9.75E-09 0.453 PDGFB 7.92E-03 0.035 DEGS2 1.90E-
03 
-0.34 
 ERC1 2.98E-03 -0.205 FANCL 1.06E-04 0.28 PDGFRA 4.33E-04 0.29 DEPDC1 6.63E-
03 
0.328 
 ERC2 3.73E-04 -0.262 FGFRL1 2.00E-04 0.254 PDYN 2.19E-03 0.208 DIRAS2 8.58E-
04 
-0.225 
 ERG 2.77E-03 -0.331 FKBP10 1.48E-04 0.454 PENK 6.59E-03 0.172 DOCK7 1.71E-
04 
-0.37 
 FABP7 1.04E-03 0.356 Fmn2 3.70E-04 -0.237 PPFIBP2 7.59E-03 -0.081 DRD2 1.33E-
03 
-0.209 
 FAM71A 4.00E-03 0.364 FMO1 8.68E-07 0.401 PRC1 6.50E-03 0.238 DUSP1 4.24E-
03 
-0.19 
 FAM89A 3.10E-07 0.444 Folh1 9.20E-05 0.6 PREX2 8.40E-03 0.217 ECI1 3.98E-
03 
0.189 
 FANCL 1.09E-03 0.226 FOXE1 3.48E-04 -0.232 PRSS8 6.46E-03 -0.209 EDNRB 2.11E-
05 
0.31 
 FCER1G 1.27E-07 0.44 FRAS1 5.38E-04 -0.23 PTHLH 3.91E-03 0.202 EFS 3.41E-
05 
0.296 
 Fcrls 6.15E-03 0.287 FRZB 7.92E-06 0.418 PTPN13 9.88E-05 0.284 EGFR 6.74E-
03 
0.186 
 FGF21 4.96E-03 0.406 FZD2 1.51E-04 0.3 PTPN6 1.80E-03 0.216 EGR2 1.36E-
03 
-0.248 
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 FGF5 4.20E-03 -0.005 G0S2 2.81E-04 0.238 Pvr 9.86E-03 0.164 EGR4 3.74E-
03 
-0.189 
 FIBIN 9.03E-04 0.298 GAD1 9.62E-04 0.214 RAB1B 4.04E-03 -0.187 ELMOD2 9.71E-
03 
0.016 
 Fmn2 6.68E-03 -0.175 GADD45G 5.82E-04 -0.222 RAC2 1.93E-05 0.334 EMP1 2.52E-
06 
-0.322 
 FMO1 1.09E-04 0.414 GAL3ST1 1.84E-04 0.312 RGD1562977 2.61E-03 -0.254 EMP2 2.36E-
03 
0.214 
 FMR1 1.96E-03 -0.211 GAMT 7.75E-04 0.217 ROBO1 9.70E-03 -0.166 ENTPD2 4.10E-
03 
0.391 
 FOXA2 8.41E-03 0.556 GAREML 4.83E-04 0.386 SHCBP1 6.61E-03 0.244 EPHA3 9.04E-
03 
-0.166 
 FRAS1 5.83E-03 -0.215 GATM 5.01E-05 0.272 SLAMF9 1.72E-04 0.72 ESPL1 3.76E-
04 
0.25 
 FZD2 4.59E-05 0.372 Gbp2 2.28E-08 0.838 SLC11A1 8.04E-03 0.326 ETV4 2.66E-
03 
-0.38 
 G6PC 4.36E-03 0.02 GFAP 2.45E-04 0.292 SLC12A1 8.70E-03 -0.028 EVI2A 3.74E-
03 
-0.185 
 GAREML 2.26E-04 0.482 GJA1 2.86E-11 0.525 SP110 6.87E-03 0.218 F12 2.70E-
03 
-0.199 
 GAS2 7.24E-03 0.182 Gpm6b 4.14E-06 0.318 ST3GAL1 6.08E-03 0.198 F2 8.42E-
03 
-0.206 
 Gbp2 1.16E-04 0.59 GPR37L1 6.16E-06 0.313 TAGLN2 2.36E-03 0.388 FABP7 7.65E-
06 
0.367 
 GDAP1 7.56E-03 -0.223 GRAMD3 2.71E-07 0.369 VIPR2 7.03E-03 -0.032 FAM150B 2.62E-
06 
-0.322 
 GINS1 6.74E-03 0.199 GSDMD 6.96E-06 0.382 Vmn1r52 6.72E-04 0.229 FAM181B 5.29E-
03 
0.23 
 GJA1 4.64E-05 0.404 GSTA2 2.50E-05 0.33 Vom2r9 7.96E-03 -0.395 Fam187a 8.66E-
03 
-0.047 
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 Gm4944 1.08E-03 0.308 GSTA3 2.51E-07 0.408 WNT16 6.06E-03 -0.177 FAM89A 2.63E-
03 
0.302 
 GPR183 1.41E-03 -0.172 Gsta3 3.80E-12 0.588 ZNF385A 3.70E-04 -0.319 FASLG 8.76E-
04 
-0.003 
 GPR37L1 8.30E-03 0.304 Gstt3 8.35E-05 0.279    FBXO36 9.18E-
04 
0.195 
 GPR63 5.22E-03 -0.24 GUCY1A2 9.53E-04 -0.216    FCER1G 7.05E-
05 
0.38 
 GRAMD3 3.69E-04 0.338 GULP1 7.41E-04 0.246    Fcrls 1.48E-
05 
0.351 
 GRHL2 3.31E-03 -0.405 H2afv 7.56E-04 0.218    FIGF 4.35E-
03 
-0.19 
 GRIK1 4.29E-03 0.192 HCN4 9.60E-04 -0.228    FOSL1 3.15E-
06 
-0.366 
 GRIK4 3.44E-03 0.24 HES5 1.97E-04 0.406    FOSL2 3.92E-
03 
-0.188 
 GSTA2 2.14E-03 0.248 HMOX1 1.75E-04 0.25    FOXA2 4.79E-
03 
0.533 
 GSTA3 1.50E-03 0.326 HSPB8 9.66E-04 0.276    FRAS1 2.84E-
04 
-0.255 
 Gsta3 2.25E-05 0.465 HTR1B 2.79E-04 -0.349    G0S2 6.15E-
03 
0.286 
 Gstt3 1.25E-03 0.36 HTRA1 6.25E-06 0.354    GADD45G 1.33E-
04 
-0.28 
 GUCY1A2 5.98E-04 -0.259 ID1 7.76E-06 0.422    GAL 9.05E-
05 
-0.272 
 GULP1 2.79E-03 0.204 IFI44 1.62E-04 0.397    GALNT7 7.81E-
03 
-0.363 
 H19 7.66E-03 -0.153 IGF1 7.24E-05 0.266    GALR1 2.22E-
03 
-0.416 
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 HDAC4 7.19E-03 -0.182 IGSF1 3.07E-06 0.366    GAMT 5.20E-
03 
0.19 
 Hdgfl1 4.99E-03 0.396 IGSF11 2.84E-06 0.33    GBP5 6.46E-
03 
0.27 
 Hist1h1d 1.30E-03 -0.21 INHBA 5.70E-04 -0.224    GCNT1 2.25E-
03 
-0.225 
 Hist2h4 
(includes 
others) 
9.62E-03 -0.232 IQGAP1 1.32E-04 -0.272    GFAP 4.40E-
03 
0.342 
 HLA-B 3.20E-03 0.229 IRX1 2.98E-07 0.454    GFRA1 3.12E-
03 
-0.193 
 HMG20A 4.56E-03 -0.184 ISG20 3.70E-04 -0.236    GFRA2 1.72E-
03 
-0.237 
 HMOX1 6.38E-05 0.276 ITGB5 1.61E-06 0.37    GJA1 1.43E-
05 
0.379 
 HOXA13 9.38E-03 -0.206 JAM2 2.46E-07 0.368    GPKOW 5.38E-
03 
-0.194 
 Hspa1l 5.91E-04 0.442 KANK1 1.31E-06 0.421    Gpm6b 6.97E-
04 
0.257 
 ID1 6.65E-04 0.282 KCNE1L 1.55E-05 0.302    GPR22 7.70E-
03 
-0.242 
 IGF1 4.38E-03 0.284 KIAA0101 3.11E-06 0.338    GPR37L1 3.72E-
04 
0.318 
 IGSF1 6.55E-03 0.262 KIF11 1.27E-07 0.422    GPRC5A 6.95E-
05 
-0.282 
 IL11RA 1.35E-04 0.292 KIF18B 2.15E-08 0.43    GPSM1 6.08E-
03 
-0.176 
 IL24 2.69E-03 0.241 KNSTRN 5.55E-06 0.314    GRAMD3 4.87E-
05 
0.359 
 IQGAP1 7.15E-04 -0.3 LAPTM4B 5.92E-04 0.269    GRID1 6.66E-
03 
-0.02 
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 IRS1 6.10E-03 -0.256 LIMS2 6.49E-04 0.674    GRIN1 1.98E-
03 
-0.218 
 ISG20 1.15E-03 -0.214 LNPEP 7.28E-04 -0.237    GRM1 5.30E-
04 
0.292 
 ITGB5 4.49E-05 0.405 LOC100359805 
(includes others) 
2.70E-04 -0.259    GRP 5.65E-
03 
0.286 
 ITIH3 2.06E-03 0.357 LOC100361411 
(includes others) 
5.78E-04 -0.229    GRTP1 5.46E-
03 
0.214 
 JAM2 2.52E-03 0.249 LOC100363229 9.92E-04 -0.212    GSTA2 5.50E-
04 
0.324 
 KANK1 5.96E-06 0.368 LOC500013 1.30E-06 0.361    Gsta3 2.13E-
06 
0.488 
 KBTBD10 1.17E-03 -0.013 LOC683470 2.20E-05 0.284    Gstm6 7.47E-
03 
0.458 
 KCTD16 1.08E-03 -0.22 LOC684327 1.84E-05 0.314    Gstt3 2.39E-
03 
0.306 
 KIAA0232 4.25E-04 -0.269 LOC686101 1.84E-06 -0.453    GUCA2B 8.91E-
03 
-0.18 
 KIF11 3.35E-04 0.264 LPGAT1 7.95E-05 -0.261    GXYLT1 2.64E-
03 
0.199 
 KIF16B 6.41E-03 0.194 LRRC7 9.75E-04 -0.212    H2afv 3.13E-
03 
0.188 
 KIF18B 1.78E-03 0.27 LTBR 2.75E-04 0.272    Hdgfl1 4.50E-
03 
0.415 
 KIF20B 4.17E-03 0.028 MAG 1.80E-04 0.806    HMGA1 2.40E-
03 
-0.224 
 KIFC1 1.76E-03 0.24 Mbp 2.75E-05 0.286    HMOX1 2.29E-
04 
0.3 
 KRT18 7.50E-03 -0.179 MCM3 1.55E-04 0.258    HRH4 9.97E-
04 
0.235 
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 KRTAP10-
1 
1.76E-03 0.228 Mcpt8 3.05E-04 -0.276    HTR1B 1.22E-
03 
-0.41 
 KRTAP4-3 4.66E-03 0.296 MDFIC 7.50E-06 0.32    HTR2C 7.06E-
03 
-0.174 
 LASP1 9.10E-03 -0.19 MEIS1 6.12E-06 0.308    HTRA1 3.34E-
04 
0.359 
 LCORL 8.77E-03 -0.248 METRN 4.64E-04 0.232    Iba57/LOC10036
3222 
1.06E-
03 
0.249 
 LIMD1 8.07E-03 0.275 MFGE8 7.60E-04 0.227    IER5 1.81E-
03 
-0.252 
 LOC10035
9536 
(includes 
others) 
3.72E-03 -0.221 MGMT 6.09E-04 0.242    Ifitm6 6.31E-
03 
-0.238 
 LOC10035
9630 
(includes 
others) 
7.84E-03 -0.174 MGP 5.02E-04 0.226    IGF1 8.26E-
05 
0.277 
 LOC10035
9805 
(includes 
others) 
1.27E-03 -0.249 MGST1 3.98E-10 0.648    IGFBP2 5.00E-
03 
0.204 
 LOC10036
3229 
8.53E-04 -0.245 MLC1 2.16E-07 0.362    IGSF11 2.27E-
03 
0.254 
 LOC10036
3421 
8.18E-03 -0.168 MMP14 1.15E-06 0.345    IL6R 3.32E-
03 
-0.192 
 LOC10036
5120 
8.93E-03 -0.166 MMP2 5.62E-07 0.38    INHBA 1.06E-
05 
-0.298 
 LOC25924
6 (includes 
others) 
5.95E-03 0.424 MN1 5.74E-04 -0.227    IQUB 2.73E-
03 
-0.244 
 LOC28699
2 
8.78E-03 -0.56 MSX1 5.79E-08 0.507    IRS1 4.02E-
03 
-0.204 
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 LOC29148
0 
9.41E-03 -0.227 MYBL2 3.88E-04 0.238    IRX1 4.51E-
03 
0.363 
 LOC31707
0 (includes 
others) 
1.58E-03 -0.228 MYH1 2.77E-10 0.551    ISM1 7.33E-
03 
-0.17 
 LOC36736
3 (includes 
others) 
9.82E-05 -0.26 MYH8 1.17E-05 0.305    ITGA8 3.95E-
05 
-0.334 
 LOC37846
7 
3.66E-03 0.272 MYO6 1.54E-04 0.284    ITGB5 7.75E-
07 
0.364 
 LOC50084
6 
6.65E-04 -0.24 MYO9A 1.92E-04 -0.277    ITGBL1 5.50E-
03 
-0.004 
 LOC68020
7 
8.61E-03 -0.168 NCAPH 5.78E-04 0.228    JAM2 7.77E-
05 
0.302 
 LOC68343
0 
7.94E-03 0.468 NDE1 8.40E-05 0.268    KANK1 1.23E-
03 
0.298 
 LOC68443
9 
7.29E-03 0.246 NDRG2 7.68E-09 0.419    KCNAB1 6.42E-
03 
-0.248 
 LOC68629
8 
7.57E-04 0.242 NEDD1 4.70E-04 0.468    KCNC2 6.04E-
03 
-0.214 
 LOC68706
2 
7.49E-03 -0.192 NFE2L2 7.28E-09 0.43    KCTD4 3.19E-
03 
-0.2 
 LOC68970
1 (includes 
others) 
4.00E-03 -0.27 NIM1 3.44E-04 0.24    KCTD8 3.02E-
03 
-0.195 
 LOC69104
7 
2.32E-04 -0.131 NKAIN4 1.58E-04 0.252    KIAA0101 2.06E-
03 
0.242 
 LOC69116
9 
4.76E-03 -0.244 NOTCH1 4.73E-06 0.312    KIF11 1.80E-
04 
0.302 
 LOC69149
5 
4.61E-03 -0.236 NPAT 9.13E-04 -0.248    KIF18B 2.51E-
04 
0.287 
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 LPGAT1 4.30E-03 -0.23 NQO1 7.02E-06 0.332    KIF27 7.12E-
03 
0.355 
 LPPR5 9.14E-03 -0.174 NR3C1 9.88E-04 0.244    KIFC1 1.48E-
03 
0.218 
 LRRC7 3.83E-03 -0.215 NRARP 9.08E-07 0.355    KNSTRN 9.59E-
05 
0.296 
 LRRIQ3 9.36E-03 -0.488 NRIP1 5.66E-04 -0.228    LDLR 8.26E-
03 
-0.189 
 LYPD8 6.59E-03 -0.214 NTRK2 1.06E-07 0.391    LHX6 2.83E-
03 
0.209 
 MAGEB3 9.65E-04 -0.228 NUSAP1 2.42E-04 0.256    LOC259246 
(includes others) 
5.07E-
03 
0.503 
 MAGEB6 3.56E-03 -0.314 NXPH1 3.00E-06 0.364    LOC367363 
(includes others) 
3.87E-
03 
0.013 
 MAOB 4.43E-03 0.286 OAF 3.58E-05 0.296    LOC378467 6.84E-
03 
0.012 
 MAP3K3 2.89E-03 0.098 Oas3 3.65E-04 0.286    LOC500013 1.10E-
03 
0.275 
 MARCH3 6.86E-03 0.194 OLFML1 7.98E-04 0.302    LOC683470 1.46E-
04 
0.254 
 MBNL1 5.40E-03 -0.209 OLFML3 1.82E-04 0.257    LOC684327 2.80E-
03 
0.282 
 Mbp 5.64E-04 -0.022 OLIG1 8.34E-06 0.302    LOC684998 2.32E-
03 
-0.195 
 MC4R 5.55E-03 0.21 OLIG2 2.36E-04 0.24    LOC686101 3.31E-
03 
-0.075 
 MCM3 5.53E-03 0.204 PAPSS2 1.14E-05 0.798    LOC688387 9.23E-
03 
-0.647 
 Mcpt8 6.38E-03 -0.223 PBK 4.30E-07 0.465    LOXL1 2.79E-
03 
0.374 
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 MCU 7.08E-03 -0.211 PDGFRA 1.54E-10 0.491    LRRTM4 5.39E-
03 
0.113 
 MDFIC 3.01E-04 0.26 PDPN 6.56E-10 0.47    LTB4R2 6.90E-
03 
0.631 
 MED21 6.44E-03 -0.262 PDS5A 2.98E-04 -0.314    LTBR 3.79E-
03 
0.261 
 MEIS1 7.68E-03 0.191 PIK3CA 2.88E-04 -0.3    LUM 5.57E-
04 
-0.362 
 METRN 3.26E-03 0.232 PLA2G16 2.62E-08 0.416    LYNX1 6.90E-
03 
-0.176 
 MGST1 1.98E-04 0.618 PLCD1 5.03E-04 0.359    MAML1 1.71E-
03 
-0.302 
 MIB1 1.08E-03 -0.217 PLD1 1.33E-06 0.346    MAN1A1 8.64E-
03 
-0.18 
 MLC1 5.95E-03 0.282 PLEKHB1 2.25E-06 0.337    MCM3 7.14E-
03 
0.186 
 MMP13 9.71E-04 0.639 PLEKHD1 4.45E-07 0.376    MCOLN3 9.77E-
03 
-0.176 
 MPC1L 5.38E-03 0.205 PLP1 2.59E-04 0.256    MCU 6.90E-
03 
-0.208 
 Mrgprb13/
Mrgprb8 
7.81E-03 -0.622 PLXNB3 2.79E-04 0.858    MDFIC 8.15E-
03 
0.243 
 MSX1 1.70E-03 0.418 PMEL 2.84E-04 0.376    MEIS1 7.57E-
05 
0.272 
 MTMR10 2.47E-03 0.286 PMP2 4.64E-05 0.838    MEPE 5.26E-
03 
-0.187 
 Muc2 5.12E-04 -0.237 PNLIP 1.17E-04 0.602    MGST1 9.06E-
04 
0.355 
 MX1 9.97E-03 -0.166 PNP 2.16E-04 0.242    MGST2 4.52E-
03 
-0.208 
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 MYH1 4.71E-06 0.542 PON2 1.12E-06 0.343    MLC1 1.37E-
03 
0.279 
 MYH8 1.86E-04 0.25 PPAP2B 4.66E-04 0.269    MMD2 8.86E-
03 
0.22 
 MYLK 2.16E-03 -0.29 PPIC 5.55E-06 0.325    MMP12 6.23E-
05 
-0.728 
 MYO6 9.72E-03 0.215 PPM1K 7.00E-04 -0.25    MMP14 2.74E-
04 
0.335 
 N4BP2L1 1.10E-03 -0.251 PRC1 3.56E-06 0.318    MMP17 6.21E-
03 
-0.312 
 NAAA 6.06E-03 0.229 PRKACB 2.39E-04 -0.248    MMS22L 2.02E-
03 
0.213 
 NCAPH 6.98E-03 0.186 PRKAR2A 2.64E-04 -0.244    MORN5 4.30E-
03 
-0.278 
 NDRG2 1.11E-03 0.336 PRODH 7.76E-07 0.396    MRE11A 5.14E-
03 
0.32 
 NEDD1 9.85E-03 0.357 PTPN13 5.22E-06 0.351    MSX1 2.64E-
03 
0.316 
 NFE2L2 2.39E-03 0.305 PTTG1 6.12E-05 0.266    MT1H 5.62E-
03 
0.176 
 NOD1 1.44E-03 0.227 PYROXD2 4.67E-04 0.287    MTMR12 3.06E-
03 
-0.334 
 NOS1 2.69E-03 -0.349 QKI 1.56E-04 0.257    MUSTN1 1.96E-
04 
-0.246 
 NOS1AP 6.98E-03 -0.304 RABGAP1 4.25E-04 -0.234    MXRA8 2.41E-
03 
0.25 
 NOV 2.85E-03 0.232 RAC2 5.81E-07 0.393    MYBL2 4.20E-
03 
0.25 
 NPY 3.07E-03 0.242 RAD51 5.90E-04 0.228    MYD88 6.63E-
03 
0.176 
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 NR4A3 8.05E-04 -0.242 RASSF3 2.75E-04 0.284    MYLK 3.58E-
03 
-0.275 
 NRARP 1.05E-03 0.342 RASSF4 1.85E-04 0.358    MYO6 3.66E-
04 
0.24 
 NRXN1 9.78E-03 -0.176 RGCC 1.85E-06 0.333    NAB1 2.66E-
03 
-0.234 
 NTRK2 5.75E-03 0.314 RGD1311564 3.11E-05 -0.386    NAPRT1 7.52E-
03 
0.19 
 NUDT7 2.74E-03 0.065 RREB1 9.05E-07 -0.472    NCAPH 2.54E-
03 
0.201 
 NXPH1 4.11E-03 0.373 RRM2 8.80E-05 0.518    NDE1 7.94E-
04 
0.255 
 OAS2 3.64E-03 -0.234 S100A1 2.60E-05 0.282    NDRG2 5.65E-
06 
0.408 
 Oas3 9.80E-03 0.202 S100A16 8.93E-07 0.346    NES 1.55E-
03 
0.221 
 Olfr1043 5.32E-03 0.192 S100A4 3.43E-06 0.416    NFE2L2 2.30E-
03 
0.324 
 Olfr1154 
(includes 
others) 
5.67E-03 0.186 S100B 2.34E-07 0.866    NGFR 7.73E-
03 
0.217 
 Olfr1229 7.92E-03 0.153 S1PR1 6.57E-07 0.345    NMBR 2.08E-
05 
-0.312 
 Olfr1262 3.56E-03 -0.318 SALL1 2.22E-05 0.353    NMU 7.84E-
04 
-0.248 
 Olfr1347 2.72E-03 0.177 SALL3 1.37E-04 0.278    NOD1 1.60E-
03 
0.22 
 Olfr456 3.53E-03 -0.305 SAMD9 4.11E-04 0.248    NOTCH1 6.52E-
03 
0.206 
 Olfr490 7.75E-03 -0.019 SAMD9L 6.28E-06 0.31    NPAS4 2.66E-
04 
-0.254 
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 Olfr559 6.84E-03 -0.236 SCRG1 7.22E-10 0.471    NQO1 4.70E-
03 
0.04 
 Olfr597/Olf
r598 
5.34E-03 -0.508 SDC4 2.24E-09 0.452    NR3C1 8.41E-
03 
0.239 
 Olr875/Olr
876 
2.91E-03 0.278 SELENBP1 5.02E-04 0.362    NRAP 4.93E-
03 
-0.212 
 OPN1SW 1.67E-03 0.467 SEMA3E 2.18E-04 -0.275    NRARP 8.20E-
03 
0.3 
 OPN4 5.66E-03 -0.178 SEPP1 1.04E-07 0.388    NRN1 9.66E-
03 
-0.167 
 OR10X1 8.78E-03 -0.348 SEPT8 2.61E-06 0.322    NSD1 2.48E-
03 
-0.276 
 OR1F1 5.76E-03 0.333 SERINC5 3.29E-05 0.302    NT5DC2 7.48E-
03 
0.178 
 OR2T1 8.54E-03 -0.42 SFRP2 2.13E-06 0.372    NTRK2 5.91E-
05 
0.315 
 OR4K5 9.02E-03 -0.316 SHCBP1 1.66E-05 0.392    NUP98 3.53E-
03 
-0.224 
 PAPSS2 8.10E-05 0.824 SHOC2 3.04E-04 -0.236    NXPH1 1.09E-
04 
0.255 
 PAX3 1.38E-03 -0.233 SHPK 9.96E-04 0.243    OLFML3 7.74E-
03 
0.17 
 PCDHGA1
1 
6.16E-03 -0.236 SIK1 2.68E-04 -0.238    Olfr1043 1.44E-
03 
0.222 
 PDGFRA 1.51E-08 0.495 SLC13A3 5.59E-07 0.354    Olfr1154 
(includes others) 
5.95E-
03 
0.193 
 PDPN 2.09E-05 0.399 SLC15A2 2.03E-06 0.576    Olfr1179 4.52E-
03 
-0.015 
 PDS5A 5.40E-04 -0.244 SLC1A3 1.55E-07 0.372    Olfr1232 8.76E-
03 
0.618 
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 PDZD8 2.99E-03 -0.214 SLC32A1 2.24E-04 0.242    Olfr159 9.74E-
03 
-0.276 
 PHC3 2.26E-03 -0.298 SLC35D3 1.45E-04 0.288    Olfr397 6.00E-
03 
0.228 
 PIK3CA 8.18E-04 -0.338 SLC38A3 2.38E-06 0.358    Olfr589 4.82E-
03 
0.275 
 PIWIL2 3.80E-04 0.304 SLC38A7 3.59E-04 -0.232    OLIG1 3.28E-
05 
0.281 
 PLAG1 7.56E-04 -0.219 SLC44A1 2.14E-04 0.534    OLIG2 1.07E-
03 
0.225 
 PLAUR 9.74E-03 0.21 SLC6A1 3.34E-06 0.316    OR2D2 3.66E-
03 
0.21 
 PLCD1 3.34E-03 0.322 SLC7A10 4.08E-04 0.304    OR8B12 1.35E-
03 
0.42 
 PLD1 1.67E-03 0.249 SLCO1C1 2.38E-05 0.319    OSBPL5 8.49E-
03 
-0.202 
 PLEKHD1 6.85E-03 0.289 SLK 5.39E-04 -0.256    OTOR 6.94E-
03 
0.209 
 PLEKHG1 7.32E-03 -0.004 SMPDL3A 2.02E-04 0.41    PAX3 1.81E-
03 
0.238 
 PLLP 6.89E-03 0.274 SOX10 2.85E-05 0.298    PCGF5 6.74E-
03 
-0.185 
 PMEL 1.19E-05 0.393 SOX2 3.84E-05 0.284    PCSK6 9.02E-
03 
0.172 
 PNMAL1 3.30E-03 -0.21 SOX8 1.01E-05 0.303    PDE12 6.38E-
03 
-0.253 
 PNO1 8.60E-03 0.167 SP110 9.57E-04 0.246    Pde4dl1 6.33E-
04 
-0.273 
 POGK 9.28E-03 -0.047 SPAG5 1.10E-04 0.281    PDGFB 4.39E-
03 
-0.488 
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 PPAP2B 9.80E-04 0.301 SPARC 9.32E-04 0.214    PDGFRA 6.60E-
05 
0.38 
 PPIC 2.39E-03 0.243 SPARCL1 1.30E-07 0.379    PDGFRB 1.31E-
04 
0.706 
 PRC1 8.22E-03 0.215 SPC25 2.65E-04 0.246    PDPN 3.25E-
05 
0.386 
 PRIMA1 7.31E-03 0.311 SPP1 3.82E-05 0.406    PERP 8.52E-
03 
-0.171 
 PRKACB 3.88E-03 -0.26 STAT1 4.34E-04 0.234    PKIB 2.54E-
03 
0.2 
 PRKAR2A 4.38E-03 -0.328 SUCLG2 8.98E-07 0.35    PLA2G16 2.11E-
03 
0.31 
 PRKCD 2.08E-03 0.218 Syna 3.38E-04 -0.26    PLCB4 8.46E-
04 
0.25 
 PRM2 1.05E-03 -0.222 TACC1 1.61E-04 -0.284    PLD1 3.34E-
03 
0.241 
 PRODH 2.14E-04 0.382 TCF7L2 6.64E-12 0.558    PLEKHD1 2.04E-
03 
0.332 
 PRSS23 6.07E-03 0.211 TEAD2 8.31E-05 0.29    PLOD1 5.83E-
03 
0.179 
 Prss32 7.86E-03 0.01 TFAP2E 5.95E-05 0.311    PNMA3 3.36E-
03 
-0.26 
 PTPN13 5.43E-03 0.225 TIMELESS 5.16E-04 0.28    PNOC 8.54E-
04 
-0.218 
 PTPN6 8.00E-03 0.238 TLE6 6.54E-04 0.238    PON2 7.47E-
04 
0.26 
 PYROXD2 3.08E-04 0.327 TLR6 2.58E-05 0.404    POU1F1 6.88E-
03 
0.196 
 RAB13 1.89E-03 0.248 TMBIM1 3.31E-09 0.456    POU4F3 6.53E-
04 
-0.288 
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 RAC2 7.05E-09 0.502 TMEM100 1.11E-07 0.392    PPIC 1.96E-
04 
0.288 
 RAMP3 8.44E-03 0.174 TMEM178B 3.44E-04 -0.237    PPM1L 6.80E-
03 
-0.202 
 RANBP2 2.22E-03 0.052 TMEM229A 4.89E-04 0.246    PPP1R3C 2.34E-
03 
0.245 
 RAPGEF6 2.28E-03 0.046 TNS1 4.65E-06 0.318    PRC1 2.63E-
03 
0.284 
 RFX5 1.84E-04 -0.255 TNS3 1.64E-06 0.328    PRODH 3.52E-
04 
0.361 
 RGCC 6.35E-04 0.332 TOP2A 1.25E-08 0.422    PRSS27 5.33E-
03 
-0.249 
 RIMS2 3.44E-03 -0.207 TPX2 2.00E-05 0.375    PTPN13 7.61E-
05 
0.311 
 RLBP1 3.12E-03 0.234 TRAF3IP2 7.91E-05 0.312    PTPN22 4.90E-
03 
-0.072 
 RNF141 8.82E-04 -0.234 TRIL 1.58E-09 0.448    PYGL 6.52E-
03 
0.246 
 RPGRIP1L 3.14E-03 -0.252 TRIM47 3.19E-05 0.306    QKI 4.81E-
03 
0.209 
 RREB1 4.48E-04 -0.32 TSPAN12 6.42E-04 0.224    RAB20 5.00E-
03 
-0.182 
 RRM2 3.51E-04 0.547 TTK 1.86E-05 0.32    RAD51AP1 9.21E-
03 
0.169 
 S100A16 8.15E-03 0.282 TXNIP 9.40E-05 0.332    REM2 1.73E-
03 
-0.226 
 S100B 3.09E-03 0.614 UBE2T 4.03E-05 0.354    RETN 8.76E-
03 
0.209 
 S1PR1 3.96E-04 0.298 UNC13A 1.44E-04 -0.25    RGCC 3.22E-
03 
0.289 
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 SALL1 2.79E-03 0.04 VAMP8 4.10E-04 0.342    RGS2 7.89E-
03 
-0.168 
 SALL3 9.61E-03 0.202 VCAM1 2.72E-10 0.477    RRAD 5.27E-
03 
-0.188 
 SAMD9 1.40E-03 0.271 VEGFA 9.64E-04 -0.284    RREB1 1.65E-
04 
-0.379 
 SCN8A 6.08E-03 -0.182 WDR16 1.64E-06 0.361    RRM2 5.14E-
05 
0.29 
 SCRG1 1.41E-05 0.393 WIPF1 7.74E-04 0.254    S100A1 1.40E-
03 
0.271 
 SDC4 1.11E-03 0.374 WNT6 1.44E-04 -0.254    S100A16 2.66E-
04 
0.31 
 SELENBP
1 
3.77E-03 0.314 XPO6 8.74E-04 -0.276    S100B 4.19E-
04 
0.324 
 SEMA3D 5.81E-03 -0.166 ZBTB38 9.54E-04 -0.226    S1PR1 8.95E-
03 
0.227 
 SEMA5B 8.99E-03 0.217 ZC3H13 4.48E-05 -0.276    SALL1 2.87E-
05 
0.43 
 SEPP1 9.10E-03 0.274 ZCCHC24 2.08E-07 0.464    SALL3 5.00E-
04 
0.316 
 SEPT8 2.18E-03 0.248 ZNF23 4.66E-04 -0.231    SAMD9L 2.53E-
04 
0.258 
 SERINC5 6.21E-03 0.227       SARDH 3.59E-
03 
0.222 
 SFRP2 3.39E-05 0.342       SCRG1 5.80E-
04 
0.328 
 SFRP4 7.22E-03 0.302       SDC4 1.72E-
03 
0.316 
 SHCBP1 6.92E-03 0.194       SEC16B 1.82E-
03 
-0.213 
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 SKA1 4.58E-04 0.386       SEMA3E 1.93E-
03 
-0.248 
 SLAMF9 2.39E-05 0.816       SEMA7A 6.93E-
04 
-0.22 
 SLC11A1 5.60E-03 0.483       SEPP1 1.38E-
04 
0.308 
 SLC12A1 9.56E-03 -0.192       SEPT8 5.97E-
04 
0.24 
 SLC13A3 3.56E-04 0.35       SERINC5 2.72E-
03 
0.194 
 SLC15A2 1.83E-03 0.453       SERPINB2 4.77E-
06 
-0.511 
 SLC16A8 9.60E-03 -0.194       SERPINH1 4.26E-
03 
0.22 
 SLC18A1 1.18E-03 -0.218       SERTAD1 2.24E-
03 
-0.2 
 SLC1A3 8.60E-03 0.284       SH3BP4 6.64E-
03 
0.18 
 SLC20A2 6.54E-03 0.188       SH3BP5L 4.40E-
03 
-0.312 
 SLC25A18 3.50E-03 0.219       SHANK2 6.61E-
03 
-0.283 
 SLC30A3 6.41E-03 0.196       SIK1 5.71E-
03 
-0.224 
 SLC32A1 8.11E-03 0.219       SLAMF9 8.98E-
03 
0.528 
 SLC35D3 2.24E-03 0.266       SLC1A2 6.75E-
03 
0.229 
 SLC39A14 3.04E-03 -0.196       SLC1A3 2.05E-
04 
0.321 
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 Slc7a12 1.08E-03 -0.216       SLC22A3 6.01E-
03 
0.257 
 SLC8A1 4.29E-04 -0.238       SLC27A5 6.15E-
04 
0.355 
 SLC9A3R1 1.04E-03 0.258       SLC32A1 1.26E-
04 
0.252 
 SLCO1C1 7.95E-03 0.27       SLC35G2 1.34E-
03 
0.212 
 SLK 7.40E-03 -0.256       SLC38A3 6.30E-
03 
0.208 
 SMPDL3A 8.85E-04 0.324       SLC40A1 3.36E-
04 
-0.242 
 SOX10 8.40E-04 0.318       SLC6A1 4.36E-
04 
0.274 
 SP110 6.04E-04 0.258       SLC7A10 8.70E-
03 
0.27 
 Spag11a 4.89E-04 -0.262       SLC7A9 9.28E-
04 
0.361 
 SPARCL1 4.62E-03 0.393       SLCO4C1 1.23E-
03 
-0.403 
 SPN 9.69E-03 0.447       SMPDL3A 9.30E-
04 
0.334 
 SPP1 3.09E-04 -0.182       SNX15 3.34E-
03 
-0.103 
 SRSF1 9.73E-03 0.165       SOX10 3.37E-
03 
0.211 
 SSH2 1.01E-03 -0.228       SOX2 2.65E-
03 
0.205 
 Ssty1 
(includes 
others) 
8.15E-03 -0.292       SOX8 8.61E-
04 
0.228 
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 ST8SIA4 5.22E-03 -0.3       SP110 1.68E-
03 
0.326 
 STOX2 7.38E-03 -0.188       SPAG7 5.36E-
03 
0.206 
 Sult2a2 1.82E-03 0.662       SPARC 1.66E-
04 
0.288 
 SUSD3 8.60E-03 -0.181       SPARCL1 6.20E-
05 
0.356 
 SYCP2 4.48E-03 -0.214       Spata31d1d 6.77E-
03 
-0.233 
 TAGLN2 6.34E-03 0.357       SPINT1 9.40E-
03 
-0.188 
 TANC2 6.16E-03 -0.192       SPP1 1.20E-
04 
0.502 
 TAS2R10 9.89E-05 -0.694       SS18 9.46E-
03 
0.176 
 TAS2R20 4.82E-03 -0.2       ST14 4.20E-
03 
0.301 
 TBC1D5 8.36E-03 -0.192       ST6GALNAC3 9.23E-
04 
0.004 
 TBR1 6.70E-03 0.198       ST8SIA1 5.40E-
03 
-0.202 
 TCF7L2 2.05E-04 0.357       STARD5 9.68E-
03 
-0.284 
 TCTEX1D
1 
5.31E-03 0.092       STAT1 4.36E-
04 
0.234 
 TGIF2 2.11E-03 0.394       SUCLG2 3.19E-
03 
0.226 
 TGM4 4.30E-03 -0.082       SUCO 4.42E-
03 
-0.192 
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 TIMELESS 1.69E-03 0.246       SULF2 4.50E-
03 
0.187 
 TLR6 4.64E-05 0.401       SYN3 2.78E-
03 
-0.252 
 TMEM100 5.20E-04 0.344       SYNGR2 9.84E-
03 
0.014 
 TMEM176
B 
7.02E-04 0.324       SYT10 1.95E-
03 
-0.225 
 TMEM178
B 
7.72E-03 -0.212       TAC1 2.64E-
03 
-0.195 
 TMEM229
A 
2.01E-03 0.252       TCF15 4.48E-
03 
0.213 
 TMEM52B 1.18E-06 -0.372       TCF7L2 5.40E-
04 
0.34 
 TNC 2.12E-04 0.25       TEAD2 7.61E-
04 
0.238 
 TNRC6B 7.43E-03 -0.211       TFAP2E 3.60E-
07 
0.42 
 TOP2A 3.38E-03 0.254       TGFBI 4.66E-
03 
-0.318 
 Trib2 7.43E-03 0.193       THBS2 7.17E-
04 
-0.27 
 TRIM47 2.35E-03 0.224       TIMELESS 9.28E-
03 
0.222 
 TSNAXIP1 5.70E-03 -0.338       TIMP4 2.33E-
05 
0.356 
 TSPAN12 6.52E-03 0.217       TM4SF1 6.22E-
03 
-0.222 
 TTC36 2.41E-03 -0.218       TMC5 7.42E-
03 
0.287 
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 TTK 3.66E-04 0.259       TMEM100 3.84E-
04 
0.284 
 TUBA1A 6.92E-03 0.215       TMEM200A 8.68E-
03 
-0.186 
 TWIST1 1.76E-03 0.282       TMEM243 9.61E-
03 
0.185 
 TXLNB 7.72E-03 0.198       TMOD1 1.10E-
03 
-0.225 
 TXNIP 5.95E-06 0.338       TNFRSF11B 1.40E-
03 
-0.284 
 UBE2T 7.34E-05 0.326       TNFRSF12A 6.41E-
03 
-0.174 
 UNC13A 3.19E-03 -0.236       TNS1 7.19E-
03 
0.217 
 UNCX 2.30E-04 -0.244       TNS3 1.96E-
03 
0.2 
 VAMP8 5.08E-06 0.46       TOP2A 4.54E-
03 
0.242 
 VCAM1 4.83E-05 0.416       TRIL 1.17E-
04 
0.368 
 VEGFA 2.95E-03 -0.226       TSPAN9 8.54E-
03 
-0.18 
 Vof16 6.51E-04 -0.291       TUBA1A 2.92E-
03 
0.195 
 Vom2r48 4.59E-03 0.24       TXNIP 3.16E-
07 
0.464 
 Vom2r9 1.94E-03 -0.34       UAP1 2.33E-
03 
-0.209 
 WAPAL 5.41E-03 -0.202       UBE2T 1.67E-
03 
0.27 
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 WDR16 4.35E-04 0.334       UCN 1.25E-
03 
-0.208 
 WIPF1 3.10E-03 0.236       UGT1A6 5.28E-
03 
0.194 
 Wnk1 5.29E-03 -0.32       USP53 9.06E-
03 
-0.171 
 WNT16 3.44E-03 -0.188       UTP15 7.42E-
03 
-0.224 
 WNT6 2.04E-06 -0.332       UTP20 2.06E-
03 
-0.267 
 ZBTB38 2.50E-03 -0.208       VAMP8 6.85E-
03 
0.741 
 ZC3H13 1.81E-03 -0.214       VCAM1 1.68E-
05 
0.413 
 ZCCHC24 1.02E-04 0.376       VCL 3.78E-
03 
-0.215 
 ZNF445 8.10E-03 -0.181       Vcsa1/Vcsa2 4.62E-
04 
-0.311 
 ZNF624 8.30E-03 -0.295       WDR16 9.37E-
04 
0.24 
          ZBTB3 2.00E-
03 
-0.149 
          ZCCHC24 6.20E-
03 
0.313 
          ZFHX4 3.16E-
03 
-0.352 
          Zim1 9.58E-
03 
-0.202 
          ZNF219 7.15E-
03 
-0.003 
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CHAPTER 5:  Conclusions 
 
Published:  Terlecky, SR, Terlecky LJ, and Giordano CR.  Peroxsiomes, Oxidative 
stress, and Inflammaton.  (2012) World J of Biol Chem 3: 93-97. 
5.1   Abstract 
Peroxisomes are intracellular organelles mediating a wide variety of biosynthetic 
and biodegradative reactions.  Included among these are the metabolism of hydrogen 
peroxide and other reactive species, molecules whose levels help define the oxidative 
state of cells.  Loss of oxidative equilibrium in cells of tissues and organs potentiates 
inflammatory responses which can ultimately trigger human disease.  In summary there 
is significant evidence for connections between peroxisome function, oxidative stress, 
and inflammation in the context of human health and degenerative disease.   
5.2  Oxidative stress, inflammation, and degenerative disease 
The peroxisome’s handling of hydrogen peroxide, a reactive oxygen species 
produced by oxidative reactions occurs within the organelle.  Under most conditions, 
hydrogen peroxide is produced and immediately processed by the organelle’s resident 
marker enzyme, catalase.  However, conditions exist in which the balance of hydrogen 
peroxide production is upset, and the potentially toxic metabolite accumulates. Another 
pivotal function carried out by peroxisomes is the ability of the organelle to break down 
the arachidonic acid derivatives known as eicosanoids.  Eicosanoids are critically 
important signaling molecules which exert tremendous control over inflammatory 
reactions.   
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  Among the arachidonic acid derivatives under consideration here are prostaglandins, 
thromboxanes, leukotrienes, and prostacyclins.  These compounds elicit broad ranging 
inflammatory reactions depending on concentration and location.  The important point is 
that through their ability to be metabolized by peroxisomes - organelle function is linked 
to the inflammatory response.  Lastly, docosahexaenoic acids, peroxisomally produced 
omega-3 fatty acids, are the pivotal precursors of resolvins (“resolution-phase 
interaction products”), maresins (“macrophage mediator in resolving inflammation”), and 
protectins (formerly called “neuroprotectins”) (Ariel et al., 2007, Das, 2010, Serhan et 
al., 2008).  These molecules possess potent anti-inflammatory, inflammatory resolving, 
and immunoregulatory activities.  
 Oxidative stress and inflammation are inextricably tied processes.  Chronic 
inflammation is associated with elevated ROS levels; anti-inflammatory cascades are 
linked to diminished ROS concentrations.  And the converse is true - elevated oxidative 
stress triggers inflammation, whereas redox balance inhibits the cellular response.  
Thus, oxidative stress and inflammation may be seen as both causes and 
consequences of cellular pathology.  We suggest here that through the peroxisome’s 
role in cellular redox balance, as well as its ability to synthesize various anti-
inflammatory molecules and degrade pro-inflammatory mediators, the organelle is part 
of a critical network controlling cell function and organismal well-being (Figure 5.1).  
What is surprising is that these vital roles for the organelle have been unappreciated for 
so long. 
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Figure 5.1.  Emergent connections between peroxisomes and cellular 
metabolism.  Image appears in World J Biol Chem. 2012 by Terlecky, SR, Terlecky LJ, 
and Giordano, CR. 
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It has been previously argued that peroxisomes function as important 
communication centers - integrating signals from various sources to alter their own 
metabolism as well as that of other organelles, and to initiate or inhibit cellular aging 
programs (Titorenko and Terlecky, 2011).  A major redox-based interplay exists 
between peroxisomes and mitochondria, a relationship that warrants additional analysis.  
Several reports indicate that altering peroxisomal redox balance triggers oxidative 
stress in mitochondria - resulting in ROS production, diminished membrane potential, 
and compromised organelle function (Koepke et al., 2008; Ivashchenko et al., 2011).  
Obviously, the cellular consequences of diminished mitochondrial function are profound.  
However, restoring peroxisomal redox balance - for example by supplementing 
(peroxisomal) catalase, renews mitochondria (Koepke et al., 2007).  Mitochondria 
repolarize and aging cells delay appearance of senescence markers.  Increasing 
oxidative stress in peroxisomes is “progeric” on cells; eliminating the stress revives 
them. 
 As summarized in Chapter 1 this approach of targeted antioxidant prophylaxis 
has also been successful in disease models.  For example, in a human cell model for 
psoriasis, catalase supplementation reduces expression of the inflammatory cytokine, 
TNF-α, that is thought to be a major initiator of the chronic inflammation seen in 
psoriatic tissue (Young et al., 2008).  Similarly, in in vitro (Undyala et al., 2011) and in 
vivo (Terlecky, unpublished) models of ischemia-reperfusion (heart attack), damage to 
cardiomyocytes and cardiac tissue is dramatically inhibited.  Enhancing peroxisomal 
catalase also reduces inflammatory cytokine production in appropriately challenged 
human fibroblasts (Terlecky, unpublished). The work presented in this dissertation 
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describes, (i) a breast cancer model where the drug sensitizes otherwise resistant 
human breast cancer cells to the TKI, gefitinib (Chapter 2) (Giordano et al., 2012), (ii) a 
diabetic retinopathy model, where CAT-SKL significantly reverses compromised retinal 
function (Chapter 3), and (iii) a rat cell model of Alzheimer’s disease, where β-amyloid 
peptide-induced neuronal toxicity is significantly reduced (Chapter 4).  The evidence is 
mounting - peroxisome redox balance is a major determinant of cell stress and the 
presence or absence of cell pathology.  Perhaps it is not surprising then that 
epidemiological studies suggest a very strong link exists between diminishing cellular 
catalase levels and the onset of degenerative disease. 
5.2  Conclusions 
The treatment of human degenerative disease requires, in our view, a distance 
from the reductionist and extremely focused approaches long applied by the scientific 
and medical communities.  Rather, we suggest a broader attack, targeting oxidative 
stress, chronic inflammation, and the resultant pro-aging programs initiated in cells and 
tissues (Figure 5.2).  There are many ways to approach this - the direction focused on 
here is the peroxisome.  The organelle plays a key role in controlling inflammation and 
maintaining oxidative balance in cells.  By targeting peroxisomes -perhaps a number of 
devastating diseases could be more effectively treated or prevented.  We suggest 
enhancing peroxisome function and maintaining the organelle’s redox balance by all 
means possible.  Mitochondrial integrity/activity will be maintained or enhanced, 
oxidative stress will be reduced, inflammation will be held in check, and cellular 
pathology will be all but eliminated. Oxidative stress and resultant damage to 
intracellular constituents is critical to the development of disease.  This analysis of a 
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potentially powerful therapeutic has further established the peroxisome as a major site 
of cellular ROS regulation and critical metabolic control involved in the protection 
against a number of degenerative diseases.  
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Figure 5.2.  Inflammation, oxidative stress, and aging as driving forces of human 
disease.  Listed here are human diseases in which the emergent connections displayed 
in Figure 1, most importantly oxidative stress and inflammation, are thought to trigger a 
pro-aging program in cells and initiate or progress pathology.  Image appears in World J 
Biol Chem. 2012 by Terlecky, SR, Terlecky LJ, and Giordano, CR. 
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Degree:  Doctor of Philosophy 
Peroxisomes are important regulators of cellular redox balance and function as a 
signaling platform to regulate anti-aging metabolic and communication networks.  In 
addition the organelle has emerged as a major player in maintaining cellular ROS at an 
optimal level. At such levels, these ROS are involved in initiation of signaling cascades 
and that produce an array of anti-aging and disease processes. However, as cells age 
over time, ROS amass within the peroxisome and elsewhere in the cell.  This leads to 
an imbalance in oxidative homeostasis and results in compromised signaling networks. 
The goal of this dissertation was to treat disease cell models with a targeted antioxidant 
approach to help elucidate its biological effects and the extent to which reprograming 
the cellular redox environment contributes to cellular homeostasis. 
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There have been many studies involving antioxidant therapies; however, for the 
most part, these approaches have not been successful. We would argue this is due to 
their non-selective, non-targeted natures. In contrast, we have chosen to examine a 
selective and carefully targeted antioxidant – CAT-SKL. It is our contention that this 
molecule efficiently and safely targets oxidative stress, chronic inflammation, and 
resultant pro-aging and pro-disease pathways initiated in cells. CAT-SKL is designed to 
enter cells by virtue of a cell penetrating peptide. Once inside, presumably mediated by 
an endocytic event, it is directed to the peroxisome via its peroxisomal targeting signal, 
SKL, and metabolizes H2O2 within the organelle and elsewhere in the cell. 
In conditions where H2O2 and related ROS are unchecked, their accumulation 
leads to a pro-aging cascade and the onset of disease.  Maintaining cellular redox 
balance and degrading pro-inflammatory mediators within the peroxisome is essential 
for normal cellular function. By specifically targeting this organelle and restoring 
peroxisomal catalase in a number of disease cells, CAT-SKL may represent a major 
therapeutic advance.  This enzyme has provided important results with respect to 
several major disease models.  In a breast cancer model the drug sensitizes otherwise 
resistant human breast cancer cells to the TKI, gefitinib; in a diabetic retinopathy model, 
CAT-SKL significantly reverses compromised retinal function; and in a rat cell model of 
Alzheimer’s disease, β-amyloid peptide-induced neuronal toxicity is significantly 
reduced.   
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